Global Clinical Development - General Medicine  
OMB157/Ofatumumab 
Clinical T
rial Protocol COMB157G2302 / [STUDY_ID_REMOVED] 
A randomized, doub le-blind, do uble-dummy, parallel -group 
study comparing t he efficacy and safety of o fatumumab 
versus t eriflunomide i n patients with r elapsing multiple 
sclerosis 
Document  type:  Amended Protocol Version 
EUDRACT number:  2015- 005419 -33 
Version number:  v02 Clean  
Clinical trial phase:  III 
Release date:  06-Au g-[ADDRESS_736278] of abbreviations ........................................................................................................ 7 
Glossary  of terms  .......................................................................................................... 10 
Amendment 2 ................................................................................................................ 11 
Amendment 1 effective 19 -JAN-2017 .......................................................................... 13 
Protocol summary  ......................................................................................................... 16 
1 Introduction ................................................................................................................... 20 
1.1 Background ....................................................................................................... 20 
1.2 Purpose .............................................................................................................. 22 
2 Study objectives  and endpoints  ...................................................................................... 22 
2.1 Primary  objective(s)  ........................................................................................... 22 
2.2 Secondary  objective(s)  ....................................................................................... 22 
  23 
3 Investigational plan ....................................................................................................... 24 
3.1 Study design ...................................................................................................... 24 
3.2 Rationale for  study design .................................................................................. 27 
3.3 Rationale for dose/regimen, route of administration and duration of treatment  ... 28 
3.4 Rationale for choice of comparator  .................................................................... 30 
3.5 Purpose and timing of interim  analyses/design  adaptations ................................. 30 
3.5.1 Interim analysis for Data Monitoring  Committee  (DMC)  ................... [ADDRESS_736279]-study treatment  ........................................ 45 
5.6.2 Discontinuation of  Study Treatment  ................................................... 46 
5.6.3 Withdrawal of  informed consent  ........................................................ 48 
5.6.4 Loss to follow-up ............................................................................... 49 
5.6.5 Early study termination by  [CONTACT_1034] .............................................. 49 
5.6.6 Role of Key  site personnel ................................................................. 49 
6 Visit schedule  and assessments  ...................................................................................... 52 
6.1 Information to be collected on screening  failures ................................................ 58 
6.2 Patient demographics/other  baseline characteristics ............................................ 59 
6.3 Treatment exposure and compliance  .................................................................. 59 
6.4 Efficacy  ............................................................................................................. 59 
6.4.1 MS Relapse ........................................................................................ 60 
6.4.
2 Expanded Disability Status  Scale (EDSS)  .......................................... 61 
6.4.3 Magnetic Resonance Imaging (MRI)  .................................................. 61 
6.4.4 Neurofilament light chain  (NfL) ......................................................... 62 
6.4.5 Timed 25-Foot Walk (T25FW)  .......................................................... [ADDRESS_736280] (9HPT)  ............................................................... [ADDRESS_736281] (SDMT)  .............................................. [ADDRESS_736282] Scale (MSIS -29) ........................................ 63 
6.4.9 Appropriateness of  efficacy  assessments  ............................................ 64 
6.5 Safety  ................................................................................................................ 64 
6.5.1 Physical  examination  ......................................................................... 64 
6.5.2 Vital signs .......................................................................................... 65 
6.5.3 Height and weight .............................................................................. 65 
6.5.4 Laboratory evaluations ....................................................................... 65 
6.5.5 Electrocardiogram  (ECG)  .................................................................. 67 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 4 
Protocol No. COMB157G2302   
6.5.6 Pregnancy and assessments  of fertility  ............................................... 68 
6.5.7 Appropriateness of  safety  measurements  ............................................ 68 
6.6 Other  assessments  .............................................................................................. 68 
  68 
6.6.2 Pharmacokinetics  ............................................................................... 70 
6.6.3 Immunogenicity ................................................................................. 70 
  70 
  71 
7 Safety  monitoring  .......................................................................................................... 71 
7.1 Adverse events  ................................................................................................... 71 
7.2 Serious adverse events  ....................................................................................... 73 
7.2.1 Definition  of SAE .............................................................................. 73 
7.2.2 SAE reporting  .................................................................................... 74 
7.3 Liver safety  monitoring ...................................................................................... 75 
7.4 Renal  safety  monitoring ..................................................................................... 76 
7.5 Reporting of study treatment errors  including misuse/abuse  ............................... 76 
7.6 Pregnancy  reporting ........................................................................................... 77 
7.7 Prospective suicidality  assessment  ..................................................................... 77 
7.8 Accelerated elimination procedure related to active  comparator  teriflunomide ... 78 
8 Data review and  database management  .......................................................................... 79 
8.1 Site monitoring  .................................................................................................. 79 
8.2 Data collection  ................................................................................................... 79 
8.3
 Database management and  quality  control .......................................................... 79 
8.4 Data Monitoring Committee  .............................................................................. 80 
9 Data analysis  ................................................................................................................. 81 
9.1 Analysis sets ...................................................................................................... 81 
9.2 Patient demographics and other  baseline characteristics  ..................................... 81 
9.3 Treatments  ......................................................................................................... 81 
9.4 Analysis of the  primary  variable ........................................................................ 82 
9.4.1 Statistical model, hypothesis, and method  of analysis  ......................... 82 
9.4.2 Handling of  missing values/censoring/discontinuations  ...................... 84 
9.4.3 Sensitivity  analyses  ............................................................................ 85 
9.5 Analysis of  secondary  variables  ......................................................................... 85 
9.5.1 Efficacy  variables  .............................................................................. 85 
9.5.2 Safety  variables  .................................................................................. 94 
  96 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 5 
Protocol No. COMB157G2302   
  96  
9.5.5 PK/PD modelling  ............................................................................... 97 
9.5.6 Immunogenicity assessment  ............................................................... 97 
  97 
  
 97 
  97 
  98 
9.7 Interim analyses  ................................................................................................. 98 
9.7.1 Unblinding interim  analysis  ............................................................... 98 
9.7.2 Blinded data reviews  .......................................................................... 99 
9.8 Summary of sample  size calculation  ................................................................. 101 
9.8.1 Sample size for the primary  endpoint (ARR)  .................................... 102 
9.8.2 Sample  size  for  3 -month   confirmed   disability  worsening 
(3mCDW)  ........................................................................................ 103 
9.8.3 Sample  size  for  6 -month   confirmed   disability  worsening 
(6mCDW)  ........................................................................................ 104 
9.8.4 Sample size for 6 -month confirmed disability  improvement 
(6mCDI)  .......................................................................................... 104 
9.8.5 Sample size for number of Gd -enhancing lesions  per scan ................ 104 
9.8.6 Sample size for annualized rate of new/newly enlarging  T2 lesions .. 105 
9.8.7 Sample size for NfL ......................................................................... 105 
9.8.8 Sample size for annualized rate of brain volume loss (BVL)  ............. 105 
10 Ethical  considerations .................................................................................................. 105 
10.1 Regulatory and ethical compliance  ................................................................... 105 
10.2 Informed  c onsent procedures  ........................................................................... 106 
10.3 Responsibilities of the Investigator  and IRB/IEC .............................................. 106 
10.4 Publication of study protocol  and results  .......................................................... 107 
10.5 Quality Control and  Quality  Assurance  ............................................................ 107 
11 Protocol adherence  ...................................................................................................... 107 
11.1 Protocol Amendments ...................................................................................... 107 
12 References  .................................................................................................................. 108 
13 Appendix 1: Liver event and Laboratory trigger Definitions and Follow -up  
Requirements  .............................................................................................................. 110 
14 Appendix 2: Specific Renal Alert Criteria  and Actions ................................................ 112 
15 Appendix 3: Safety monitoring Guidance .................................................................... 112 
15.1 Guidance on monitoring of patients with symptoms of  neurological 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 6 
Protocol No. COMB157G2302   
deterioration suggestive of PML  ...................................................................... 112 
15.2 Guidance on monitoring of patients  with infections .......................................... 113 
15.3 Guidance on immunization  .............................................................................. 114 
15.4 Guidance on monitoring of patients with low  immunoglobulin levels ............... 114 
16 Appendix 4: List of drugs/drug classes with teriflunomide  interaction  potential ........... 114 
17 Appendix 5: Statistical appendix (information from a controlled clinical trial with 
count data)  .................................................................................................................. [ADDRESS_736283] of abbreviations  
Ab Antibody  
ACR Albumin/Creatinine Ratio 
ADA Anti-drug-antibody  
ADCC Antibody -dependent cell-mediated cytotoxicity 
AE Adverse Event  
AEP Accelerated Elimination Procedure 
AIDS  Acquired Immune Deficiency  Syndrome 
Alb Albumin  
ALT Alanine Aminotransferase 
AP/ALP Alkaline Phosphatase 
ARBA Annualized Rate of Brain Atrophy  
ARR Annualized Relapse Rate 
AST Aspartate Aminotransferase  
BCRP  Breast Cancer Resistant  Protein 
BIL Bilirubin  
BUN Blood Urea Nitrogen 
BVL Brain Volume Loss 
C-CASA Columbia Classification Algorithm for Suicide Assessment 
CDC 
6mCCD Complement -dependent cytotoxicity 
6-month Confirmed Cognitive Decline 
CDI Confirmed Disability  Improvement  
6mCDI  6-month Confirmed Disability Improvement 
CDW  Confirmed Disability  Worsening  
3mCDW  3-month Confirmed Disability Worsening 
6mCDW  6-month Confirmed Disability Worsening 
CNS  Central Nervous  System 
COA  Clinical Outcome Assessments 
CQA  Compliance Quality  Assurance 
CRF Case Report/Record Form (paper or  electronic)  
CRO  Contract Research Organization 
CRP  C-Reactive Protein 
(e)CSSRS (electronic) Columbia Suicide Severity Rating Scale 
CTCAE  Common Terminology Criteria for Adverse Events 
CTRD Clinical Trial Results  Database 
DAR Dose Administration Record  
DMC Data Monitoring Committee  
DMT  Disease-Modifying Therapy  
DNA  Deoxyribonucleic  Acid 
DS&E Drug Safety &  Epi[INVESTIGATOR_560083] v02 Clean  Confidential  Page [ADDRESS_736284] 
IB Investigator  Brochure 
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human  Use 
ITT Intention-To -Treat  
Ig Immunoglobulin  
IEC Independent Ethics  Committee  
INR International Normalized Ratio 
iv Intravenous(ly)  
IRB Institutional Review Board  
IRT Interactive Response Technology  
KM Kaplan-Meier  
LDL Low Density  Lipoprotein 
LFT Liver Function Test 
LLN Lower Limit of  Normal  
LLQ Lower Limit of  Quantification  
M Month 
mAb Monoclonal Antibody  
MedDRA  Medical Dictionary for Regulatory Activities 
MRI Magnetic Resonance Image 
MS Multiple Sclerosis  
MSIS Multiple Sclerosis Impact  Scale  
n.a. Not applicable  
NB Negative Binomial  
NEDA  No Evidence of Disease Activity  
NYHA  [LOCATION_001] Heart  Association  
NfL Neurofilament light  chain 
OC/RDC  Oracle Clinical/Remote Data Capture 
PBVC Percentage Brain Volume Change 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 90 
Protocol No. COMB157G2302   
 
 
PCR Polymerase Chain Reaction 
PD Pharmacodynamic  
PG Pharmacogenetics  
PK Pharmacokinetic  
PML Progressive Multifocal Leukoencephalopathy  
po oral(ly)  
PRO  Patient Reported Outcome  
PT Prothrombin Time 
q4, q12 Every 4, every [ADDRESS_736285] of the world 
RRMS  Relapsing-Remitting MS 
SAE Serious Adverse  Event  
SAF Safety  Set 
sc Subcutaneous(ly)  
sCR Serum  Creatinine 
SDMT Symbol Digit Modalities  Test 
SPMS Secondary progressive  MS 
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions 
T25FW  Timed 25-Foot  Walk  
TBIL/TBL  Total Bilirubin 
TEAE Treatment Emergent Adverse Event  
ULN Upper Limit of  Normal  
US [LOCATION_002]  
VAS Visual Analog Scale 
WBC White Blood Cell 
 
  
 
WHO  World Health Organization 
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 10
0 Protocol No. 
  
 
Glossary of terms 
Cohort  A specific group of patien ts/subjects fulfilling certain criteria  
Control drug Drugs(s) used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or 
evaluate comparative effects of the investigational drug  
Dosage  Dose of the study treatment given to the patient in a time unit (e.g. 100 mg once a day, 75 mg twice a day)  
Enrollment  Point/time of patient entry into the study at which informed consent 
must be obtained (e.g. prior to starting any of the procedures 
described in the protocol)  
Epoch A portion of the study which serves a specific purpose. Typi[INVESTIGATOR_18501]: Screening/recr uitment, wash -out, treatment, and follow -up 
Investigational drug The drug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug” or “investigational medicinal product.”  
Medication pack number  A unique identifier on the  label of each investigational drug package  
Part A single component of a study which contains different objectives or populations within that single study. Common parts within a study are: a single dose part and a multiple dose part, or a part in 
patients/subjects with established disease and in those with newly - 
diagnosed disease.  
Patient/subject ID A unique number assigned to each patient upon signing the informed 
consent  
Personal Data  Subject information collected by [CONTACT_351966]. This 
data includes subject identifier information, study information  
and biological samples.  
Randomization number  A unique identifier assigned to each randomized patient, 
corresponding to a specific treatment arm assignment  
Study drug/ treatment  Any single drug or combination of drugs administered to the patient as  
part of the required study procedures; includes investigational drug (s), 
placebo/comparator active drug run -ins or background therapy  
Study Treatment 
Discontinuation (TD)  When the patient permanently stops taking study treatment prior to the 
defined stud y treatment completion date  
Variable  A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being 
tested in the study  
Withdrawal of consent  Withdrawal of consent from the study occurs only when a 
subject does not want to participate in the study any longer, and  
does not allow any further collection of personal data  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 11
0 Protocol No. 
  
 
Amendment 2 
 
 
Amendment rationale  
 
Amendment 2 was created to update the secondary objectives of the study and to provide 
clarification of the rescreening of patients.  
Modifications to the secondary objectives include:  
• Addition of endpoints related to neurofilament light chain (NfL) as secondary objectives  
• Additional endpoint related to cognitive decline as measured on the Symbol Digit 
Modalities Test (SDMT)  
• Addition of composite endpoint related to physical disability and cognition, as measured by [CONTACT_560113] (EDSS) and cognitive decline 
on SDMT  
The Withdrawal of consent and study discontinuation language have been modified to fully implement the European Economic Area General  Data Protection Regulation.  
Other non- substantial changes and updates have been made to correct/clarify minor errors or 
omissions throughout the protocol.  
 
Changes to the protocol  
The main changes and Sections affected are listed as follows:  
Protocol summary and Section 2.2: additions to the secondary objectives:  
• Neurofilament light chain (NfL) concentration in serum as key secondary objective 
• Time to a 6 -month confirmed cognitive decline (6mCCD), defined as a 4- point worsening 
on Symbol Digit Modalities T est (SDMT), and a composite endpoint of time to 6-month 
confirmed disability worsening (6mCDW) or 6- month confirmed cognitive 
decline(6mCCD) as other secondary  objectives  
• Analyses related to NfL in the subgroup of newly diagnosed, treatment -naïve patients  
Section 3.1: addition of the allowance of rescreening in patients.  
Section 5.5.1: clarification of numbering when patients are rescreened. 
Section 5.5.6: clarification on multiple sclerosis (MS) relapse treatment. 
Section 5.5.8: clarification on the prohibited medications.  
Section 5.6.3: clarification on the withdrawal of consent  
Section 5.6.6: text was updated to provide further clarity that T25FW, 9HPT, SDMT may be 
administered by [CONTACT_560114], including the 
EDSS rater  
Table 6 -1: addition of footnote for liver function test (LFT) testing at Day 14. 
Section 6.4: addition of NfL as efficacy assessment.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 12
0 Protocol No. 
  
 
Section 6.4.3: modification of the contrast that is used as standard. 
Section 6.4.4: addition of section regarding NfL.  
Section 6.4.7: addition  of reference on SDMT.  
Section 6.5.2: clarification on number of pulse measurements taken. Figure 9-1: update to reflect changes in analysis.  
Section [IP_ADDRESS]: added NfL as part of secondary analysis. Section [IP_ADDRESS].1: clarification on analysis with cognition.  
Section [IP_ADDRESS].2: additional confirmation of analysis for disability -related endpoints. 
Section [IP_ADDRESS].5: additional section added on NfL.  
Section [IP_ADDRESS]: clarification on the other secondary endpoints  
 
 
Section 9.8: addition of NfL to sample size calculation  
Section 9.8.7: additional section added on NfL sample size calculations Section 12: additional references added  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736286] of several Health Authorities to provide additional 
guidance to the Investigators in regards to:  
• switching  to alternative  disease  modifying therapy  for patients  that have discontinued study 
drug 
• re-evaluation of benefit/risk of continuing study treatment in patients,  who experience 
relevant progression of their disease (have met criterion for 6- month confirmed disease 
worsening) while on study medication.  
Further clarification and instructions to Investigators in regards to the use of pre -medication in 
the home-admini stration  setting  have been  added. This was part of the Local  Amendment 1 for 
[LOCATION_013] (COMB157G2302 v00.01 DE, clean version electronic document identifier 090095a889dac40e) which was created and released on [ADDRESS_736287] of the 
Paul-Ehrlich  Institut  (PEI,  German  Federal  Institute  for Vaccines  and Biomedicines).  Since the 
study in [LOCATION_013] has not yet started, the decision was taken to incorporate these clarification and instructions in the amendment 1. The amendment [ADDRESS_736288]/clarify minor errors or 
omissions throughout the protocol.  
 
 
Changes to the protocol  
The main changes and Sections affected are listed as follows:  
Section 3.1 : a new sentence has been added to clarify that after study drug discontinuation, 
patients who continue to stay in the study may initiate an alternative MS therapy if clinically appropriate and corresponding reference to section 5.6.2, where details are provided, has been 
inserted.  
Section 3.5.1 : the purpose of the interim analyses for DMC has been clarified. 
Section 4.2: the exclusion criteria # 11, 12, 14, [ADDRESS_736289] been updated:  
• #11 with a footnote stating that Quantiferon®- TB Gold test may be requested to be done 
by [CONTACT_560115]'s  eligibility  
• #12 with the hepatitis C testing  steps 
• #14 with daclizumab, which is now an approved MS  therapy  
• #19 to clarify  that this exclusion criterion  refers  to either  one or both serum  immunoglobulin 
(IgG, IgM) level(s) below  LLN  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 14
0 Protocol No. 
  
 
• # 23 clarifies that in regards to lactose intolerance only severe conditions are  exclusionary 
Section  5.5.4: the time window for Day7  and Day14  subcutaneous injection  has been  added  and 
guidance on missing injections and subsequent injections has been clarified.  
Section 5.5.7: this section has been modified to add and clarify specific instructions for the 
Investigators in regards to the use of premedication in the home -administration setting and to 
ensure that appropriate information and material on potential injection related reactions and their treatment are provided to the patients.  
Table 5 -1: daclizumab has been added to  prohibited medications while patients are on study 
medication.  
Section 5.6.2: a paragraph has been added to clarify that study drug discontinuation should be considered if patients meet the criterion for 6 -month confirmed disability worsening on EDSS 
and if the Investigator assesses the benefit/risk as negative for study treatment continuation.  
Section 5.6.2: a paragraph has been added to clarify that after study drug discontinuation, 
patients  may initiate  alternative  MS therapy  if clinically  appropriate and guidance on switching 
to another MS therapy is  provided. 
Sections 5.6.6 and 6.4.3 : the starting point (randomization) of blinding of efficacy data (EDSS 
and MRI) has been clarified.  
Section 5.6.6: T25FW, 9HPT and SDMT may be administered by [CONTACT_560116]. 
Therefore no specific blinding procedures apply to these assessments.  
Table 6 -1: clarifications have been provided:  
• the line for Samples for Total IgG and IgM has been shaded in grey to clarify that this sample should be taken as per schedule after study drug discontinuation 
• the following footnotes have been  updated: 
• #8 to clarify that it refers to both End of Study (EOS) and End of Treatment  (EOT) 
• #[ADDRESS_736290] syphilis and tuberculosis as part of the eligibility check 
(unless completed in the last 6 months prior to screening with documented negative 
results
) and that the Quantiferon®- TB Gold test may be requested to be done by [CONTACT_560117]'s eligibility  
• #[ADDRESS_736291] -injection vital signs  collection  
• #[ADDRESS_736292] be drawn to allow adequate time for results to be obtained before randomization to ensure patient's eligibility  
• the starting  points for additional LFT testing  (Day  14) and phone interviews  (Month 2) have 
been  clarified.  
Table 6 -2: time points for Routine laboratory and for Total IgG and Ig M assessments have 
been added.  
Sections  6.4.5 and 6.4.6 and 6.4.7:  T25FW, 9HPT and SDMT may be administered by [CONTACT_560118].  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 15
0 Protocol No. 
  
 
Section 6.5.2: the timing of the pre and post -injection vital signs collection has been added for 
clarity.  
Section [IP_ADDRESS]: the hepatitis C testing steps have been clarified,  In addition clarity has been 
provided on the need to test syphilis and tuberculosis as part of the eligibility check (unless 
completed  in the last 6 months prior  to screening  with documented negative results ) and on the 
possibility to request the Central laboratory to do the Quantiferon®- TB Gold test to assess 
patient's eligibility.  
Section 7.2.2 : the first paragraph has been updated to clarify the SAE reporting time frame. 
Section 12: new reference has been added.  
Section  15.1: clarification  has been  added  with regards  to the MRI  seque nces recommended  for 
differential  diagnosis. 
In addition, several updates have been made in the Data analysis section ( Section 9 ) to correct 
some errors and align with the Statistical Analysis Plan.  
Changes to specific sectio ns of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethic s Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  
The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 16
0 Protocol No. 
  
 
Protocol summary 
Protocol number  COMB157G2302  
Title A randomized, double-blind, double-dummy, parallel- group study 
comparing the efficacy and safety of ofatumumab versus teriflunomide in 
patients with relapsing multiple sclerosis  
Brief title  Study of efficacy and safety of ofatumumab compared to teriflunomide in 
patients with relapsing multiple sclerosis  
Sponsor and Clinical Phase [COMPANY_001]  
Phase 3 (confirmatory)  
Investigation type  Biological (human IgG1k lytic monoclonal antibody (mAb) to human CD20 
antigen)  
Study type  Interventional  
Purpose and rationale Study, in conjunction with second study of identical design 
(COMB157G2301) conducted in parallel, to provide data in support of 
regulatory approval worldwide as a treatment for patients with relapsing 
multiple sclerosis  
Primary Objective  To demonstrate that ofatumumab is superior to teriflunomide in reducing 
the frequency of confirmed relapses as evaluated by [CONTACT_560119] (ARR) in patients with relapsing MS  
Secondary Objectives  Key secondary objectives 
To evaluate if ofatumumab is superior to teriflunomide on:  
• Time to disability worsening as measured by 3-month confirmed 
worsening (3mCDW) on Expanded Disability Status Scale (EDSS) 
• Time to disability worsening as measured by 6-month confirmed worsening (6mCDW) on EDSS 
• Time to disability improvement as measured by 6-month confirmed improvement (6mCDI) on EDSS 
• Number of T1 gadolinium (Gd) -enhancing lesions per Magnetic 
Resonance Image (MRI)  scan 
• Number of new or enlarging T2 lesions on MRI per year (annualiz ed 
T2 lesion rate) 
• Neurofilament light chain (NfL) concentration in serum  
• Rate of brain volume loss (BVL) based on assessments  of percentage 
brain volume change from  baseline 
 
Other secondary objectives  
To evaluate if ofatumumab is superior to teriflunomide on:  
• Time to first  relapse  
• Annualized relapse rates > 8 weeks after the onset of  treatment  
• Risk of a 3mCDW > 8 weeks after the onset of treatment  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 17
0 Protocol No. 
  
 
 • Risk of a 6mCDW > 8 weeks after the onset of treatment  
• Time to a 6-month confirmed cognitive decline (6mCCD),  defined as a 
4-point worsening on Symbol Digit Modalities Test  (SDMT) 
• Time to 6mCDW or  6mCCD, whichever is reached first  
• Change in cognitive performance relative to baseline as measured by 
[CONTACT_83049]  
• Time to 6-month confirmed worsening of at least 20% in the timed 
25-foot walk test  (T25FW)  
• Time to 6-month  confirmed worsening of at least  20% in the 9-hole peg 
test (9HPT)  
• Time to 6mCDI sustained until end of study as measured by  [CONTACT_454408] 
• Number of new or enlarging T2 lesions between Month 12 and End of 
Study  (EOS) 
• Change in T2 lesion volume relative to baseline  
• Proportion of patients  with no evidence of disease  activity  (NEDA -4) at 
year 1 and 2 
• Physical and psychological impact of MS disease as measured by  [CONTACT_560120] (MSIS-29)  
In the subgroup of newly diagnosed, treatment -naïve patients, evaluate if:  
• High NfL (above median) concentration at baseli ne is predictive of 
higher disease activity post  baseline 
• Patients with a high NfL (above median) concentration at baseline 
benefit from a stronger relative treatment effect of ofatumumab vs 
teriflunomide  
• The safety profile of ofatumumab vs terifluomide is comparable in 
patients with high NfL (above median) concentration at  baseline  
To evaluate the safety and tolerability of ofatumumab compared to teriflunomide  
To evaluate the pharmacokinetic (PK) of ofatum umab  
Study design  Randomized, double-blind, double-dummy, parallel-group, active- comparator controlled, adaptive design, maximal treatment duration of 30 
months for an individual patient  
Population  Adult patients with relapsing multiple sclerosis (MS)  
Key Inclusion criteria  • Male or female patients aged 18 to 55 years (inclusive) at  Screening 
• Diagnosis of MS according to the 2010 Revised McDonald criteria 
• Relapsing MS: relapsing-remitting course (RRMS), or secondary progressive (SPMS) course with disease  activity  
• Disability  status  at Screening with an EDSS score of 0 to 5.5 (inclusive)  
• Documentation of at least: 1 relapse during the previous 1 year OR 2 relapses during the previous 2 years prior to Screening OR a positive 
Gd-enhancing MRI scan during the year prior to randomization  (Note:  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736293] from prior year).  
• Neurologically stable within 1 month prior to  randomization  
Key Exclusion criteria  • Patients  with primary  progressive MS or SPMS without  disease activity  
• Patients meeting criteria for neuromyelitis  optica  
• Disease duration of more than 10 years  in patients  with an EDSS score 
of 2 or  less 
• Pregnant or nursing (lactating)  women  
• Women of child- bearing potential unless using highly effective 
methods of contraception during study drug dosing and for [ADDRESS_736294]-dosing 
• Sexually active males unless they agree to use condom during 
intercourse while on study  drug 
• Patients with an active chronic disease of the immune system other 
than MS 
• Patients with neurological findings consistent with PML or confirmed PML 
• Patients at risk of developi[INVESTIGATOR_21341]: 
positive results at Screening for serology markers for hepatitis A, B,  C 
and E (HA, HB, HC, and HE) indicating acute or chronic infection 
• Patients with active systemic infections or known to have AIDS or to test positive for HIV antibody at  Screening 
• Patients at risk of developi[INVESTIGATOR_560084]  
• Have received any live or live- attenuated vaccines within 2 months 
prior to randomization 
• Have been treated with medications as specified or within timeframes 
specified (e.g. corticosteroids, ofatumumab, rituximab, ocrelizumab, 
alemtuzumab, natalizumab, cyclophosphamide, teriflunomide, 
leflunomide,  etc.) 
• Any other disease or condition that could interfere with participation in 
the study according to the study protocol, or with the ability of the 
patients to cooperate and comply with the study procedures.  
Study treatment  Ofatumumab (OMB157G) 20 mg sc injections once every 4 (q4) weeks 
(following initial loading regimen of three 20 mg sc doses/week in first 14 
days) + teriflunomide-matching placebo capsules orally once daily  
Teriflunomide 14 mg capsules orally once daily + ofatumumab-matching 
sc placebo injections  
Efficacy assessments MS relapse, Expanded Disability Status Scale (EDSS), Magnetic 
Resonance Imaging (MRI), Timed 25-Foot Walk (T25FW), Nine Hole Peg Test (9HPT), S
ymbol Digit Modalities Test (SDMT), Multiple Sclerosis 
Impact Scale (MSIS -29), Neurofilament light chain (NfL)  
Key safety 
assessments  Adverse events, Physical examinations (including skin), Vital signs,  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 19
0 Protocol No. 
  
 
 Laboratory evaluations (blood and urine), Pregnancy testing, 
electrocardiogram (ECG), Columbia Suicide Severity Rating Scale 
(CSSRS)  
Other assessments  Pharmacokinetics,  
 
Data analysis  All efficacy data will be analyzed according to the intent -to-treat principle. 
The primary analysis (ARR) will use a negative binomial regression model 
with log-link and time-in-study as offset. Key -secondary analyses include 
disability endpoints (i.e., time- to-3mCDW, 6mCDW and 6mCDI all 
analyzed in Cox proportional hazards models), MRI -endpoints (i.e., 
number of T1 Gd-enhancing lesions, number of new/ enlarging T2 lesions 
both analyzed in negative binomial regression models and percentage 
brain volume chan ge analyzed in a random coefficients model) and 
log(NfL) analyzed in a repeated measures model . 
The primary hypothesis (ARR) and all MRI - and NfL-related hypotheses 
will be addressed within the present  study  (COMB157G2302).  All disability 
endpoints will be addressed in the combined data from 2 studies of 
identical design (COMB157G2302 and COMB157G2301).  To adjust  for 
multiplicity, a testing procedure is implemented in order to control the 
Type -I error rate.  
Key words  Interventional, clinical trial, efficacy and safety, double-blind/double- 
dummy, ofatumumab, teriflunomide, relapsing multiple sclerosis  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 20
0 Protocol No. 
  
 
1 Introduction  
1.1 Background 
Multiple Sclerosis (MS) is a chronic, immune -mediated disease of the central nervous system 
(CNS) characterized by [CONTACT_2898], demyelination and axonal/neuronal destruction, 
ultimately leading to severe disability. MS affects ~ 2.[ADDRESS_736295]  frequent clinical presentation  of the disease.  Approximately 
85% of patients  present  with relapsing -remitting  MS (RRMS),  characterized  by [CONTACT_560121] (relapses) of neurological dysfunction followed by [CONTACT_454342]. After 15-20 years,  
~50% of patients with RRMS have progressed to secondary progressive MS (SPMS), which is 
a stage of the disease characterized by [CONTACT_560122]. SPMS can be segregated based on whether patients continue to experience relapses (relapsing SPMS) or not (purely progressive SPMS).  
There is accumulating evidence that the immune -mediated damage in MS involves more than 
just T cells. Specifically, the early role of B -cells in the contribution to the immune -mediated 
histopathology in MS (Archelos  et al. 2000; Frohman et al. 2006; McFarland 2008),  has become 
clearer. B -cells have essential functions in regulating immune response and may contribute to 
disease  pathogenesis by [CONTACT_6270]-antigen  presentation, serving as cellular  adjuvants for CD4
+ T-cell 
activation  (Bouaziz et al. 2007) and by [CONTACT_52361] T- cell function and inflammation  via cytokine 
production ( Lund 2008), in addition to producing autoantibodies. B -cells are present in the 
chronic plaques, areas  of demyelination, and in the cerebrospi[INVESTIGATOR_560085]  (Klaus  et 
al. 2013 ). 
Clinical evidence from randomized, placebo -controlled Phase 2 studies with the chimeric 
mouse/human anti -CD20 monoclonal antibody (mAb) rituximab ( Hauser et al. 2008 ) and the 
humanized  anti-CD20  mAb  ocrelizumab  (Kappos et al. 2011 ) showed B- cell depletion by [CONTACT_560123] -measured inflammatory activ ity in relapsing MS 
patients.  Recently  the efficacy  of ocrelizumab  was confirmed  in 2 Phase  3 trials  in patients  with 
RMS  (Hauser  et al. 2015).  These  studies showed that ocrelizumab  significantly  reduced  relapse 
rates, reduced MRI disease activity and, delayed the time to disability worsening vs interferon 
beta 1a over 2 years. Ocrelizumab was well tolerated with no major safety findings reported in 
these clinical  trials.  
Both rituximab and ocrelizumab are  delivered in a clinical setting by [CONTACT_33980] (iv) infusion. 
There is still unmet need for an advanced treatment targeting B -cell pathology with a similar 
mechanism of action with high efficacy, an acceptable safety profile and the convenience of 
self-administration.  
Ofatumumab  
Ofatumumab  is a human anti-CD20  monoclonal antibody (mAb)  approved for the treatment  of 
patients with chronic lymphocytic leukemia (Arzerra®). The actions of ofatumumab on B -cells 
are similar to rituximab and ocrelizumab. Ofatumumab recognizes a unique epi[INVESTIGATOR_560086] 2 extracellular domains of the CD20+ molecule, N -proximal 
of the epi[INVESTIGATOR_188585] -CD20 monoclonal antibody (mAb) rituximab. CD20- binding of 
ofatumumab induces B- cell lysis primarily  through complement -dependent cytotoxicity  (CDC)  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 21
0 Protocol No. 
  
 
and antibody- dependent cell -mediated cytotoxicity (ADCC). As a fully human antibody (Ab), 
ofatumumab is predicted to have low potential for immunogenicity, as confirmed by [CONTACT_560124] -drug antibodies (ADA) against ofatumumab observed in clinical studies 
(< 1% of patients in oncology studies, Arzerra® US prescribing information ). 
Ofatumumab has been evaluated in 2 Phase 2 studies in patients with RRMS (Studies 
OMS115102 and OMS112831). Study OMS115102 was a 48- week (24 -week cross -over), 
double- blind, placebo- controlled study that evaluated the effects  of ofatumumab administered 
iv in 38 patients with RRMS ( Soerensen et al. 2014 ). The study consisted of 3 dose cohorts 
(100 mg, 300 mg, 700 mg) with 12 patients randomized in each cohort to ofatumumab or placebo in a 2:1 rati o. After 24 weeks, patients on ofatumumab were switched to placebo and 
patients on placebo were switched to the ofatumumab dose of their cohort and followed for 24 weeks (Week 24 -48). The study showed that iv administration of ofatumumab resulted in a 
profound reduction in circulating B -cell counts and suppression of MRI lesion activity at each 
dose level evaluated in both treatment periods (Week 0- 24 and Week  24-48). 
Study OMS112831 was a randomized, placebo- controlled, dose -ranging, 48- week study (24- 
week double -blind treatment phase, then 24- week follow -up phase) that examined the efficacy 
and safety of repeat -dose subcutaneous ofatumumab in RRMS. Patients were randomized 
(2:1:1:1:2) to placebo,  ofatumumab 3mg, 30mg, or 60mg every  12 (q12) weeks,  or ofatumumab 
60 mg every 4 (q4) weeks. The primary endpoint was the cumulative number of new 
gadolinium-enhancing lesions  during weeks  0–12 on brain  magnetic  resonance imaging  (MRI). 
MRI  and relapse outcomes, safety  and tolerability  and B-cell counts were also assessed.  Of 232 
randomized patients, 231 received ≥ 1 study drug dose; 214 (92.6%) completed 24 weeks, 212 (91.8%) completed 48 weeks. Ofatumumab reduced the mean cumulative number of new 
gadolinium-enhancing lesions by 65% vs placebo  during weeks  0–12 (p < 0.001), and by ≥ 90% 
during weeks 4–[ADDRESS_736296] hoc analysis of cumulative ofatumumab doses ≥ 30mg (p < 0.001). Dose -dependent decreases were maintained up to week 48, with the greatest 
reduction in the ofatumumab 60 mg q4 weeks treatment group versus other dose groups. Ofatumumab reduced cumulative new/newly enlarged T2 lesions vs placebo during weeks 0– 
12 (60–72%; p ≤ 0.002). Between 24–48 weeks, new/newly enlarged T2 lesion counts were 
stable  for all ofatumumab  doses apart  from  the [ADDRESS_736297] being less 
pronounced with the 3 mg q12 regimen. Monthly dosing showed no signs of B -cell repletion 
during the inter-dosing interval.  Both  30 mg and 60 mg q12 weeks  showed approximately 75% 
suppression of B- cells prior to re-dosing. Once dosing was ceased,  all treatments  showed similar 
rate of B -cell repopulation over 60 weeks of follow  up. 
Overall, ofatumumab was safe and well tolerated in patients with RRMS. The safety profile of 
ofatumumab was consistent with previous data; no new signals were reported.  
In study OMS112831 of sc ofatumumab, the most commonly reported AEs across the ofatumum ab dose groups were injection- related reactions (52% for ofatumumab, 15% for 
placebo). Injection -related reactions occurred primarily post -first dose, diminished on 
subsequent dosing and were mostly  mild/moderate  in severity  (97% of the events).  There were  
no notable differences  across  treatment  groups in the overall  incidence of infection -related  AEs, 
including urinary and respi[INVESTIGATOR_6014]. Few serious adverse events (SAEs) were 
reported. These were mainly systemic injection -related reactions ( 3 patients), all occurring  on 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 22
0 Protocol No. 
  
 
Day 1 and in the 60 mg ofatumumab dose groups. There were no cases of opportunistic 
infections reported during the study.  
For further details about ofatumumab, please refer to the Investigator’s Brochure.  
 
1.2 Purpose 
The study is designed, in conjunction with a second study of identical design conducted in 
parallel, to provide efficacy, safety and tolerability data for ofatumumab sc compared to oral (po) teriflunomide (Aubagio
®) in patients with relapsing MS. Th e data will support regulatory 
approval to make ofatumumab sc available for clinical use worldwide as a treatment for this patient population.  
 
2 Study objectives and  endpoints  
2.1 Primary objective(s) 
Demonstrate that ofatumumab 20 mg sc once every 4 (q4) weeks is superior to teriflunomide 14 mg po once daily in reducing the frequency of confirmed relapses as evaluated by [CONTACT_560125] (ARR) in patients with relapsing MS.  
 
2.2 Secondary objective(s) 
Key secondary objectives  
All disability -related key -secondary objectives will be addressed in the combined data (meta - 
analysis) from this study and the second study of identical design. All other objectives will be 
addressed based on the data  from this study alone.  
The key secondary objectives are to evaluate if ofatumumab 20 mg sc q4 weeks is superior to teriflunomide 14 mg po once daily on the following efficacy measures:  
• Time to disability worsening as measured by 3- month confirmed worsening (3mCDW) on 
The Expanded Disability Status Scale  (EDSS)  
• Time to disability worsening as measured by 6- month confirmed worsening (6mCDW) on 
EDSS  
• Time  to disability  improvement as measured  by 6-month confirmed  improvement (6mCDI) 
on EDSS  
• Number of T1 Gd- enhancing lesions per MRI  scan 
• Number of new or enlarging T2 lesions on MRI per year (annualized T2 lesion rate) 
• Neurofilament light chain (NfL) concentration in serum  
• Rate of brain volume loss (BVL) based on assessments of percentage brain  volume change 
from  baseline 
 
Other secondary objectives  
Evaluate if ofatumumab 20 mg sc q4 weeks is superior to teriflunomide 14 mg po once daily on the following efficacy measures:  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 23
0 Protocol No. 
  
 
• Time to first relapse 
• Annualized relapse rates > 8 weeks after the onset of  treatment  
• Risk of a 3mCDW > 8 weeks after the onset of  treatment 
• Risk of a 6mCDW > 8 weeks after the onset of  treatment  
• Time to a 6 -month confirmed cognitive decline (6mCCD), defined as a 4- point worsening 
on Symbol Digit Modalities Test (SDMT)  
• Time to 6mCDW or 6mCCD, whichever is reached  first 
• Change in cognitive performance relative to baseline as measured by [CONTACT_560126]  
• Time to [ADDRESS_736298] 20% in the timed 25- foot walk test 
(T25FW) 
• Time to [ADDRESS_736299] 20% in the 9- hole peg test  (9HPT)  
• Time to 6mCDI sustained until End of Study (EOS) as measured by [CONTACT_454408]  
• Number of new or enlarging T2 lesions between Month 12 and EOS  
• Change in T2 lesion volume relative to  baseline 
• Proportion of patients with no evidence of disease  activity  (NEDA -4;  defined  in  
Section [IP_ADDRESS]) at year 1 and  2 
• Physical and psychological impact of MS disease as measured by [CONTACT_560127] (MSIS -29) 
In the subgroup of newly diagnosed, treatment -naïve patients, evaluate if:  
• High NfL (above median) concentration at baseline is predictive of higher disease activity post baseline 
• Patients with a high NfL (above median) concentration at baseline benefit from a stronger relative treatment effect of ofatumumab vs teriflunomide  
• The safety profile of ofatumumab vs terifluomide is comparable in patients with high NfL 
(above median) concentration at  baseline  
Evaluate the safety and tolerability of ofatumumab 20 mg sc q4 weeks compared to teriflunomide 14 mg po once daily.  
Evaluate the pharmacokinetics (PK) of ofatumumab.  
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 24
0 Protocol No. 
  
 
 
3 Investigational  plan 
3.1 Study design 
This is a randomized, double -blind, double -dummy, active comparator -controlled, parallel - 
group, multi -center study with variable treatment duration in approximately 900 patients with 
relapsing  MS. The treatment  duration for individual patients  will be variable based  on when  the 
End of Study (EOS)  criteria  are met. The maximal  duration for an individual patient  will be 30 
months (2.5  years).  
Eligible  patients  will be randomized  to receive either  ofatumumab 20 mg sc injections  q4 weeks 
(after  initial  loading regimen  of three  weekly  [ADDRESS_736300] 14 days) or teriflunomide 
14 mg orally  once daily. In order to blind for the different  formulations, a double-dummy design 
will be used: patients in the active ofatumumab treatment arm will additionally take placebo 
capsules orally once daily; patients in the active teriflunomide treatment arm will additionally 
take q4 weeks  placebo -containing sc injections  (after  initial  regimen  of three weekly  injections 
in the first 14 days) ( Section 5.5 ). Other measures to protect study blind include: 
• Use of an independent EDSS rater for clinical efficacy assessments ( Section 5.6.6), who is 
not the same person as the Investigator (Section  5.6.6) 
• MRI scans are read by a blinded central MRI reading center ( Section  6.4.3 ) 
• And laboratory assessments that may lead to potential unblinding ( Section 6.5.4 ) will not 
be revealed to the site staff or Sponsor study team.  
A second  study of identical  design (COMB157G2301) will be conducted simultaneously. Both 
studies have the same primary (reduction in ARR) and key -secondary objectives. Both studies 
will be conducted globally, but individual sites can only participate in one study to ensure 
independence between the 2 studies. Key- secondary hypotheses with high sample size 
requirements,  i.e. those related  to disability  worsening or disability  improvement, will be tested 
on the basis of the combined data from the 2 studies (meta -analysis). Multiplicity adjustments 
are defined in Section [IP_ADDRESS]. Poolability of the [ADDRESS_736301] between the 2 studies will be tested for disability -related 
outcomes in the  meta -analysis.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 25
0 Protocol No. 
  
 
Prior to the completion of enrolment , a blinded data review (i.e. the treatment code will not be 
broken) will be performed for the 2 studies to re -assess sample size assumptions for ARR (for 
each study separately) and for 3mCDW (for pooled studies). Based on this blinded review, the 
number of patients  to be enrolled  may be increased  to a maximum  number of 1250 randomized 
patients in each study ( Section  [IP_ADDRESS] ). 
End of Study (EOS) will be reached for both studies when all of the following conditions are 
met simultaneously: 
1. Each study has collected sufficient data to provide 90% power for the primary ARR 
endpoint. 
2. Across the [ADDRESS_736302] been observed to provide 90% power for the key- secondary 3mCDW  endpoint. 
3. Across the [ADDRESS_736303] been observed to provide 80% power for the key- secondary 6mCDW  endpoint. 
An analysis of blinded data will be conducted to determine the time point at which EOS is 
reached.  Blinded data reviews  are described  in Section  9.7.2  and a formal  definition  of the EOS 
criteria can be found in the statistical Section  [IP_ADDRESS] . 
The EOS  analysis  will be based  on the completed  core study i.e. based  on all patients  who have 
completed the Treatment epoch including partial data from the Safety Follow -up epoch 
available at the time of EOS cut- off (Section  [IP_ADDRESS]).  
The core study consists of 3 epochs;  Screening  epoch  (including Baseline),  Treatment  epoch 
(double- blind) and Safety Follow -up (FU) epoch ( Figure 3 -1). Patients who complete the 
double- blind Treatment epoch may be eligible to enter an open- label ofatumumab Extension 
study that is planned (under separate protocol). Patients  who complete  the Treatment  epoch  (on 
study drug), but do not enter the Extension study will be followed up for safety in the Safety 
Follow- up (Safety FU) for a minimum of [ADDRESS_736304] up to 45 days and consists of 2 periods, Screening  and Baseline: 
The Baseline period can last up to the point of first study drug administration (Day - 7 to Day 
1). Patient eligibility will be determined based on the Screening and/or Baseline assessments. If a patient is declared a screen failure, he/she may be rescreened and all assessments must be 
repeated.  
 
The double -blind Treatment epoch will start on Day [ADDRESS_736305] 4 weeks, injectable study treatment 
(ofatumumab or placebo)  will be administered  on Day 1, Day 7 and Day 14 and Day 28 (Week 
4, study Month 1). Thereafter, injections will be administered every 4 weeks. All patients will 
also take one capsule orally once daily (teriflunomide or placebo) starting on Day 1. The 
Treatment epoch for an individual patient will continue until th e End of Study (EOS) has been 
declared, or for a maximal duration of [ADDRESS_736306] sc injection at the site administered by [CONTACT_5984] 
(Investigator or Study Nurse/Study Coordinator), and will return to the site on Day 7, Day 14 
and Day 28 (Month 1) for sc injections under supervision of the study staff (refer to Section  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 26
0 Protocol No. 
  
 
5.5.4 for further details). Patients will thereafter return to the site for assessments at Month [ADDRESS_736307] an 
EOS Visit at the end of the Treatment epoch (either when EOS is declared for all patients, or 
when the patient has reached the maximum of 30 months, or if the patient discontinues from 
study drug and is not willing to follow the Treatment epoch visits and assessments  further).  
Patients who prematurely discontinue double -blind study medication and agree to continue to 
follow the assessment schedule of the Treatment epoch (recommended) will have their end of 
treatment (EOT) visit and assessments at the time of study medication discontinuation. These 
patients will then be asked to continue to f ollow the schedule of assessments ( Table 6 -1) and 
have their EOS Visit at the end of the Treatment epoch. After study drug discontinuation, patients may initiate alternative MS therapy according to local standard of care if clinically 
indicated (see Section 5.6.2).  
The Safety FU epoch (Table 6 -2) will be applicable for the following patients:  
• Patients who complete the Treatment epoch on study drug and do not enter the planned 
Extension study 
• Patients who prematurely discontinue study treatment and do not agree to continue to be followed in the Treatment  epoch  
• Patients who have prematurely discontinued study treatment, are being followed in the Treatment epoch but have had less than 9 months of  off-treatment follow up at the time of 
EOS/Month 30 (whichever is earlier)  
All Safety FU visits must be scheduled relative to the EOS Visit.  
All patients will be followed for a total of at least 9 months after study drug discontinuation in the Treatment epoch and/or the Safety FU epoch (by [ADDRESS_736308] repleted their circulating B -cells, see Section 3.3 ). The duration of the Safety 
FU epoch  for an individual patient  will depend on how long the patient  has been off study drug 
at the time he/she enters the Safety FU epoch. For example, a patient who completes the 
Treatment epoch on study drug and has EOS (and does not enter the extension study), will be 
followed for at least 9 month s in the Safety FU epoch. However, a patient who discontinues 
study drug at an earlier time point and had 4 months of follow up after study drug discontinuation in the Treatment epoch, may only need to be followed for an additional 5 
months in the Safety FU epoch (for a total of 9  months). 
A longer than [ADDRESS_736309]- treatment  follow up in the Safety  FU epoch  will be required  for 
the following patients:  
• Patients who have not repleted their B -cells (i.e. B -cells not back to baseline value or to 
lower  limit of normal (LLN)  whichever  comes  first as determined  by [CONTACT_104073]) at 9 months 
• Patients in whom teriflunomide plasma levels are above 0.02 mg/L (analyz ed centrally) at 
[ADDRESS_736310] repleted or teriflunomide plasma levels are below 0.02 mg/L. To protect the study blind, 
the assessment of B -cell counts and teriflunomide plasma levels will be performed centrally 
and the Investigators and Sponsor study team  will only be infor med of whether  or not continued 
follow up is  necessary.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 27
0 Protocol No. 
  
Screening epoch  Treatment epoch  
(double -blind, double -dummy)  Safety FU epoch* o r 
Extension study**  
Baseline  
Teriflunomide 14 mg po qd + placebo injections sc  
M1 M2 M3 M4 M5 EOS  
Randomization   
 
Ofatumumab 20 mg sc + placebo capsules po qd   
Patients  who have initiated  therapy  with another disease  modifying/immunosuppressive therapy 
before the end of the 9- month follow up will not be monitored beyond 9 months. 
Due to th e long elimination of teriflunomide (8 months up to 2 years), all patients who have 
discontinued study drug and have completed at least 9 months of follow up (in the Treatment 
epoch or the Safety FU epoch) and who plan to become pregnant/father a child or do not agree 
to continue to use highly effective contraception,  should undergo the teriflunomide -accelerated 
elimination procedure (AEP) described in Section 7.[ADDRESS_736311] be made without knowledge of the core study 
treatment assignment. Patients may not re -start study drug after accelerated  elimination.  
Patients  who complete  the Treatmen t epoch  (while  on study drug) may be eligible  to participate 
in the long- term, open -label ofatumumab Extension study . The details of the design and 
assessments of the Extension study will be described  in a separate protocol. This extension will 
last for up to 5 years  for individual patients  or until the development of ofatumumab in relapsing 
MS has been decided to be discontinued, if  earlier.  
 
Figure 3 -1 Study  design  
 
*Patients who complete the Treatment Epoch and do not enter the planned Extension study or who prematurely 
discontinue study drug and do not agree to complete the study Treatment epoch or have less than 9 mont hs of 
follow up after study drug discontinuation, will enter the Safety FU epoch. **Extension study will be conducted under separate protocol. M=month, EOS=End of Study, FU=Follow -Up, po qd= orally once a day  
 
3.2 Rationale for study design 
Double- blind, parallel group, active comparator design is an established scientific method to 
assess safety and efficacy of a new therapy in conditions where approved medications are 
available. Double -dummy blinding is necessary to blind treatment group assignment when the 
investigational and comparator drugs utilize different formulations/routes of administration.  
Screening  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 28
0 Protocol No. 
  
 
The study has a flexible duration where the end of the study is determined by [CONTACT_560128]. The End of Study is declared when sufficient data has been collected to provide 
the required power for the statistical tests (explained in Section [IP_ADDRESS] ). 
The sample size of the study can be adjusted if the disease activity of the recruited patient population is lower than initially assumed as indicated by [CONTACT_560129] 
(explained in Section [IP_ADDRESS]). Adaptive  design features aim to maximize the efficiency of the 
trial by [CONTACT_560130] -dummy treatment to the minimum that is 
required  to address  the scientific  objectives  of the study. All design adaptations in this study are 
based on an analysis of blinded data and do not jeopardize the scientific integrity of the  study. 
Two studies (COMB157G2302 and COMB157G2301) of identical  design will be conducted in 
parallel as part of the ofatumumab Phase 3 program in order to allow an assessmen t of the 
reproducibility of the primary results. Both studies will be independently powered to address 
the primary  objective (ARR)  and key secondary  MRI  objectives,  and results  from  the 2 studies 
will be independent as centers/sites/Investigators can only participate in one or the other trial 
(but not in both). The design makes  efficient  use of the patients’  data.  If the ARR is significantly 
lower in ofatumumab treated patients compared wit h those treated with teriflunomide in both 
studies,  all disability -related  key-secondary endpoints will be analyzed  in a meta -analysis  of the 
combined data from the [ADDRESS_736312]. A testing procedure and multiplicity adjustments 
are specified to control the false positive rate (one -sided) to ≤ 2.5% within study ( Section  
[IP_ADDRESS] ). 
Patients with r elapsing MS (RRMS or SPMS with disease activity as defined by [CONTACT_188615].  
2014) with EDSS scores of [ADDRESS_736313] of ofatumumab on B -cells and the long half -life of teriflunomide, 
all patients who discontinue study drug (prematurely or at study completion) and do not enter 
the planned long- term Extension study, will continue to be followed up for safety for at leas t 9 
months until B- cell repletion  or teriflunomide  plasma  levels  are below 0.02 mg/L  (Section  3.1). 
 
3.3 Rationale for dose/regimen, route of administration and duration 
of treatment 
The dose regimen for ofatumumab for this study  is a loading dose regimen of 20 mg at Day 1, 
Day 7 and Day 14, followed by a monthly maintenance dose regimen of 20 mg administered 
every 4 weeks starting at week 4. The dose selection relies on the clinical hypothesis that the 
depletion of B- cells in lymphatic  tissues is key for efficacy  (as measured  by [CONTACT_560131]), 
and that the depletion of brain parenchymal and meningeal B -cells may be an additional factor 
for the mode of action; blood B -cell count is an imperfect, epi[INVESTIGATOR_560087]. This hypothesis suggests that in order to attain the desired efficacy, 2 conditions should be met: 
• A loading regimen with high enough initial PK for lymphatic depletion,  and 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 29
0 Protocol No. 
  
 
• A continued maintenance dose that would keep B -cell depletion levels below desired 
threshold. 
The Phase 2 study of ofatumumab sc in relapsing MS patients (Study OMS112831) provided 
important information regarding the relationship between peripheral B -cell depletion and 
efficacy  as measured  by [CONTACT_560132]-enhancing brain  lesions.  Clear  dose-response relationship  was 
detected  using a quasi- Poisson  regression  model that related  new Gd-enhancing lesion  volumes, 
baseline lesion number and treatment group. The dose -response was fully explained by [CONTACT_560133]19+ cell count drop. The model indicates that lower CD19+ cells levels lead to 
better  control of lesion  volumes and, subsequently, high level  of depletion of CD19+ cells (e.g. 
≤ 8 cells/µL) should be maintained throughout the treatment course in order to ensure desired efficacy.  
Pharmacokinetic/pharmacodynamic (PK/PD) modeling on the Phase 2 data of study OMS112831 suggested that a single dose o f ofatumumab 20 mg sc is insufficient to reduce B - 
cell levels to ≤ 8 cells/µL. A loading regimen of 3 separate 20 mg (at weeks 0, 1 and 2) was required  to attain  target  depletion (≤ 8 cells/µL)  in > 95% of patients  based  on modeling, and is 
extrapolated  to be more effective than a single 60 mg load.  In study OMS112831, patients  dosed 
with 60 mg q4 weeks  showed no signs of B-cell repletion  during the inter-dosing interval.  Based 
on PK/PD  modeling, 20 mg ofatumumab  appears  to be sufficient  to either  maintain  or to further 
deplete B -cells in > 95% of patients who have previously depleted, even in patients with high 
repletion  rates.  
High number of PK values below the lower limit of quantification (LLQ) did not allow for use 
of a full PK/PD modeling. For  this reason, a second modeling approach (K -PD) was used to 
relate the individual time-course of B- cells to the dosing history and patient  specific  covariates, 
taking the inter -patient variability into account. This approach also confirmed that the desired 
levels of B -cell depletion in nearly all patients can be attained through the described 
loading/maintenance dose  regimen.  
With regards to safety an d tolerability, the dose regimens of 60 mg q12 and q4 weeks were 
associated with more adverse events (AEs) than the lower dose regimens of [ADDRESS_736314] started repleting, systemic reactions are an expected AE and their severity is likely to be dose and B -cell count  related.  
With  regards  to repletion  of B- cells after discontinuation of ofatumumab, simulations  based  on 
a model developed using the data from the Phase 2 study (OMS112831) predict that the vast 
majority of patients will replete their B -cells within 9 months of follow -up. Based on these 
simulations it is estimated that around 5 months are needed to achieve  80% of repletion after 
treatment  discontinuation. 
Since relapsing MS is a chronic disease with anticipated long -ter
 m treatment, dose selection 
should therefore aim to balance efficacy and safety aspects. The ofatumumab subcutaneous 
loading dose regimen  of 20 mg at Day 1, Day 7 and Day 14, followed  by a monthly maintenance 
dose regimen of 20 mg administered every 4 weeks (starting at week 4) is selected because it will deplete and subsequently maintain B -cells at the levels below 8 cells/µL for nearly all 
patients  and it is expected  to have maximal  clinical benefit  and better  tolerability  than higher 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 30
0 Protocol No. 
  
 
doses.  Taken  together, the strong relationship  between  MRI  lesions and relapses  (Sormani et al. 
2009; Sormani et al. 2013 ) and the observed inhibition of lesions at the cumulative  doses tested, 
combined with maintaining B -cells below threshold support selection of the proposed dose 
regimen.  
 
Duration of treatment  
The treatment duration is variable for individual patients. Double -blind treatment will end for 
all patients  when  End of Study is declared  based  on reaching  a sufficient  amount of data for the 
primary endpoint (ARR) and disability worsening- related key secondary endpoint analyses 
(see Section  3.1). For an individual patient  the maximum treatment  duration will be 30 months, 
if the End of Study has not been reached  earlier.  
 
3.4 Rationale for choice of comparator 
The comparator used in this study is teriflunomide (Aubagio®). Teriflunomide is an oral, once 
daily  tablet  approved as a first line disease  modifying treatment  for patients  with relapsing  MS. 
It is approved at once daily doses of 14 mg in countries and regions worldwide including the 
[LOCATION_002] (US) and the European Union (EU). In the US, teriflunomide is additionally 
approved at a lower 7 mg dose. Since this study will be conducted globally, the dose of 14 mg 
will be used in this study. The efficacy  and safety  of teriflunomide  14 mg once daily  in reducing 
clinical  and MRI  disease  activity  and brain  volume loss in patients  with relapsing  MS has been 
demonstrated in Phase 3 clinical studie s (O’Connor et al. 2011; Confavreux et al. 2014;  
Freedman 2013; Radue et al.  2015).  
Oral administration increases compliance compared to treatments requiring frequent injections 
such as interferon -beta and glatiramer acetate. As an oral, once daily treatment, teriflunomide 
is becoming increasingly used as an alternative to these current i njectable first line therapi[INVESTIGATOR_014]. 
Furthermore, an once daily oral agent is preferred in a double -blind/double- dummy design as 
frequently injected comparators (e.g. interferon- beta) increases the difficulty of successful 
blinding, a critical element for the d esign of a successful trial.  
For these reasons, teriflunomide was selected as an appropriate agent to be used as active comparator in this study of ofatumumab in patients with relapsing MS.  
 
3.5 Purpose and timing of interim analyses/design adaptations 
No unblinding interim analysis for efficacy is planned for this study.  
 
3.5.1  Interim analysis for Data Monitoring Committee (DMC)  
Regular interim analyses for safety and for benefit/risk assessment will be performed for the DMC  by [CONTACT_560134]. The review will be done by [CONTACT_354042].  
 
3.5.2  Reviews of blinded study  data 
The purpose of blinded d ata reviews  by [CONTACT_560135]  (e.g. sample 
size, follow -up time) in order to maximize the efficiency of the study by [CONTACT_560136]. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 31
0 Protocol No. 
  
 
Reviews  of aggregate data (i.e. analysis  that consider all patients  as one group without revealing 
treatment  allocation)  do not pose a scientific  risk in terms  of bias or type-I- error  control and can 
be used to modify the sample size or follow up time if this is indicated by [CONTACT_560137].  
Blinded data in this study will be reviewed for:  
1. Sample size re- assessment: The initial sample size for this trial is planned as 900 
randomized patients. The sample size can be increased to a maximum of 1250 randomized 
patients following an analysis -based review of blinded relapse and disability data if the 
activity of the recruited patient is lower than initially anticipated. The blinded sample size re-assessment w ill be done prior to completion of enrollment  and  is  described  in  
Section  [IP_ADDRESS] . 
2. Declaration of End of Study: Patients are followed up for a flexible period of time (but for 
a maximum of 30 months) in this study. The  amount  of  information  (defined  in  
Section [IP_ADDRESS] ) for the primary ARR analysis, and the number of confirmed disability 
worsening will be monitored in the accumulating blinded data. End of study (as defined in 
Section [IP_ADDRESS]) will be declared when sufficient information has been captured to provide 
sufficient  power for the primary  and the key-secondary  objectives  of this study. End of study 
will be declared only once as described in Section  9.7.2 . 
 
3.6 Risks and  benefits 
The risk to subjects in this trial will be minimized by [CONTACT_560138], close clinical  monitoring, avoidance of prohibi ted treatments  and adherence to protocol contraception 
requirements and Investigator guidance regarding specific safety areas.  
Ofatumumab is approved for patients with chronic lymphocytic leukemia and is administered 
via iv infusion at doses up to 2000 mg.  Risks in this population include: infusion reactions, 
tumor lysis syndrome, cytopenia, progressive multifocal leukoencephalopathy (PML),  hepatitis 
B virus infection and reactivation, and bowel obstruction (please refer to Arzerra
® Prescribing 
Information). 
The experience with ofatumumab in MS patients to date is limited (approximately 267 RRMS 
patients in total exposed to ofatumumab iv (N=38) and sc (N=229) in 2 Phase 2 studies). No 
unexpected safety findings were observed to date. In the 48- week, placebo -controlled, cross - 
over study (cross -over at 24 weeks)  of intravenous doses of ofatumumab up to 700 mg, adverse 
events reported more frequently on ofatumumab vs placebo included: rash, throat irritation, 
erythema,  fatigue, viral infection  and flushing. In the placebo -controlled, dose-ranging study of 
ofatumumab administered  at sc doses up to 60 mg every  4 weeks for up to 24 weeks,  injection - 
related reactions were observed more frequently in the overall ofatumumab group. There may 
be yet unknown risks to MS patients  taking ofatumumab, which  may be serious and unforeseen. 
Ofatumumab sc has demonstrated profound suppression of MRI lesion activity (≥ 90% versus placebo over weeks 4 -12) in relapsing RRMS patients in the Phase 2 studies. Confirmation of 
clinical  efficacy  will be evaluated  in the present  study. The efficacy  of ocrelizumab,  another B- 
cell depleting compound on clinical and MRI disease activity has been reported in 2 Phase 3 trials in relapsing MS patients ( Hauser et al. 2015 ).
  Taken together, available information 
provides support f or the potential of ofatumumab to demonstrate efficacy on relevant clinical 
and MRI outcomes in patients with relapsing MS. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 32
0 Protocol No. 
  
 
The comparator, teriflunomide is approved for the treatment of relapsing MS. The risks of 
teriflunomide  in patien ts with relapsing  MS include:  elevated  liver enzymes  (especially  alanine 
aminotransferase (ALT)), infections, elevated blood pressure, respi[INVESTIGATOR_560088], hematological reactions, skin reactions, peripheral neuropathy and teratogenicity (please refer 
to the local product information for details). The efficacy of teriflunomide in reducing clinical 
(ARR and disability progression) and MRI disease activity as well as brain volume loss, has 
been demonstrated in Phase 3 clinical trials ( Confavreux et al. 2014; O’Connor et al. 2011;  
Freedman 2013; Radue et al.  2015).  
The inclusion of an active comparator arm ensures all patients in the study will receive active 
therapy (i.e. no placebo arm).  
Overall, the balance of benefit and risk supports the proposed clinical study to evaluate the potential of ofatumumab sc as an effective and safe therapy to address the medical need in the 
target population of patients with relapsing MS.  
 
[ADDRESS_736315]  of adult patients  with relapsing  MS fulfilling  all the eligibility 
criteria listed  below*. 
The study is planned to be conducted in approximately [ADDRESS_736316] to fulfill all of the following criteria:  
1. Written informed consent must be obtained before any assessment is  performed  
2. Male or female patients aged 18 to 55 years (inclusive) at  Screening  
3. Diagnosis of MS according to the 2010 Revised McDonald criteria ( Polman et al.  2011) 
4. Relapsing MS: relapsing- remitting course (RRMS), or secondary progressive (SPMS) 
course with disease activity, as defined by [CONTACT_188615]  2014  
5. Disability status at Screening with an EDSS score of 0 to 5.5  (inclusive) 
6. Documentation of at least: 1 relapse during the previous 1 year OR 2 relapses during the 
previous 2 years prior to Screening OR a positive Gd- enhancing MRI scan during the year 
prior to randomization. Note:  Screening  MRI scan may be used if no positive Gd-enhancing 
scan exist from prior  year.  
7. Neurologically stable within 1 month prior to  randomization 
 
4.2 Exclusion criteria 
Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No 
additional exclusions may be applied by [CONTACT_737], in order to ensure that the study 
population will be representative of all eligible patients.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 33
0 Protocol No. 
  
 
1. Patients s uspected of not being able or willing to cooperate or comply with study protocol 
requirements in the opi[INVESTIGATOR_14270] 
2. Patients  with primary  progressive MS (Polman  et al. 2011 ) or SPMS  without disease  activity 
(Lublin et al.  2014) 
3. Patients meeting criteria for neuromyelitis optica ( Wingerchuk et al.  2006 ) 
4. Disease duration of more than 10 years in patients with EDSS score of 2 or  less 
5. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female 
after conception and until the termination of gestation, confirmed by a positive hCG 
laboratory test. 
6. Women of child- bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception during 
dosing and for at least 12 months after stoppi[INVESTIGATOR_14930]. Given the long 
elimination time of teriflunomide of up to 2 years, women planning to become pregnant may undergo the accelerated elimination process (as per teriflunomide label) after the 12 - 
month period. Highly effective contraception methods  include: 
• Total  abstinence (when  this is in line with the preferred  and usual lifestyle  of the subject, 
if accepted by [CONTACT_18600]). Periodic abstinence (e.g., calendar, ovulation, 
symptothermal,  post-ovulation methods) and withdrawal  are not acceptable methods of 
contraception. 
• Female sterilization (have had surgical bilateral oophorectomy  with or without 
hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone,  only when  the reproductive status 
of the woman has been confirmed by [CONTACT_560139] 
• Male  partner  sterilization  (at least 6 months prior to Screening).  For female  patients  on 
the study, the vasectomized male partner should be the sole  partner. 
• 
 Use of oral (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterine device or intrauterine system or other 
forms  of hormonal contraception  that have comparable efficacy  (failure  rate < 1%),  for 
example hormone vaginal ring or transdermal  hormone contraception.  In case of use of 
oral contraception, women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of 
3 months before taking study  drug. 
Note:  Women  are considered  post-menopausal and not of child  bearing  potential if they 
have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical 
bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal 
ligation at least six weeks ago. In the case of oophorectomy alone, only when the 
reproductive status of the woman has been confirmed by [CONTACT_560140].  
7. Sexually active males, unless they agree to use a condom during active treatment. Male patients should not father a child in this period. Given the long elimination time of 
teriflunomide of up to 2 years, the male patient wishing to father a child during the study 
should discontinue study drug and undergo the accelerated  elimination  process  (refer to 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 34
0 Protocol No. 
  
 
Section 7.8 ). A condom is required to be used also by [CONTACT_560141] y drug via seminal fluid  
8. Patients with an active chronic disease (or stable but treated with immune therapy) of the 
immune  system  other than MS (e.g. rheumatoid arthritis,  scleroderma,  Sjögren’s syndrome, 
Crohn’s disease, ulcerative colitis, etc.) or with immunodeficiency syndrome (hereditary 
immune deficiency, drug- induced immune deficiency)  
9. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to test positive for HIV antibody at  Screening  
10. Patients with neurological findings consistent with PML or confirmed  PML  
11. Patients  at risk of developi[INVESTIGATOR_560089] (e.g. patients 
with known exposure to or history of syphilis or tuberculosis). Testing for syphilis and tuberculosis will be done at Screening unless such testing has been performed in the past 6 
months prior to Screening with documented negative result. Testing  should be done per 
local clinical practice (for syphilis e.g. by [CONTACT_560142] (RPR); for 
tuberculosis** e.g. skin test or blood test as per local  practice).  
NOTE:  The Investigator may consult with an infectious disease  expert  if e.g. test results  are 
unclear or there is suspi[INVESTIGATOR_538238]. If the infectious disease expert considers the test results false positive and not clinically relevant, the Investigator must 
document (in source data and as a comment in the electronic case report form (eCRF)) that 
the test results are considered false positive and may then randomize the  patient.  
12. Patients at risk of developi[INVESTIGATOR_21341]: Positive results at Screening  for serological  markers  for hepatitis  (H) A, B, C, and E indicating  acute or chronic 
infection: 
• anti-HA Immunoglobulin (Ig) M  (IgM) 
• HBs Ag and/or anti -HBc IgM and/or HB virus deoxyribonucleic acid (DNA)  
• anti-HBs negative and Anti -HBc positive 
• anti-HC IgG (if positive IgG, HCV -RNA  PCR  will be performed  and if negative,  patient 
can be randomized) 
• anti-HE IgM (if positive IgG and/or IgM,  perform  HE-RNA  PCR and if negative,  patient 
can be randomized) 
NOTE: If the Investigator suspects false positive hepatitis serology results, such as an 
antibody pattern  indicating  acute hepatitis  infection  but no corresponding elevated  liver 
enzymes  and no signs or symptoms of liver disease,  an infectious disease  expe rt may be 
consulted. If the infectious disease  expert  finds no evidence of acute  or chronic hepatitis 
infection  and considers the serology results  false  positive  and not clinically  relevant,  the 
Investigator must document (in source data and as a comment in the eCRF) that the serology results are considered false positive and may then randomize the  patient.  
13. Have received any live or live- at
 tenuated vaccines (including for varicella- zoster viru s or 
measles) within [ADDRESS_736317] been treated with any of the medications listed below (Note: no wash -out period is 
required in the case of prior treatment with interferon -β or glatiramer  acetate):  
Medication Exclusionary if used/used within required 
wash -out period  
Systemic cortico steroids, adrenocorticotropic 
hormone  30 days prior to Screening MRI scan  
Dimethyl fumarate  1 month prior to randomization  
Intravenous immunoglobulin, fingolimod, 
natalizumab (patients who have discontinued 
natalizumab in the 6 months prior to randomization should be evaluated to rule out 
PML)  2 months prior to randomization 
Daclizumab  4 months prior to randomization  
Teriflunomide 3.5 months prior to randomization or 1 month prior to randomization if patient undergoes AEP and has documented teriflunomide plasma level below 0.02 mg/L before randomization (if discontinued for reason related to safety or lack of efficacy, 
patient is not eligible, see below)  
Mildly to moderately 
immunosuppressive/chemotherapeutic 
medications (e.g. azathioprine, methotrexate)  6 months prior to randomization 
Highly immunosuppressive/chemotherapeutic medications (mitoxantrone, cyclophosphamide, cladribine)  
B-cell targeted therapi[INVESTIGATOR_560090], ocrelizumab  
Laquinimod  2 years prior to randomization 
Mitoxantrone (with evidence of cardiotoxicity 
following treatment or cumulative life- time 
dose > 60 mg/m2) 
Alemtuzumab 
Lymphoid irradiation; bone marrow 
transplantation 
Other strongly immunosuppressive treatments 
(with effects potentially lasting over 6 months) 
Ofatumumab 
Teriflunomide (if discontinued for reasons 
related to safety or lack of efficacy)  Any time  
15. Patients currently treated with or needing treatment with ch olestyramine (unless for 
accelerated teriflunomide elimination, Section 7.8 ) or leflunomide during the  study 
16. Use of other investigational drugs at the time of enrolment (Screening) or within the prior 
[ADDRESS_736318] has 
returned to baseline, whichever is  longer 
17. History of malignancy of any organ system (other than basal cell carcinoma, in situ 
squamous cell carcinoma of skin, or in situ carcinoma of cervix of the uterus that have been  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 36
0 Protocol No. 
  
 
radically treated e.g. completely excised with clear margins), within the past [ADDRESS_736319] the safety of the  patient:  
• History of, or current, significant cardiac disease including cardiac failure (NYHA 
functional class  II-IV), myocardial  infarction  (within  6 months), unstable angina (within 
6 months), transient ischemic attack (within 6 months), stroke, cardiac arrhythmias 
requiring treatment or uncontrolled arterial  hypertension 
• Concomitant clinically significant cardiac arrhythmias, e.g., sustained  ventricular 
tachycardia, and clinically significant second or third degree AV block without a 
pacemaker on Screening electrocardiogram  (ECG)  
• History of familial long QT syndrome or known family history of Torsades de  Pointe 
• History of or active severe res pi[INVESTIGATOR_3765], including Chronic Obstructive 
Pulmonary Disease, interstitial lung disease or pulmonary fibrosis 
• Patients with asthma requiring regular treatment with oral steroids 
• Severe hepatic impairment (Child -Pugh class C) or any chronic liver or biliary disease  
• Patients  with severe renal  impairment (Glomerular  Filtration  Rate < 30 ml/min/1.73  m2) 
• Any medically unstable condition as determined by [CONTACT_16032] 
19. Any of the following abnormal laboratory values prior to  randomization: 
• Total or conjugated bilirubin (BIL) greater than 1.5 times upper limit of normal (ULN) range, unless in the context of Gilbert’s  syndrome 
• Alkaline phosphatase (ALP) greater than 1.[ADDRESS_736320]  range 
• AST  or ALT greater  than 1.[ADDRESS_736321]  or gamma -glutamyl- transferase (GGT)  greater 
than [ADDRESS_736322]  range 
• White blood cell (WBC) count < 3,500/mm3 (< 3.5 x 10
9/L) 
• Lymphocyte count < 800/mm3 (< 0.8 x  109/L) 
• Serum IgG and/or serum IgM < lower limit of normal (according to central laboratory range)  
• Any other clinically  significant laboratory assessment  as determined  by [CONTACT_737] 
(e.g. significant anemia,  neutropenia, thrombocytopenia, signs of impaired  bone marrow 
function) 
20. Patients with severe hypoproteinaemia e.g. in nephrotic  syndrome 
21. Patients with any of the following neurologic/psychiatric disorders prior to  randomization: 
• Score “yes” on item 4 or item 5 of the Suicidal  Ideation  section  of the Columbia - Suicide 
Severity  Rating  Scale (C-SSRS),  if this ideation  occurred  in the past 6 months, or “yes” 
on any item of the Suicidal Behavior section, except for the “Non- Suicidal  Self- 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 37
0 Protocol No. 
  
 
Injurious Behavior” (item also included in the Suicidal Behavior section), if this 
behavior occurred in the past 2 years  
• Ongoing substance abuse (drug or alcohol) or any other factor (i.e. serious psychiatric 
condition, recurrent substance abuse) that may interfere with the subject’s ability to 
cooperate and comply with the study procedures  
• History  of clinically  significant CNS  disease  (e.g. stroke, traumatic  brain or spi[INVESTIGATOR_342220], 
history or presence of myelopathy) or neurological disorders which may mimi c MS 
22. Patients unable or unwilling to undergo MRI  scans  
23. History  of hypersensitivity to any of the study drugs or excipi[INVESTIGATOR_840]  (including rare hereditary 
problems of galactose intolerance, Lapp lactase deficiency and glucose- galactose 
malabsorption) or to drugs of similar chemical  classes  
Note: If a patient fails on one or more laboratory (or other) assessment criteria, as part of the Screening p rocess, the assessment(s) may be repeated at the discretion of the Investigator, and 
the patient may be included if criteria are then met, provided the assessments are completed within the Screening or Baseline time window.  
*If additional restrictions  and/or assessments are required in order  to comply with the local  legal 
(e.g. in regards to a higher legal age for study participation) or regulatory (e.g. in regards to 
compliance with local prescribing informations) requirements, the local r equirements must be 
followed. 
** For sites that don’t have the possibility to test tuberculosis locally, Quantiferon®- TB Gold 
test may be requested to be done by [CONTACT_560115]'s eligibility.  
 
5 Treatment  
5.1 Study treatment 
5.1.1  Investigati onal and control  drugs  
Investigational drug will be provided in pre -filled syringes for subcutaneous administration 
containing 20 mg ofatumumab  (50 mg/ml,  0.4 ml content). Ofatumumab  (OMB157) is clear  to 
opalescent, colorless to pale yellow, essentially pa rticle -free liquid in a pre -filled syringe. The 
matching placebo to ofatumumab pre -filled syringe will have the same appearance as the 
investigational drug. 
Control treatment, teriflunomide (Aubagio®) 14 mg, will be provided as over -encapsulated 
tablets (either a hard gelatin capsule or a hydroxy propyl methyl cellulose (vegetarian- based) 
capsule will be used, referred to as capsule hereafter) for oral administration. Teriflunomide- 
matching  placebo  capsule (capsule containing placebo -tablet)  will have the same  appearance as 
the active comparator. Teriflunomide and teriflunomide -matching placebo capsules will be 
provided in blisters.  It is possible that a switch  from  blisters  to bottles  will be perform ed during 
the course of the  study. 
Study drug will be supplied by [CONTACT_5343].  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 38
0 Protocol No. 
  
 
5.1.2  Additional  treatment  
No additional treatment beyond investigational drug and comparator drug are provided as part 
of study drug supplies for this study.  
 
5.2 Treatment arms 
The study includes 2 treatment arms:  
• Ofatumumab arm: ofatumumab 20 mg sc injections on Day 1, 7, 14, Week 4 (Study Month 1) and every  4 weeks  thereafter  + teriflunomide -matching  placebo  capsule orally 
once daily. 
• Teriflunomide arm: teriflunomide 14 mg capsule orally once daily + ofatumumab- matching  placebo  injections  on Day 1, 7, 14, Week  4 (Study Month 1) and every  4 weeks 
thereafter.  
 
5.3 Treatment assignment and randomization 
Eligible  patients  will be randomized  in a 1:1 ratio to either  the active ofatumumab  20 mg group 
or to the active  teriflunomide  14 mg group. The randomization  will be stratified  by [CONTACT_560143] (RRMS, SPMS). Study sites can only participate in one of the 2 
studies to ensure independence of each study. 
On Day 1 (randomization visit), all eligible patients will be randomized via Interactive Response Technology (IRT) to one of the treatment arms. The Investigator or his/her delegate 
will contact  [CONTACT_560144]/exclusion criteria. 
The IRT will assign  a randomization number to the patient,  which  will be used to link the patient 
to a treatment arm and will specify a unique medication number for the first package of 
investigational treatment to be dispensed to the patient. The randomization number will not be 
communicated to the  caller.  
The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from patients and Investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validated  system  that automates 
the random assignment of patient numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication 
numbers. A separate medication  list will be produced by [CONTACT_560145] a validated system that automates the random assignment of medication numbers to packs containing the investigational drug(s).  
 
5.4 Treatment blinding 
This study will be conducted using a double -blind, double -dummy design.  Patients will be 
assigned to receive either active ofatumumab (plus teriflunomide -matching placebo) or active 
teriflunomide (plus ofatumumab- matching placebo) as described in Section 5.2 . 
A double -dummy design is used because the identity of the study drug cannot be disguised, as 
the drug products utilize different formulations.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 39
0 Protocol No. 
  
 
Patients, Investigator staff, persons performing the assessments, and data analysts will remain 
blinded to the identity  of the treatment  from  the time of randomization until database lock, using 
the following methods: (1) Randomization data are kept strictly confidential until the time of unblinding, and will not be accessible by [CONTACT_560146]: Data Monitoring Committee (DMC) members, Independent Statisticians and 
Independent Programmers. (2) The identity of the treatments will be concealed by [CONTACT_560147], labeling, schedule of administration, 
appearance, taste and  odor. 
The randomization codes associated with PK samples will be disclosed to the Bioanalysts who 
will keep PK and ADA results confidential until data base lock.  
The following measures will be taken to protect the blinding of the Independent EDSS Rater (Rater):  
• Prohibited access to patients’ study data 
• Separate binders of worksheets and CRF materials for Investigator and the  Rater  
• Prohibited cross -over of Investigator and Rater  
• Use of appropriate clothing by [CONTACT_560148]  
• Limited interactions between Rater and patient: permitting only a minimum required to perform the EDSS  rating.  
Additionally, potentially unblinding laboratory parameters (e.g. B -cell counts, teriflunomide 
plasma level results) will no t be communicated to the Investigator or other study staff as 
described in Section 3.1 and Section 6.5.4 . 
Unblinding will only occur in the case of patient emergencies (see Section 5.5.9 ) and at the 
conclusion of the core study.  
 
5.5 Treating the patient 
Sponsor qualified  medical  personnel will be readily  available to advise the Investigator on trial 
related medical questions or  problems. 
 
5.5.1  Patient numbering  
Each patient is uniquely identified by a Patient Number which is composed by [CONTACT_560149] a sequential  number assigned  by [CONTACT_737] (as described  below). 
Once assigned to a patient, the Subject Number will not be  reused.  
If an enrolled  patient  fails to be randomized  or treated  for any reason,  the reason  will be entered 
on the Screening Study Disposition CRF. If the patient is re -screened later on, a new Patient 
Number will be assigned; site will capture  the re-screening  information  in the CRF book. Upon 
signing the informed consent form, the patient is assigned the next sequential number by [CONTACT_3786]. The Investigator or his/her staff will contact [CONTACT_560150]. At each site, the first patient 
is assigned patient number 1, and subsequent patients/subjects are assigned consecutive numbers (e.g. the second patient is assigned patient number 2; the third patient is assigned 
patient  number 3). The Investigator or his/her staff will contact  [CONTACT_560151] v02 Clean  Confidential  Page [ADDRESS_736323] Number from the electronic data capture (EDC) system to enter data.  
If the patient fails to be treated for any reason, the IRT must be notified within 2 days that the patient  was not treated.  The reason  for not being treated  will be entered  on the Screening  epoch 
Study Disposition CRF.  
 
5.5.2  Dispensing the study  drug  
Each study site will be supplied with study drug in packaging of identical appearance.  
The study drug packaging has a 2- part label. A unique medication number is print ed on each 
part of this label which corresponds to one of the 2 treatment arms and a specific visit. Investigator staff will identify the study drug package(s)  to dispense to the patient  by [CONTACT_37246](s). Immediately before dispensing the package to the patient, Investigator staff will detach the outer part of the label from the packaging and 
affix it to the source document (Drug Label Form) for that patient's unique subject  number. 
 
5.5.3  Handling of study and additional  treatment  
 
[IP_ADDRESS]  Handling of study  treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely  and properly, and kept in a secured  location  to which  only the Investigator and designees 
have access. Upon receipt, all study treatment must be stored according to the instructions 
specified on the labels. Clinical supplies are to be dispensed only in accordance with the 
protocol. Technical complaints are to be reported to the respective Sponsor local Quality 
Assurance  contact.  
Medication  labels  will be in the local  language and comply with the legal  requirements  of each 
country. They will include storage conditions for the study treatment but no information about 
the patient except f or the medication  number. 
The Investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by 
[CONTACT_30798]. Patients/subjects will 
be asked to return all unused study treatment and packaging at the end of the study or at the 
time of discontinuation of study treatment.  
At the conclusion of the study, and as appropriate during the course of the study, the Investigator 
will return  all unused study treatment,  packaging, drug labels,  and a copy of the completed  drug 
accountability  log to the Sponsor monitor or to the Sponsor address  provided in the Investigator 
folder at each  site. 
 
5.5.4  Instructions for prescribing and taking study  treatment  
The study medication (ofatumumab injections + teriflunomide -matching placebo containing 
capsules  or teriflunomide  containing capsules  + ofatumumab- matching  placebo  injections)  will 
be dispensed starting at the Randomization Visit (Day 1). Drug will then be dispensed at 
scheduled visits throughout the treatment period according to Table 6-1.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736324] 4 weeks after randomizatio n, patients will receive 4 sc injections of ofatumumab or 
matching placebo (on Day 1, Day 7, Day 14 (loading dose regimen) and week 4 (study Month 
1)), followed by [CONTACT_560152] (every 4 weeks) sc injections (maintenance dose regimen). 
Injection volume is 0.[ADDRESS_736325] sc injection on site administered by 
[CONTACT_5984] (e.g. Investigator, Study Nurse/Study Coordinator) and will return to the site on 
Day 7, Day 14 and week  4 (study Month 1) for sc self-injections  under supervision of the study 
staff . Site personnel will provide training to the patients on the correct procedure for self - 
administration of the sc injections. Ability to self -administer must be demonstrated and 
documented before home -administration is permitted after  Month 1. If a patient is 
unable/unwilling to self -administer injections, home -administration may be performed by 
[CONTACT_560153] (e.g. partner,  relative  or a healthcare professional) who has accompanied  the 
patient to the site and has been trained on and demonstrated ability to correctly administer the 
sc injections. The patient may also continue to have injections administered at the site if this is the patient's preference. Patients with severe neurolog ical deficits should not self -administer 
injections.  
A patient injection instructions leaflet will be provided which includes detailed information, precautions and instructions for administering sc injections. This information should be 
reviewed with the p atient (and his/her partner/relative as applicable) to ensure that they 
understand the correct procedure for self/home administration.  
Capsules (teriflunomide or matching  placebo)  must  be taken  orally  once a day, preferably  at the 
same time every day, with  or without food and should be swallowed whole. The first capsule 
on Day 1 will be taken on site under the supervision of the study staff (e.g. Study Nurse/Study 
Coordinator). 
In order  to assess tolerability  of the initial dose of study medication  (injecta ble + oral),  patients 
will be closely  monitored following administration  for any reactions  including injection  related. 
Patients must remain at the site under observation for a minimum of approximately 5 hours 
following dosing on Day 1. 
On Day 7 and Day 14, the same time -window (+/ - 1 day) as for study visit applies. Starting at 
week 4, the subcutaneous injections should be administered at 4- week (28 days) intervals (+/ - 
3 days). Injections may not be advanced by [CONTACT_726] [ADDRESS_736326] any missed doses in the patient diary provided for the study and to inform the study 
staff of any missed sc injection(s). This can be done at the visits and/or during the monthly 
structured telephone interviews (according to the script provided to the sites for the study) 
during which the study site staff will inquire about the patient's status and  compliance with 
study drug administration or issues related to the home administration.  
Patients,  who miss sc injections  or temporarily  interrupt study drug without discontinuing from 
the study or withdrawing consent, will be permitted to resume study drug if determine to be safe and appropriate in the opi[INVESTIGATOR_689]. When resuming study drug, the timing 
of the next sc injection  will be determined  based  on the original study schedule as followed: 
• If one monthly injection  is missed  by 1 week  or less, the patient  should take the injection 
as soon as possible. The next injection should then be administered according to the original schedule.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 42
0 Protocol No. 
  
 
• If one monthly  injection  in missed  by [CONTACT_726] 1 week,  the patient  should skip the dose 
and take the next dose at the time when  the next injection  would be due according  to the 
original schedule.  
• If 2 or more consecutive monthly injections are missed, the Investigator should inform 
the local Sponsor Medical Advisor before re -starting dosing. Missed injection syringes 
should not be used and returned to the site at the next  visit.  
If a patient misses  any daily capsules, daily dosing should be resumed as soon as possible (i.e. 
patients should not compensate for a missed dose by [CONTACT_560154]).  The patient  should be instructed  to record  any missed  doses in the patient  diary provided 
for the study and to inform the study staff at the next visit or during the monthly telephone interview of any missed doses. The patient should be instructed to return any missed doses. If 
more than 3 consecutive months are missed,  resumption of oral dosing should only be initiated 
if it is determined to be safe and appropriate in opi[INVESTIGATOR_14270]. 
All kits of study medication assigned by [CONTACT_560155].  
All dosages prescribed to the patient and all dose interruptions/changes during the study must be recorded on the Dosage Administration Record eCRF.  
The Investigator must  promote compliance by [CONTACT_560156]'s 
safety and the validity of the study. The patient must also be instructed to contact [CONTACT_560157]/she is unable for any reason to take the study treatment as prescribed. 
The patients will record information concerning their home study drug administrations in a diary provided for the study. The information to be recorded includes date and ti me of each sc 
injection and any symptoms related to the administration as well as any missed doses of study drug. The Investigator will review the diary with the patient at each visit and record the 
information on the relevant eCRFs.  
 
5.5.[ADDRESS_736327] ments and interruptions of study  treatment  
Study treatment  dose adjustments  are not permitted  during the study. Interruptions are permitted 
if clinically  indicated.  
Conditions/events that may lead to the study drug interruptions based on Investigator judgment 
and overall clinical assessment include:  
• reported serious adverse  event;  
• emergency medical condition, unplanned hospi[INVESTIGATOR_059], involving use of excluded 
concom itant medications; 
• abnormal laboratory value(s) or abnormal test or examination result(s)  
Should the patient interrupt the study drug for whatever reason, both sc and oral study medication  must  be interrupted. Re-start decision  should be made on a case-by- case basis (refer 
also to Section  5.5.4 ). Should the Investigator decide,  after informing the Sponsor, to re-initiate 
treatment with study drug, depending on the duration of the interruption, the first sc and oral 
dose at re-start may need  to take place at the study site to ensure observation in a similar  manner 
as on Day  1. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736328] eCRF.  
 
5.5.6  Recommendations for the treatment of MS  relapses  
The decision  to treat MS relapses  should be based  on the Investigator’s judgement and or local 
clinical practices. If MS relapses require treatment, the standard treatment should consist of a short course of corticosteroids of 3- 5 days and up to 1,000 mg methylprednisolone/day or  
equivalent on an impatient or outpatient basis. Standard of care will be followed during treatment.  
Taper with oral steroids is not permitted. Plasmaspheresis may be used if subject does not respond to standard treatment with corticosteroids.  
Investigator s should consider the added immunosuppressive effects of corticosteroid therapy 
and increase vigilance regarding infections during such treatment and in the weeks following 
administration.  
Use of steroids for treatment of relapse must be recorded on the Prior or Concomitant medications eCRF.  
 
5.5.[ADDRESS_736329] the patient to notify the study site about any new medications he/she takes after the patient was enrolled into the study. All medications (including dose changes), procedures and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and blood 
transfusions) administered after the patient was enrolled into the study must be recorded in the concomitant medications / surgical and medical procedures  CRF.  
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited medication. If in doubt the Investigator should contact [CONTACT_560158] a patient or allowing a new medication to be  started.  
If a patient is receiving dalfampridine (Ampyra
®) concomitantly with study drug, the patient 
should remain as far as possible on stable dose throughout the Treatment epoch.  
Based on the double -blinded design, the Investigator will need to consider the drug interaction 
potential of teriflunomide when study drug is co- administered with certain classes of drugs 
(refer to list of drugs and potential interactions in Appendix 4).  
 
Premedication prior to sc injection  
Premedication with acetaminophen and/or antihistamines (or equivalent) is recommended and 
may be administered at the discretion of the Investigator. For the first injection only, the 
addition of premedication with steroids (methylprednisolone 100 mg iv or equivalent) is recommended. Premedication should be administered [ADDRESS_736330] be recorded in the Prior and Concomitant 
medications CRF.  
Additional information in regards to premedication for home -administration use: 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 44
0 Protocol No. 
  
 
From Month 2 (5th injection) onwards, patients may inject study medication at home (refer to 
Section 5.5.4). Use of premedication is at the discretion of the Investigator. Based on the 
experience with the initial 4 injections administered at the site and with the use of any 
premedication, the Investigator will evaluate whether or not premedication (such as 
acetaminophen and/or antihistamines) should be used before injections administered at home. 
If premedication is prescribed, the study staff  must ensure that the patient will receive a 
sufficient  supply of premedication  for home- use (i.e. to last at least until the next visit)  and clear 
instructions (oral and written) about type and dose of premedication, and when to take it (i.e. 
30-60 minutes before the injection). The Investigator will evaluate the need for premedication, 
or a change in the prescription, at each visit (scheduled and unscheduled) including at the monthly telephone interview appointments (interview script includes specific questions about 
any injection- related symptoms and the use of premedication). If, based on the telephone 
interview, a change in premedication may be needed, the patient should be asked to return to 
the site for an unscheduled visit.  
The patients must be comprehensively informed (through the patient information and consent process) about the possibility that injection- related reactions may occur despi[INVESTIGATOR_560091]- 
medications and about the possible symptoms of a systemic injection reaction and their management . The patients  will additionally receive  an injection  instructions leaflet  (Instructions 
for Home administration and Use) which also includes information about such reactions, their management as well as Investigator/site contact [CONTACT_15750]. Furthermore, patients must be 
reminded to always carry their Patient Card which includes the Investigator and site telephone 
contact [CONTACT_560159].  
 
5.5.8  Prohibited medication  
Use of the treatments displayed in Table 5 -1 is NOT allowed in combination with study 
treatment,  due to increased  risk of immunosuppression and confounding of efficacy  evaluations. 
Exclusionary medications for study eligibility are listed in the exclusion criter ia (Section 4.2). 
Use of excluded medications is not allowed after randomization while the patient is on study 
medication.  
 
Table  5-1 Prohibited  medication  
 
Medication  Additional action to be taken  
Immunosuppressive/chemotherapeutic 
medications (including herbal) or procedures, 
including but not limited to cyclosporine, 
azathioprine, methotrexate, cyclophosphamide, 
mitoxantrone, lymphoid irradiation and hematopoietic stem cell transplantation Discont inue study treatment, increase vigilance 
regarding infections.  
 
NOTE: Restarting study treatment in patients exposed to these medications is not permitted.  
Monoclonal antibodies targeting the immune 
system, including but not limited to natalizumab, 
alemtuzumab, daclizumab and B -cell depleting 
agents such as but not limited to rituximab, ocrelizumab and obinutuzumab  Discontinue study treatment, increase vigilance regarding infections.  
 
NOTE: Restarting study treatment after exposure to B-cell depleting agents is not permitted. For 
others only after consultation with the Sponsor 
Medical Advisor.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 45
0 Protocol No. 
  
 
Medication  Additional action to be taken  
Any other immunomodulatory or disease - 
modifying MS treatment, including but not limited 
to fingolimod, interferon beta, glatiramer acetate, 
dimethyl fumarate  Discontinue study treatment, increase vigilance 
regarding infections.  
Systemic corticosteroids (except for when given 
for MS relapse treatment as defined in Section 
5.5.6 ). Interrupt study treatment, increase vigilance regarding infections.  
Leflunomide  Discontinue study treatment  
Administration of any live or live-attenuated vaccine (including for measles) is prohibited while patients are exposed to study drug (long-lasting effects of the study drugs should be taken into consideration)  They may be administered when patients are no longer exposed to study drug. Consider risk/benefit and follow local labels  
 
5.5.[ADDRESS_736331] often, study treatme nt discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study patient who presents with an emergency 
condition. Emergency treatment code breaks are performed using the IRT. When the 
Investigator contacts  the system  to break  a treatment  code for a patient,  he/she must  provide the 
requested  patient  identifying  information  and confirm the necessity  to break  the treatment  code 
for the patient. The Investigator will then receive details of the investigational drug treatment 
for the specified patient and a fax or email confirming this information. The system will 
automatically inform the Sponsor monitor for the site and the Study Team that the code has 
been  broken. 
It is the Investigator’s responsibility to ensure that there is a dependable procedure in place to 
allow access to the IRT at any time in case of emergency. The Investigator will provide:  
• protocol number 
• study drug name  
• patient  number 
In addition, oral and written information to the patient must be provided on how to contact [CONTACT_737]’s backup in cases  of emergency,  or when  the Investigator is unavailable,  to ensure 
that un- blinding can be performed at any  time.  
After an emergency treatment code break, the patient should discontinue study drug and 
continue to be followed in the study Treatment epoch ( Table 6 -1) or in the Safety Fo llow-up 
(Table 6 -2) (if the patient does not agree to be followed under Table 6 -1). If the patient does 
not agree to stay in the study, the EOS Visit should be competed.  
 
5.[ADDRESS_736332] -study  treatment  
A patient  has completed  the core study when  the patient has completed  the End of Study (EOS) 
visit of the double -blind core study Treatment  epoch.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 46
0 Protocol No. 
  
 
The core study is completed  for all patients  when  EOS  is declared  for the study as described  in 
Section  3.1. 
Patients, who complete the core study ( Table 6 -1) on study drug, may be eligible for inclusion 
in the planned Extension study (under separate protocol).  
Patients who complete the core study on study drug and do not enter the Extension study will 
enter the Safety Follow -up period ( Table 6 -2) for continued follow up.  
Patients who prematurely discontinue study drug and either a) complete the core study Treatment epoch off study drug but have less than 9 months of follow up after study drug 
discontinuation, or b) do not agree to complete the Treatment epoch, will enter the Safety 
Follow- up period ( Table 6 -2) for continued follow up.  
The Safety Follow -up is complete when all patients who entered have been followed for the 
stipulated period of time or have withdrawn participation prematurely.  
The Investigator must provide follow -up medical care for all patients who are prematurely 
withdrawn from the study, or must refer them for appropriate ongoing care.  
 
5.6.[ADDRESS_736333] discontinue study treatment for a given pat ient if, on balance, he/she 
believes that continuation would negatively impact the risk/benefit of trial participation.  
Discontinuation of study treatment does not mean discontinuation from study. After stoppi[INVESTIGATOR_56220],  the patient  is encouraged  to return  for all regular  visits  as detailed  in the schedule 
of assessments ( Table 6 -1). The patient should return to the clinic as soon as possible, after 
discontinuation of study drug, for an end of treatment visit (EOT).  EOT  visit assessments should 
be completed and results recorded in the CRF. The Investigator must determine the primary reason  for the patient's premature discontinuation of study treatment  and record  this information 
on the appropriate  CRF.  
Study treatment must be permanently discontinued under the following circumstances:  
• Patient wish (withdrawal of consent Section  5.6.3 ) 
• Pregnancy (see Section 6.5.6  and Section  7.6) 
• Use of prohibited treatment ( Table  5-1)  
• Diagnosis of  PML  
• Patient  with active serious infections or reactivation  (e.g. tuberculosis, hepatitis  B or C) 
• Skin and /or mucosal reactions which raise the suspi[INVESTIGATOR_560092] (Stevens -Johnson syndrome, or toxic epi[INVESTIGATOR_194] -Lyell’s 
syndrome) 
• Hypersen sitivity to the study  medication  
• Any situation in which study participation might result in a safety risk to the  patient  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 47
0 Protocol No. 
  
 
• Protocol violation that results in a significant risk to the patient's  safety  
• Emergence of certain adverse events, such as malignancy (except successfully treated 
basal  cell carcinoma,  in situ squamous cell carcinoma and in situ carcinoma of cervix  of 
uterus), liver failure or, serious chronic infection (such as  HIV)  
• Laboratory abnormalities (e.g. liver function tests (LFT)) and abnormal test procedure as defined in Appendix 1  
• Severe hypoproteinemia 
• Interstitial lung disease or new onset or worsening of pulmonary symptoms, such as persistent  cough and dyspnea, with or without associated  fever,  suspi[INVESTIGATOR_188600]  
• Non-compliance with study treatment  
Study treatment discontinuation should be considered under the following circumstance:  
• For patients who meet the criterion for 6- month confirmed disability worsening on EDSS 
(see definition in Section [IP_ADDRESS].1 ) during the study, the benefits and risks of continuing 
study treatment must be reassessed by [CONTACT_737]. The Investigator will also discuss the further treatment with the patient, including any other MS treatment options that may be available to the patient. The outcome of the discussion with the patient must be 
documented in the patient's  file. 
• In case the Investigator deems the benefit -risk of continuing study treatment to be 
unfavorable or if the patient does not wish to continue the study treatment, the patient will 
be discontinued from study treatment and continues to follow the schedule of assessments 
(Table  6-1 and/or Table  6-2 as applicable).  The Investigator will be notified  by [CONTACT_560160] a patient meets the criterion for 6 -month confirmed disability  worsening. 
 
If the patient cannot attend any further study visit(s), the site staff should maintain regular 
telephone contact [CONTACT_10970], or with a person pre -designated by [CONTACT_102], unless the 
patient has withdrawn informed consent (see Section 5.6.3). This telephone contact [CONTACT_6636].  
The Investigator must also contact [CONTACT_105253]'s discontinuation from study treatment.  
After discontinuation of study drug, the patient may undergo the teriflunomide accelerated elimination procedure ( Section 7.8) if the Investigator deems this to be indicated.  
If study drug discontinuation occurs because treatment code has been broken, please refer to Section 5.5.9. 
Note:  Patients  who discontinue from  study drug, but agree to follow in the assessment  schedule 
should have an EOT evaluation at the time of discontinuation from study drug. Every patient 
will have an EOS assessment when discontinuing from the study. Follow -up in the Safety 
follow-up epoch  (Table 6-2) may be required  after EOS  if patients  have not had at least [ADDRESS_736334] dose of study  drug. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 48
0 Protocol No. 
  
 
The Investigator should consider the benefit/risk  of initiation  of alternative  MS therapy  in terms 
of the patient's clinical status, local regulations, treatment guidelines and local prescribing 
information. In some cases, as described below, information on the patient's circulating B -cell 
status may be requested if in the Investigator's opi[INVESTIGATOR_1649] t his is needed to ensure safe switch to 
another MS  therapy. 
The duration of the washout period after last dose of study drug will depend on the type of therapy to be initiated and the patient’s clinical status: 
• A washout period of at least 5 months is recommended before initiation of lymphocyte 
depleting/suppressing/trafficking blocking agents (e.g. alemtuzumab, fingolimod, 
natalizumab, etc.). This is in line with the teriflunomide product information (at least 3.5 
months washout in absence of accelerated el imination) and the expected circulating B -cell 
repletion course after ofatumumab discontinuation (estimated around 5 months needed for 80% repletion; see protocol Section  3.3) 
• If, in the opi[INVESTIGATOR_689], the safe initiation of another therapy cannot be considered without the patient's B -cell status, the Investigator must submit a request to 
[COMPANY_001] in writing.  The request  of B- cell status  must  be justified  based  on clinical  grounds. 
The Investigator must ensure data entry is complete for any such patients. The Investigator will be notified of whether or not the patient has B -cell counts at or above lower limit of 
normal or baseline values, whichever is lower.  
The detailed procedure fo r requesting and receiving the information on a patient's B -cell 
status will be provided separately.  
The patients  should be encouraged  to stay in the study  and continue to follow the procedures 
and assessment schedule as specified in the  protocol. 
 
5.6.[ADDRESS_736335]:  
 
• Does not want to participate in the study anymore,  and 
• Does not allow further collection of personal  data 
In this situation,  the Investigator should make  a reasonable effort  (e.g. telephone, e- mail,  letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and record this  information.  
Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_201077] -up. 
All efforts should be made to complete the assessments prior to study withdrawal. A final evaluation (EOS) at the time of the subject’s study withdrawal should be made as detailed in 
the schedule of assessments ( Table 6 -1). 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 49
0 Protocol No. 
  
 
[COMPANY_001]/Sponsor will continue to keep  and use collected  study information  (including any data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law. 
 
For US: All biological samples  not yet analyzed  at the time of withdrawal  may still be used for 
further testing/analysis  in accordance with the terms  of this protocol and of the informed  consent 
form.  
 
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no longer be used, unless permitted  by [CONTACT_61285]. They  will be stored according  to applicable 
legal  requirements.  
 
5.6.4  Loss to  follow -up 
For patients whose status is unclear because they fail to appear for study visits without stating an intention to discontinue or withdraw, the Investigator should show "due diligence" by 
[CONTACT_560161],  e.g. dates  of telephone 
calls, registered letters, etc. A patient cannot be considered as lost to follow -up until the time 
point of his/her scheduled End of Study visit has  passed.  
 
5.6.5  Early study termination by [CONTACT_560162]. This may include 
reasons related to the benefit risk assessment of participating in the study, practical reasons, or for regulatory or medical reasons (including slow enrolment). Should this be necessary, the 
patient must be seen as soon as possible and treated as a prematurely withdrawn patient. The 
Investigator may be informed of additional procedures to be followed in order to ensure that 
adequa te consideration is given to the protection  of the patient's interests.  The Investigator will 
be responsible for informing the Institutional Review Board/Independent Ethics Committee (IRBs/IECs) of the early termination of the  trial. 
 
5.6.6  Role of Key site pers onnel  
Key site personnel include (but are not limited to) the following individuals:  
 
Investigator  
The Investigator will be responsible for:  
• Overall conduct of the study at the study site including assigning per protocol required 
study staff 
• Management of the routine clinical care of the study patients  
• Administration  and supervision of initial  sc injections  and training/supervision of ability 
to self/home -administer. The Investigator may delegate this responsibility to the Study 
Nurse/Study Coordinator as appropriate and permissible by [CONTACT_560163] 
• Confirmation of patient's eligibility for  randomization 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 50
0 Protocol No. 
  
 
• Administration of T25FW, 9HPT and SDMT (may be delegated to the Independent 
EDSS rater, a back -up physician, a Study Nurse/Study Coordinator or other 
accordingly experienced medical  professionals) 
• Referral of patients with neurological symptoms consistent with MS relapse to the Independent EDSS Rater  
• Management of adverse events and MS  relapses  
• Review of patient  diaries  
• Ensuring that all site personnel are informed of concomitant medications excluded per protocol (e.g. the use of systemic  steroids other than for the treatment  of MS relapses  or 
as pre -medication before  injection)  
It is strongly recommended  that the Investigator remain  unchanged throughout the entire  course 
of the study. Occasionally, the Investigator may designate other medical personnel/health care professionals (other than the Independent EDSS Rater, e.g., a back- up physician or Study 
Nurse/Study Coordinator) at the study site to perform some of the tests and evaluations listed above. The Investigator is also responsible for ensuring access to appropriate expertise for 
consultation (e.g. infectious disease, ECG interpretation, mental health care) du ring the study 
as needed.  
Independent EDSS Rater  
The Independent EDSS Rater will be responsible for:  
• Obtaining an EDSS score based on detailed neurological examination of patients with 
neurological symptoms consistent with MS relapse as referred by [CONTACT_560164]  
• Obtaining an EDSS  score  based  on detailed  neurological  examination  at scheduled  visits  
• Administration of T25FW, 9HPT and SDMT if delegated by [CONTACT_560165] a physician, or other trained healthcare professional who is qualified  to perform the neurological examination  and has been  trained  and certified  as an EDSS 
rater.  
The Independent EDSS Rater must not be involved in any other aspect of the patient's care 
and/or management of his/her MS treatment and have no access to patient study data.  
To ensure consistency in the EDSS scoring across Raters, the Independent EDSS Rater must participate in the standardized training and certification session on EDSS scoring (unless 
already certified at required level (highest level) in past 12 months) prior  to enrollment of 
patients at their site and will need to obtain recertification on a yearly basis. The Independent EDSS Rater should remain the same throughout the study, whenever possible.  
The communication of new neurological findings on the neurological examination, including the EDSS score, from the Independent EDSS Rater to the Investigator is not permitted after 
Randomization. The roles of the Investigator and the Independent EDSS Rater, including their 
back -ups, are not interchangeable. The Independent EDSS Rater must remain blinded to  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736336] the 
potential of revealing the treatment assignment.  
The patient and his/her caregiver should be instructed to ta ke care not to discuss aspects of the 
patient's treatment or potential AEs, including injection site reactions, with the Independent 
EDSS Rater. During the examination, the patient should wear appropriate clothing that covers 
injection sites.  
 
Study Nurse/Study Coordinator  
The Study Nurse/Study Coordinator’s responsibilities may include:  
• Assisting the Investigator in patient management, including the assessment and 
treatment of adverse events, MS relapses and the recording of adverse events, 
concomitant med ications and monitoring of compliance (returned capsule and syringe 
counts) 
• Administration and supervision of initial injections and training/supervision of ability 
to self/home -administer as delegated by [CONTACT_16032] 
• Administration of T25FW, 9HPT and SDMT as delegated by [CONTACT_560166] 
• Scheduling visits  and assessments as outlined in the protocol, maintaining  proper source 
documentation and transcription of the data to the CRFs  
• Coordination with and between the study selected central labs, drawing and processing lab samples  
• Ensuring patient understanding of injection handling and home administration instructions, questionnaires, diaries and the completion of  these  
• Providing patient with a Patient Information Card (identifying patients as study participant  in a clinical  trial with pertinent information  and site contact  [CONTACT_3031]  (see 
also Section  15.2 ) 
• Conducting monthly phone calls with the study patients,  as delegated  by [CONTACT_560167]:  
• Familiarization with the MRI manual procedures and the study specific MRI  protocol 
• Performance of a “dry” or “dummy” run using the MRI  parameters  outlined by [CONTACT_560168] 
• Performance of high- quality MRI scans using the study specific parameters stored in 
the designated MRI scanner for the duration of the  study 
• Submission of the MRIs in the appropriate format  to the central  MRI  reader  immediately 
upon completion  
Neuroradiologist/Radiologist  
The local neuroradiologist/radiologist will be responsible for:  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 52
0 Protocol No. 
  
 
• Reviewin g each MRI scan performed for the study patients and contact[CONTACT_560169] -related findings detected on the MRI  scan 
 
6 Visit schedule and  assessments  
Table 6 -1 lists all of the assessments an d indicates with an “x” when the visits are performed.  
Patients should be seen for all visits on the designated day per the schedule of assessments, or 
as close  to it as possible within  the visit windows. Missed  or rescheduled  visits  should not lead 
to aut omatic  discontinuation. 
In case a visit is performed  outside the schedule,  subsequent visits  shall  be performed  in keepi[INVESTIGATOR_560093] (one month is defined as 28 calendar days). In addition to the 
scheduled visits, patients may have unscheduled visits due to a MS relapse, an acute illness of 
undetermined cause, for other reasons, or at the discret ion of the Investigator. Data collected 
during unscheduled visits will be recorded in the unscheduled visit  CRFs.  
 
Patients who stop taking study medication should be scheduled for the end of treatment (EOT) visit as soon as possible. The patients will be asked to remain in the study and continue 
completing the study visits and assessments (shaded in Table 6 -1) until the end of the study 
(EOS).  
End of treatment  (EOT)  visit is not mandatory for all patients.  It is only applicable to patients 
who prematurely discontinue double -blind study treatment and will continue to follow the 
assessment schedule of the Treatment epoch ( Table  6-1).  
End of study (EOS) visit is mandatory for all patients. The EOS Visit is conducted at the end of the Treatment epoch (i.e. when the patient has completed up to 30 months, or when E OS is 
declared for all patients, or at time of premature withdrawal from study). At the time EOS is declared for all patients, all patients ongoing in the Treatment epoch should be contact[CONTACT_560170]. 
Patients who prematurely discontinued study drug but do not agree to continue to be followed in the study Treatment epoch per Table [ADDRESS_736337] 
their EOS Visit and then enter the Safety Follow -up (FU) according to schedule in Table [ADDRESS_736338] their EOS Visit and then enter the Safety Follow -up (FU) schedule in Table 6-2. 
During the study, patients will be asked to complete a diary from Month [ADDRESS_736339] 
information  pertinent to study drug administration  (including date and time of sc injections)  and 
home pregnancy testing (date and results) for females of childbearing potential. The patient is requested to bring the completed diaries with them to each visit and the Investigator/Study 
Nurse/Study Coordinator must review these for completeness and for potential AEs, injection 
related  reactions,  study drug interruptions etc. and record  information  obtained from  the diaries 
on the relevant  CRFs.  
A structured telephone interview script provided for the study will be conducted by [CONTACT_560171] 2 ( Table 6-1).  The interview  should take place around 
time of the monthly sc self/home -injection  to query about any new or worsening symptoms 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 53
0 Protocol No. 
  
 
warranting an unscheduled visit, injection reactions, and, as applicable, results of home 
pregnancy testing, compliance with contraception requirements and with any scheduled local 
LFT lab te sting. 
Some protocol procedures may be done via an outpatient setting (e.g. at patient's home) with the support of study staff or a healthcare professional registered  with the study site for the study, 
if this is permissible per the local regulatory  authority.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 54
4 Protocol No. 
  
 
 
Table  6-1 Assessment schedule  
 
Epoch  Screening  Treatment  
Visit SCR 
(D-45  
to 
D-8) BL 
(D -7 
to D1 
(pre- 
treat 
ment)  D11 D7 D14 M1 M3 M6 M9 M12/24  M15/21/279 M18 EOT9 EOS9 
Visit No.  1 2 101 102 103 104 105 106 107 108/112  109/111/113  110 198 199 
Visit Window (days)  n.a. n.a. n.a. ±1 ±1 ±3 ±14 ±14 ±14 ±14 ±14 ±14 n.a. n.a. 
Informed consent  X              
Demography, Height  X              
Medical history  X              
MS History/Treatments  X              
Incl/Excl  X18 X             
IRT contact  X  X X X X X X X X X X X X 
Dispense study drug    X X X X X X X X X X   
Phone interview       monthly between scheduled visits11   
Physical Exam21 X2a X2a      X  X  X X X 
Patient diary review        X X X X X X X X 
Contraception status16 X X    X X X X X X X X X 
Vital signs, Weight  X X X20 X20 X20 X20 X X X X X X X X 
Routine lab samples19, 
including urine  X3 X23    X X X X X X X X X 
Sample for B -cells  X X  X X X X X X X X X X X 
Teriflunomide plasma 
levels               X15 
Additional LFT testing      X10 X10   
Sample for Total IgG, 
IgM X2a X2a    X X X X X X X X X 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 55
4 Protocol No. 
  
 
Epoch  Screening  Treatment  
Visit SCR 
(D-45  
to 
D-8) BL 
(D -7 
to D1 
(pre- 
treat 
ment)  D11 D7 D14 M1 M3 M6 M9 M12/24  M15/21/279 M18 EOT9 EOS9 
Visit No.  1 2 101 102 103 104 105 106 107 108/112  109/111/113  110 198 199 
Pregnancy Test4 X  X   X X X X X X X X X 
ECG X2a X2a           X X 
MRI X         X   X8 X8 
AEs X X X X X X X X X X X X X X 
Prior/Con Meds14 X X X X X X X X X X X X X X 
Sample for population 
PK13  X    X X X  X   X X 
Sample for ADA13  X    X  X  X   X X 
Samples for 
biomarkers22 X2a X2a     X   X   X X 
eCSSRS X6 X6 X X X X X X X X X X X X 
MS Relapse    X X X X X X X X X X X X 
EDSS X X2b X2b    X X X X X X X X 
T25FW  X2a X2a     X X X X X X X X 
9HPT  X2a X2a      X  X  X X X 
SDMT (oral)  X2a X2a      X  X  X X X 
MSIS -297 X2a X2a      X  X  X X X 
PRO completion form  X2a X2a      X  X  X X X 
AEP   X12 
End of Treatment     X X17 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 56
4 Protocol No. 
  
 
Epoch  Screening  Treatment  
Visit SCR 
(D-45  
to 
D-8) BL 
(D -7 
to D1 
(pre- 
treat 
ment)  D11 D7 D14 M1 M3 M6 M9 M12/24  M15/21/279 M18 EOT9 EOS9 
Visit No.  1 2 101 102 103 104 105 106 107 108/112  109/111/113  110 198 199 
Study Phase  
Completion      X 
ADA= Anti -drug- antibody ; AEs= Averse events; AEP= Accelerated elimination procedure; BL=baseline; D= day;  eCSSRS =electronic 
Columbia -Suicide Severity Rating Scale; EDSS=Expanded Disability Status scale; ; EOS=End of Study: EOT=End of 
Treatment; Excl.=exclusion; HPT=9- Hole Peg Test; Ig= immunoglobulin; Incl.=inclusion; IRT= Interactive response technology; LFT=liver function test; M=month; 
MRI=magnetic resonance imaging ;MS=multiple sclerosis; MSIS= Multiple Sclerosis Impact Scale; n.a=not applicable; PK=pharmacokinetic; PRO= Patient Reported 
Outcome; SDMT= Symbol Digit Modalities Test; T25FW=Timed 25 -foot Walk;  
1. Randomization and first dose (usually expected on the same day). If first dose occurs on a different day after randomization,  the day of first dose 
should be considered to be Day  1 
2. a) Assessment can be conducted either at Screening OR Baseline visit b) Assessment can be conducted at either the Baseline OR the Day 1 visit 
(they must be conducted before the first dose of investigational treatment).  
3. Serology testing to check patient eligibility conducted at Screening only 
4. Female patients  only:  Serum  pregnancy  tests  will be conducted at Screening,  EOT and EOS Visits.  Urine pregnancy  test on Day [ADDRESS_736340] for confirmatory testing at the Investigator’s  discretion 
 
6. The eCSSRS must be assessed once before randomization, either at the Screening (recommended) or the Baseline visit. 
 
8. MRI scan at the End of Treatment (EOT) and/or End of Study (EOS) is needed if there was no MRI scan in the last 3 months  
9. For patients who reach Month 27 visit, the next (and last) 3- monthy scheduled visit is the EOS Visit;  EOS assessments will be done for all patients; 
End of treatment (EOT) assessments are done only for patients who prematurely discontinue study drug (at the time of study drug discontinuation) 
and who continue to stay in the Treatment  epoch 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736341] 6 months  in all patients.  More frequent  LFT 
testing may be required in patients  in countries/regions  where the local teriflunomide prescribing information  stipulates  more frequent  LFT testing.  E.g. 
in the EU LFT testing should be performed every [ADDRESS_736342] 6 months and every 8 weeks thereafter (i.e., once between 3-monthly  scheduled 
visits). A local lab for the additional LFT testing may be used (Section [IP_ADDRESS]) 
11. Telephone interview by [CONTACT_560172]  2. The interview  should take place around  time of the monthly  sc self/home  injection to 
query  about  any new or worsening symptoms warranting an unscheduled visit, injection reactions,  results  of home  pregnancy  testing,  compliance with 
contraception requirements and compliance with local LFT lab testing as  applicable  
12. AEP: applicable only for patients who have permanently discontinued study drug. Patients may undergo an accelerated elimination process at 
Investigator’s discretion ( Section 7.8) 
13. PK and ADA visits: at the Month [ADDRESS_736343] ion. For later PK and 
ADA visits, if the monthly injection is scheduled for the same day as the visit, the patient should take the injection after the PK/ADA sample has been drawn (patient should be instructed not to take the injection before coming to the site for the visit) 
14. Including corticosteroids  used to treat MS relapse;  any newly  started MS treatment  as applicable (for patients  who have discontinued study  medications)  
15. Only for patients who had EOT ≥ [ADDRESS_736344] be reviewed and documented to ensure method of contraception continues to be appropriate per protocol requirement for highly effec tive contraception  
17. Only for patients for whom the EOT page has not already been completed (i.e. have not had an EOT  visit) 
18. Syphilis and Tuberculosis testing must be done as part of eligibility check (Exclusion criterion #11) unless completed in the last 6 months prior to 
screening with documented negative results.  If sites don’t  have the possibility  to test tuberculosis  locally, Quantiferon® -TB Gold test may be requested 
to be done by [CONTACT_560115] 's eligibility.  
19. More frequent hematology testing (excluding B-cells and IgG and IgM for blinding purpose) may be performed by [CONTACT_560173]  
20.  Vital signs should be obtained 30-60 min before sc injection (if premedication is administered, pre-injection vital signs should be obtained before 
premedication is administered), and again approximately [ADDRESS_736345] be drawn to allow adequate time for results to be obtained before randomization to ensure patient's  eligibility  
Note: Patients who have prematurely  discontinued study drug (EOT) and continue to be followed under the Table 6-1  schedule after study drug 
discontinuation, will only do the assessment shaded in grey  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 580 
Protocol No. COMB157G2302   
1. Time measured from the EOS Visit.  M=month.  
2. If scheduled visit and End of Safety -FU occur at the same time only End of Safety -FU visit should 
be done. If patient is prematurely withdrawn from the Safety -FU epoch, the End of Safety -FU 
assessments should be done at time of  withdrawal.  
3. Female patients  only:  monthly  urine home  pregnancy  testing will be conducted between clinic  visits. 
The patient  must contact  [CONTACT_560174] a positive  test for confirmatory 
testing at the Investigator’s  discretion.  
4. AEP. Patients may undergo an accelerated elimination process at Investigator’s discretion as 
described in Section 7.8 
5. As needed for patients requiring prolonged B -cell/teriflunomide plasma level monitoring ( Section  
3.1) 
6. As needed (teriflunomide level assessed only when patient has had a total of at least 9 months of 
follow up and then 3-monthly as needed after study drug discontinuation as described in Section  
3.1) 
*including steroids for MS relapse and newly started DMT as applicable   
 
Table  6-2 Assessment schedule for Safety Follow -up epoch  
 
Visit Month1 
(relative to EOS)  +M3 +M6 +M9 Every 3 months5 End of Safety -FU2 
Visit Number  201 202 203 204/20X  299 
Visit window 
(days)  ±14 ±14 ±14 ±14  
AEs X X X X X 
Concomitant Meds*  X X X X X 
Vital Signs  X X X X X 
eCSSRS X X X X X 
Urine pregnancy 
test3 X X X X X 
Contraception status  X X X X X 
Routine lab samples  X X X X X 
Sample for Total IgG, 
IgM X X X X X 
Sample for B -cells  X X X X X 
Sample for 
teriflunomide plasma 
level6 X X X X X 
MS Relapse  X X X X X 
EDSS X X X X X 
AEP X4 
AEs=  Averse events;  AEP=Accelerated  elimination  procedure;  DMT=disease  modifying  therapy; 
eCSSRS=electronic Columbia -Suicid e Severity Rating Scale; EOS=End of Study:  FU=Follow- up 
 
6.[ADDRESS_736346] 
the Screening disposition CRF for the Screening epoch completed. Demographics, inclusion/exclusion, and serious adverse event (SAE) data will be collected for these  patients. 
Adverse events  that are not SAEs  will be followed by [CONTACT_560175].  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 590 
Protocol No. COMB157G2302   
 
6.2 Patient demographics/other baseline characteristics 
Patient demographic data and baseline characteristics to be collected on the Demography CRF 
will include date of birth, sex, race and ethnicity. Alcohol and smoking history and relevant 
medical history/current medical condition present before signing informed consent and any 
medications taken to treat these conditions will also be captured on the corresponding CRFs. 
Where possible, diagnoses, and not symptoms should be recorded. Investigators will have the 
discretion to record abnormal test findings on the medical history CRF whenever in their 
judgment, the test abnormality occurred prior to the informed consent signature.  
MS disease history (including date of onset and diagnosis, number of previous MS relapses), 
previous MS treatment  and employment status  will also be collected  on the corresponding CRFs.  
 
6.[ADDRESS_736347] accurate inform ation about the study drug exposure, the following records 
should be maintained for each randomized patient: records of study medication dosages administered and intervals between visits. These data should be transcribed on the Dosage 
Administration Record  CRFs.  
Compliance will be assessed by [CONTACT_11219]/or study personnel at each visit using syringe and capsule counts and information provided by [CONTACT_102] (patient diary is provided 
for recording of missed doses). This information should be captured in the source document at 
each visit. A monitor will perform and document drug accountability during site visits and at 
the end of the study. All study treatment dispensed and returned must be recorded in the Drug 
Accountability Log.  
 
6.4 Efficacy 
This study includes the following efficacy  assessments conducted at visits  as shown in Table 6-  
1: 
• MS relapse 
• EDSS  
• Magnetic resonance imaging  (MRI) 
• Neurofilament light chain  (NfL) 
• Timed 25- foot walk  (T25FW) 
• Nine Hole Peg Test  (9HPT)  
• Symbol Digit Modalities Test (SDMT) 
• Multiple Sclerosis Impact Scale 29 items  (MSIS -29) 
An overview of each of these assessments is provided in the sections below. Details of the 
administration of each of these assessments will be provided in the site manuals.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736348] be scheduled as soon as possible (whenever possible within 7 days of onset of the 
symptoms). 
The assessment, management and reporting of MS relapse is made by [CONTACT_737]. 
Confirmation of MS relapse and severity grading, based on the EDSS score (provided by [CONTACT_560176]), will be done centrally.  
MS relapse definition: appearance of a new neurological abnormality or worsening of previously stable or improving pre -existing neurological abnormality, separated by [CONTACT_2669] 30 
days from onset of a preceding clinical demyelinating event ( McDonald  et al. 2001). The 
abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or known infection.  
Diagnosing MS relapses during the study : a patient  may report symptoms indicative  of a relapse 
at a scheduled vi sit or at any other time. Patients will be instructed to immediately contact [CONTACT_560177]/she develops new or re -occurring or worsening neurological symptoms. At 
each Telephone interview ( Table 6 -1), the patient will also be asked whether any such 
symptoms have occurred. If a patient reports new neurological symptoms or worsening of previous symptoms, an unscheduled visit is to be scheduled as soon as possible, preferably 
within [ADDRESS_736349] assess whether the new/worsening 
neurological abnormality is consistent with the definition of MS relapse above. If so, the standard neurological examination (for the EDSS score) will be performed by [CONTACT_560178].  If there  is any doubt in the opi[INVESTIGATOR_689], the default must  always  be 
to refer the case to the Independent EDSS Rater to perform an EDSS rating. The independent EDSS  rater should perform the EDSS  rating  the same  day as the patient's visit to the Investigator 
whenever possible. Later EDSS assessments can still be utilized for confirmation of MS relapses, but should be avoided to reduce the risk of changes in patient status in between the 
initial assessment by [CONTACT_560179].  
Confirmation of MS relapse: the definition of a confirmed MS relapse is one accompanied by 
a clinically relevant change in the EDSS performed by [CONTACT_560180], i.e. an 
increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional 
scores (FSs) or 2 points on one FS, excluding changes involving bowel/bladder or cerebral FS 
compared to the previous available rating (the last EDSS rating that did not occur during a 
relapse). Confirmation  of MS relapse based on these definitions will be done centrally.  
All MS relapses, regardless if they meet definition for confirmation based on EDSS or not, are reported  on the MS relapse CRF.  Severity  of MS relapse  will be calculated  centrally  per criteria 
in Table 6 -3 below. MS relapse should not be reported as an AE/SAE unless, in the judgment 
of the Investigator it is unusually severe or medically unexpected and warrants specific 
notification as an SAE (as described in Section  [IP_ADDRESS] ). 
 
Table  6-3 Severity of MS  relapse  
 
Mild relapse  Moderate relapse  Severe relapse  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 610 
Protocol No. COMB157G2302   
 
EDSS increase of 0.5 point  EDSS increase of 1 or 2 points  Exceeding Moderate criteria  
Or Or Or 
1 point FS change in one to 
three systems  2-point FS change in one or 
two systems  Exceeding Moderate criteria 
 Or Or 
 1-point change in four or more 
systems  Exceeding Moderate criteria 
EDSS=Expanded Disability Status Scale; FS=Functional Score 
(Panitch et al. 2002) 
 
6.4.2  Expanded Disability Status Scale (EDSS)  
EDSS  will be determined,  based  on neurological examination, by [CONTACT_560181] 6 -1 and in case of a suspected MS  relapse.  
The EDSS is an ordinal scale used for assessing neurologic impairment in MS based on a 
neurological examination. It consists of scores in  each of seven functional systems (FSs) and 
an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The FSs are Visual, Brain Stem, Pyramidal, Cerebellar, 
Sensory, Bowel & Bladder, and Cerebral functions (Fatigue contributes). The FSs and EDSS 
steps will be assessed  in a standardized  manner.  EDSS  is a widely  used and accepted  instrument 
to evaluate disability status at a given time and, longitudinally, to assess accumulation of disability in clinical studies in  MS. 
Definitions for disability worsening and disability improvement based on the EDSS and confirmation of worsening (3 and 6- month confirmed worsening) and improvement (6-month 
confirmed improvement) are provided in Section [IP_ADDRESS] . 
Disability worsening should not be reported as an AE/SAE unless, in the judgment of the 
Investigator it is unusually severe or medically  unexpected  and warrants  specific notification  as 
an SAE (as described in Section  [IP_ADDRESS] ). 
 
6.4.3  Magnetic Resonance Imaging  (MRI) 
All patients will undergo MRI scanning of the brain according to the schedules in Table 6 -1. 
MRI scans will be read  by [CONTACT_188648]. The central reading center will be 
blinded with no access to information on treatment assignments. Prior to the start of the study, MRI technician from each center will receive an MRI Manual, outlining technical 
implementation,  image  quality  requirements  and MRI  administrative  procedures. Each  site will 
be asked  to program the MRI  scanner  that is designated  for evaluation  of the study patients  and 
perform and submit a dummy scan (so called “dummy or dry run”) to the MRI reading center 
to assess the image  quality  and to evaluate  the compatibility  of the electronic  data carrier.  Once 
the dummy run has been accepted, all the parameter settings for the study specific MRI sequences must remain unchanged for the duration of the  study. 
Each MRI scan performed for the study needs to be previewed by a local neuroradiologist/radiologist. The Investigator will review the MRI performed during the 
screening epoch to assess patient's eligibility. After Randomization, the Investigator will be  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 620 
Protocol No. COMB157G2302   
 
contact[CONTACT_560182] (e.g. not consistent with MS) detected on the MRI 
scan.  
During the study, the quality of each scan performed will be assessed by [CONTACT_560183]. The MRI scan should be sent to the central MRI reading center upon 
completion. As soon as the scan is received by [CONTACT_188648], it will be 
evaluated  for quality,  completeness  and adherence to the protocol. Confirmation of MRI  quality 
or a description of the quality  problems, if detected,  will be communicated  to the site. If scan is 
incomplete or incorrectly performed, the study center will be asked to repeat it as soon as 
possible. After  completion  of the quality  check,  all scans  will be analyzed  according to the MRI 
protocol. 
 
Restrictions for MRI schedule  
To avoid interferences  caused  by [CONTACT_188650] (in regards  to Gd-enhancing lesions)  for the treatment 
of MS relapse, the following restrictions apply for this  study: 
• In case of relapse, if an MRI has been scheduled within 30 days of the initiation of steroid treatment, MRI (with Gd -enhancement) should be performed before steroid 
treatment is initiated.  
• No MRI (with Gd -enhancement) should be performed while a patient is  on steroid 
therapy  for relapse and within  the following 30 days upon termination  of steroid  therapy.  
As a result of these restrictions, MRI scheduling can be adjusted accordingly. In case a visit is 
performed outside the visit window, any subsequent visits should be performed according to 
the original visit schedule.  
 
Scanning  
All sequences/scans will be performed according to the MRI manual.  
Sequences  include T1 hypointense images  (with  and without gadolinium-based contrast agent ), 
T2-weighted images, and  brain volume will be  performed. 
The gadolinium based contrast medium may occasionally cause nausea and vomiting. Allergic reactions  may also occur  very rarely  and, in extremely  rare instances,  can be potentially  serious 
and require immediate anti -anaphylactic treatment.  
 
6.4.4  Neurofilament light chain (NfL)  
Blood samples for analysis of NfL levels will be drawn according to the schedule in Table 6 -1 
(refer to Samples for Biomarkers). NfL is a component of the neuronal cytoskeleton and is 
released into the cerebrospi[INVESTIGATOR_560094]-axonal 
damage. It has been identified as biomarker to indicate treatment response and to predict 
disability worsening in pa tients with MS ( Kuhle et al. 2016; Disanto et al. 2017; Pi[INVESTIGATOR_560095].  
2017; Barro et al. 2018; Siller et al. 2018).  
The details describing the collection, handling, storage, and shipment requirements of samples 
will be provided in the laboratory manuals.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 630 
Protocol No. COMB157G2302   
 
6.4.5  Timed 25 -Foot Walk  (T25FW)  
The Timed 25 -Foot Walk (T25FW) will be assessed according to the schedule in Table [ADDRESS_736350] of neurological function. It is widely  used in clinical 
MS trials. It is an ambulation measurement assessing speed of walking: a timed (in seconds) 
walk of 25 feet (7.62 meters). The T25FW will be administered (2 trials) according to 
standardized instructions by [CONTACT_560184] T25FW (refer to Section  5.6.6 ). 
 
6.4.[ADDRESS_736351]  (9HPT)  
The Nine Hole Peg Test (9HPT) will be assessed according to the schedule in Table [ADDRESS_736352] of neurological function. It is widely  used in clinical  MS 
trials  to assess upper extremity  function. It is measured  to assess both right and left arm scores, 
the metric is the time, in seconds, required to insert and remove 9 pegs. The 9HPT will be administered  (2 trials  per hand) according  to standardized  instructions by [CONTACT_560185] 9 -HPT 
(refer to Section  5.6.6 ). 
 
6.4.[ADDRESS_736353]  (SDMT) 
The SDMT will be assessed according to the schedule in Table [ADDRESS_736354] to assess processing speed which is typi[INVESTIGATOR_560096] (Benedict et al. 2017) . During the administration of the SDMT only the examiner 
and the patient should be in the testing room.  The SDMT will be administered according to 
standardized instructions by [CONTACT_560186]  (refer  to Section  5.6.6 ). Patients  are presented 
with a test instrument at the top of which  is a row of nine numbers paired  with unique symbols. 
Below this part of the test instrument is an array of symbols paired with empty spaces, the 
patient's task is to verbally  match  the number for each symbol as rapi[INVESTIGATOR_2595]. The SDMT 
incorporates a number of practice items at the start of each test to familiarize the patient (these results  are not included in the final score).  The test takes  approximately [ADDRESS_736355] Scale  (MSIS -29) 
The Multiple  S clerosis  Impact  Scale (MSIS -29) version 2 ( Hobart and Cano, 2009) will be used 
to assess health -related quality of life and will be evaluated according to the schedule in Table  
6-1. MSIS -29 is a 29- item, self -administered questionnaire that includes 2 domains, physical 
and psychological. Responses are captured on a 4 -point scale ranging from “not at all” (1) to 
“extremely” (4), where higher scores reflect greater impact on day to day life. 
It is a clinically useful and scientifically sound measure of the impact of MS from the patient's perspective suitable for clinical trials and epi[INVESTIGATOR_9037] ( Hobart et al. 2001 ). It is 
considered a reliable,  valid and responsive PRO measure that complements other indicators of 
disease severity used to improve our understanding of the impact of MS.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736356] 2 weeks. The MSIS -29 takes approximately 5 minutes to complete, 
and has been translated into many languages.  
 
6.4.9  Appropriateness of eff icacy  assessments  
The relapse,  disability  (EDSS)  and MRI  assessments to be performed  in this study are standard 
and widely  accepted  efficacy  assessments used in clinical  MS studies to monitor  disease  activity 
and to evaluate  treatment  effects.  They  also serve  to characterize the patient  population in terms 
of their MS disease  status.  
The T25FW, 9HPT, SDMT and MSIS -29 assess ambulation (walking speed), upper extremity 
function, cognitive function (processing speed) and physical and psychological impact of 
disease, respectively. They are widely used in MS clinical trials and assess relevant additional 
aspects of the MS pathology.  
 
6.5 Safety 
Safety assessments will include:  
• Adverse events  
• Physical examination (including skin) 
• Vital signs 
• Laboratory evaluati ons 
• Pregnancy testing (females of childbearing  potential) 
• ECG  
• Columbia Suicide Severity Rating Scale (CSSRS) ( Section  7.7) 
Additional safety assessments may be conducted should these be requested by [CONTACT_30029]. Any new or worsening clinically relevant findings from such additional assessments meeting definition of an adverse event (AE) or serious AE should be recorded as 
AE/SAE (refer to Section 7 ). 
Medical history, including MS history and prior MS treatments will be assessed during the Screening.  Concomitant medications  will be assessed  at every  visit following informed consent. 
Periodic safety reviews (generally twice a year) will be performed by a Data Monitoring 
Committee (DMC).  
 
6.5.1  Physical  examination  
A complete physical examination will be performed at the visits indicated in the Study 
Assessments ( Table 6 -1) and will include an assessment of skin, head and neck, lymph nodes, 
heart, lungs, abdomen, back, neurological function and comments on general appearance. A complete  neurological examination  will be part of the initial physical examination  at Screening.  
Information for all physical examinations (including skin exams)  must  be included in the source 
documentation at the study site. All significant findings that are present prior to signing 
informed consent must be reported on the relevant medical history/current medical  conditions 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736357] be recorded on the adverse events CRF.  
 
6.5.2  Vital signs  
Vital signs will include sitting pulse rate (measured as radial pulse for 60 seconds), sitting 
systolic and diastolic blood pressure and body temperature (oral, or per local practice) which 
will be assessed at the visits indicated in Table [ADDRESS_736358] 4 injections (Days 1, 7, 14 and Month 1), vital signs should be obtained 30-[ADDRESS_736359] -injection. If pre - 
medication is administered, the vital signs should be taken prior to pre -medication 
administration.  
After  the patient  has been  sitting  for five minutes,  with their back supported and both feet placed 
on the floor, systolic  and diastolic  blood pressure  will be measured  3 times  using an automated 
validated  device  (manual  sphygmomanometer may be used if automated  device is not available 
at the study site). The pulse will also be measured [ADDRESS_736360] been calibrated according to the manufacturer’s guidelines. In case the cuff sizes available are not large enough for the patient's arm circumference, a 
manual sphygmomanometer with an appropriately sized cuff may be  used. 
 
6.5.3  Height and weight  
Height will be assessed at the Screening visit only.  
Weight  will be assessed  at the visits  indicated  in Table 6-1. Body weight (to the nearest  0.1 kg) 
in indoor clothing, but without shoes, will be  measured.  
 
6.5.4  Laboratory  evaluations  
A central laboratory will be used for analysis of all specimens collected (exception: additional 
frequent LFT panels  as described  in Section  [IP_ADDRESS]  below). Details  on the collections,  shipment 
of samples  and reporting of results  by [CONTACT_560187]. Abnormal laboratory parameters, inconsistent with clinical presentation of 
MS or which cause suspi[INVESTIGATOR_560097], should be repeated for 
confirmation. 
Parameters that may lead to unblinding to treatment assignment such as B -cell counts will be 
blinded to the Investigator and Sponsor study team (e.g. will not be included on the routine 
safety lab reports sent to the Investigators by [CONTACT_2237]). This information will 
remain blinded during the double -blind Treatment epoch and Safety FU epoch until the 
treatment code for the study has been broken.  
 
[IP_ADDRESS]  Hematology  
Blood samples will be collected at the scheduled visits indicated in Table 6 -1 and Table 6 -2. 
The parameters assessed will include: red blood cell (RBC) count, hemoglobin, hematocrit,  
platelets, total WBC count, WBC differential counts (neutrophils, lymphocytes, basophils, eosinophils, monocytes) and CD19
+ B-cell counts.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 660 
Protocol No. COMB157G2302   
 
For study blinding purposes, the B -cell counts will not be provided to the Investigators and 
Sponsor study team. B -cell counts will be assessed by [CONTACT_560188] ( Section 3.1 ) 
 
[IP_ADDRESS]  Clinical chemistry  
Blood samples will be collected at the scheduled visits indicated in Table 6 -1 and Table 6 -2. 
The parameters  assessed  will include: electrolytes  (Na, K, Cl, bicarbonate,  Ca, Mg, P), random 
glucose, total protein, blood urea nitrogen (BUN), albumin (Alb), alkaline phosphatase, ALT, 
AST, GGT, total bilirubin (TBIL), conjugated bilirubin, creatinine, amylase, total cholesterol, 
triglycerides, high density lipoprotein (HDL) and low density lipoprotein (LDL), C -Reactive 
protein (CRP).  
To assist for patients with travel restrictions, blood samples for liver panel assessments as 
described  in Table  6-1 (LFT -only Visits)  may be drawn  by a local  lab and the results  report sent 
to the Investigator within [ADDRESS_736361], AP, GGT, BIL (total and conjugated) . If any significant findings are observed on these 
reports, a confirmatory blood sample should be drawn by [CONTACT_560189]. If no significant findings are observed then the results  of any local  laboratory  values 
(including reference ranges) should be included in the local liver function test results CRF to document the values. Blood samples for these visits may also be obtained by [CONTACT_560190] a particular country or region and processed through the central laboratory (e.g., 
flying nurse, local phlebotomist  etc.).  
All patients with laboratory tests containing clinically significant abnormalities should be followed regularly until the values return to within the normal ranges or until a valid reason 
other than drug- related adverse events is identified, even after study medication has been 
discontinued. See Appendix 1 and Appendix 2 for definition and follow up requirements of 
liver and renal events.  
 
[IP_ADDRESS]  Urinalysis  
Urine  will be collected  at the scheduled  visits  indicated  in Table  6-1 and the dipstick  parameters 
assessed will include: blood, glucose, specific gravity and protein. In case of an abnormal dipstick  test, a urine sample  will be sent to the central  laboratory for testing  including additional 
parameters such as microscopy and white blood cell and red blood cell  sediments.  
 
[IP_ADDRESS]  Other  
Testing of lab samples will be conducted at Screening to determine the patient's eligibility for inclusion in the study with respect to hepatitis and HIV viruses, total IgG and IgM serology status.  Testing  for syphilis and tuberculosis at Screening  is needed  unless such testing  has been 
done in the past 6 months with documented negative results  (see Exclusion criterion  11, Section  
4.2). If sites don’t have the possibility to test tuberculosis locally, Quantiferon®- TB Gold test 
may be requested to be done by [CONTACT_560115]'s  eligibility.  
A positive result for any of the following serological markers for hepatitis A, B, C, and E 
indicating acute or chronic infection is an exclusion criterion:  
• anti-hepatitis A virus  IgM 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 670 
Protocol No. COMB157G2302   
 
• hepatitis B surface antigen and anti -hepatitis B core an tigen IgM/IgG, HBV -DNA 
PCR: if negative, patient can be  included 
• anti-hepatitis C virus IgG (if positive IgG, HCV -RNA PCR will be performed: if 
negative, patient can be included) 
• anti-hepatitis E virus IgM (positive IgG and/or IgM: do HEV -RNA PCR: if negative, 
patient can be included). 
NOTE: If the Investigator suspects false positive hepatitis serology results, such as an 
antibody pattern  indicating  acute hepatitis  infection  but no corresponding elevated  liver 
enzymes and no signs or symptoms, an infectious disease expert may be consulted. If the infectious disease expert finds no evidence of acute or chronic hepatitis infection 
and considers the serology results false positive and not clinically relevant, the 
Investigator may document (in source data and in a CRF comment) that the serology results are considered false positive and randomize the patient.  
Samples will additionally be collected during the study according to Table 6 -1 and Table 6 -2 
for: 
• total IgM and IgG  levels  
• teriflunomide plasma levels  
For study blinding purpose, the results of these tests will not be included as part of the laboratory reports provided to the Investigators or Sponsor study team during the study. 
Teriflunomide levels will be assessed by [CONTACT_560191] ( Section 3.1 ). IgM and IgG 
levels  will be assessed  by [CONTACT_6404], not otherwise involved in the study,  for the purpose of 
safety and guidance provided in Appendix 3  should be  followed. 
Additional samples for PK, ADA,  will be taken ( Sections 6.6.2 to 6.6.5)  
 
6.5.5  Electrocardiogram (ECG)  
An ECG will be performed in this study as part of the eligibility assessment and at end of treatment/end of s tudy. Additional unscheduled ECGs may be performed at Investigator’s 
discretion if clinically indicated.  
Single 12 lead ECGs are collected. The ECG should be recorded (after [ADDRESS_736362] in the 
supi[INVESTIGATOR_188597] a stable reading) according to the local site practice. Clinically 
significant ECG  findings at Baseline must  be discussed  with the Sponsor before administration 
of study treatment.  
The preferred sequence of cardiovascular data collection during study visits is ECG collection 
first,  followed by [CONTACT_18651],  and blood sampling. The Fridericia  QT correction  formula  (QTcF) 
should be used for clinical  decisions. 
The original ECGs on non-heat -sensitive paper / and a certified copy on non- heat sensitive 
paper),  appropriately  signed, must  be collected  and archived  at the study site. Each  ECG  tracing 
must  be labeled  with study number, subject  initials,  subject  number, date and time,  and filed in 
the study site source  documents. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736363]  be recorded  on the relevant  section  of the 
Medical history/Current medical conditions and AE CRF page as  appropriate.  
 
6.5.[ADDRESS_736364] in a diary provided for the study. A monthly  structured  telephone interview  (Table 6-1) will also be conducted with the 
patients which includes questions to confirm that the home urine pregnancy testing was done and the result. In the case of a positive test result the patient must contact [CONTACT_560192]’s  discretion. 
In addition, the Investigator will review the contraception status with the patient at each visit per Table 6 -1 and Table 6 -2 to ascertain that the patient continues to com ply with protocol 
requirements for highly effective contraception as applicable.  
 
6.5.7  Appropriateness of safety  measurements  
The safety assessments included in this study ( Table 6 -1) are standard for the MS indication 
and study patient  population and appropriate based  on the current  safety  profile of ofatumumab 
iv and sc (Investigator’s Brochure) and the teriflunomide (Aubagio®) prescribing  information.  
The use of an instrument such as the C- SSRS to detect  suicidal  ideation  or behavior is currently 
mandated in studies of CNS active  drugs. 
 
6.6 Other assessments  
MS is associated with a variable combination of symptoms, including sensory loss, imbalance, mobility  loss, bladder and bowel dysfunction, cognitive dysfunction, spasticity,  pain, and sexual 
dysfunction. Measurement of these wide -ranging effects of MS on the lives of patients is 
beyond the scope of the clinician assessed endpoints commonly used to evaluate therapeutic effectiveness in MS studies. Patient -reported outcome measures  are 
included in this study to provide an empi[INVESTIGATOR_560098]'s perspective of the benefits of treatment that cannot be gained from MRI, EDSS, or relapse  measurement.  
Samples for PK, immunogenicity potential (ADA),   
 will also be assessed and evaluated as applicable 
in relation to efficacy, safety data and population under study.  
 
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736365] be entered on the appropriate CRF.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 710 
Protocol No. COMB157G2302   
 
 
 
7 Safety monitoring  
7.1 Adverse  events  
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign including abnormal laboratory findings, symptom or disease) in a subject or clinical investigation subject after providing written informed consent for part icipation in the 
study until the end of study participation. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
In addition, all reports of intentional misuse and abuse of the product  are also considered an 
adverse event irrespective if a clinical event has occurred.  
The occurrence of adverse events  must  be sought by [CONTACT_105]- directive  questioning of the patient  at 
each visit during the study. Adverse events also may be detected when they are volunteered by 
[CONTACT_105267], laboratory test 
findings, or other assessments.  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the f ollowing criteria:  
• they induce clinical signs or  symptoms 
• they are considered clinically  significant 
• they require  therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from 
Baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_90160]. Investigators have the responsibility for managing the safety of individual patient and identifying adverse events. Clinically notable laboratory findings are defined 
according to the Common Terminology Cri teria for Adverse Events (CTCAE).  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736366] be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by [CONTACT_6644]:  
• the Common Terminology Criteria AE (CTCAE) grade (1 -4) 
If CTCAE grading does not exist for an adverse event,  use: 
1=mild 
2=moderate 3=severe  
4=life -threatening (see Section 7.2  for definition of SAE)  
CTCAE Grade 5 (death) is not used, but is collected as a seriousness criteria and also 
collected in other CRFs (Study Completion, Death/Survival).  
There may be cases  where a CTCAE  with a grade of 4 (life-threatening) may not necessarily 
be an SAE  (e.g. certain  laboratory abnormalities  in the absence of meeting  other seriousness 
criteria)  
• its relationship to the study  treatment  
o Yes 
o No 
• its duration (start  and end dates)  or if the event  is ongoing, an outcome of not recovered/not 
resolved must be reported.  
• whether  it constitu tes a serious adverse event  (SAE  - See Section  7.2 for definition  of SAE) 
and which seriousness criteria have been  met 
• action taken regarding (investigational)  treatment  
All adverse events must be treated appropriately. Treatment may include one or more of the 
following: 
• no action taken (e.g. further observation  only) 
• study treatment dosage  increased/reduced  
• study treatment  interrupted/withdrawn 
• concomitant medication or non- drug therapy  given 
• patient hospi[INVESTIGATOR_057]/patient's hospi[INVESTIGATOR_18533] (see Section 7.2  for definition of 
SAE)  
• its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with  sequelae; fatal; or  unknown) 
Once an adverse event  is detected,  it must  be followed  until its resolution or until it is judged to 
be permanent, and assessment must be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study drug, the interventions if any 
required to treat it, and the outcome. The action taken to treat the adverse event should be 
recorded on the Adverse Event  CRF.  
Information about common side effects already known about the investigational drug (ofatumumab) can be found in the Investigator Brochure (IB). For information about risks and 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 730 
Protocol No. COMB157G2302   
 
common side effects  related  to the comparator  (teriflunomide), please refer  to the local  product 
label.  This information  will be included in the patient informed consent and should be discussed 
with the patient during the study as needed. Any new information regarding the safety profile 
of ofatumumab that is identified  between  Investigators Brochure updates will be communicated 
as appropriate, for example, via an Investigator Notification or an Aggregate Safety Finding. New  information  might require an update to the informed  consent and has then to be discussed 
with the  patient.  
The Investigator must also instruct each patient to report any new adverse event (beyond the 
protocol observation period) that the patient,  or the patient's personal physician, believes  might 
reasonably  be related  to study treatment.  This information  must  be recorded  in the Investigator’s 
source documents; however, if the AE meets the criteria of an SAE, it must be reported to 
[COMPANY_001]. 
 
7.2 Serious adverse events  
7.2.1  Definition of  SAE 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s),  symptom(s) or medical  conditions(s) which  meets  any one of the following 
criteria:  
• is fatal or  life-threatening  
• results in persistent or signific ant disability/incapacity  
• constitutes a congenital anomaly/birth  defect  
• requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:  
• routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition (e.g. hospi[INVESTIGATOR_560099])  
• elective or pre-planned treatment  for a pre- existing  condition that is unrelated  to the 
indication under study and has not worsened since signing the informed consent 
• treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_105904]  
• social reasons and respi[INVESTIGATOR_064]'s general  condition 
• is medically significant, e.g. defined as an event that jeopardizes the patient or may 
require medical or surgical  intervention. 
All malignant neoplasms will be assessed as serious under “medically significant” if other seriousness criteria are not met.  
Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736367] visit (defined as End of Study (EOS) visit or End of Safety FU visit) must be reported to [COMPANY_001] within [ADDRESS_736368] be reported separately as a new  event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable se ctions of the form must be completed in order to provide a clinically 
thorough report. The Investigator must assess the relationship of each SAE to each specific component of study treatment (if study treatment consists of several components) complete the 
SAE Report Form in English, and submit the completed form within [ADDRESS_736369]  be reported  as a follow-up to that event 
regardless of when it occurs. The follow -up information should describe whether the event has 
resolved or continues, if and how it was treated, whether the blind was broken or not, and whether the patient continued or withdrew from study participatio n. 
If the SAE  is not previously documented in the Investigator’s Brochure or Package Insert  (new 
occurrence)  and is thought to be related  to the study  treatment  a Drug  Safety  and Epi[INVESTIGATOR_623] 
(DS&E) Department associate may urgently require further information from the Investigator 
for health authority reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to 
inform all Investigators involved in any study with the same study treatment that this SAE has 
been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected 
and reported  to the competent  authorities  and relevant  ethics  committees  in accordance with EU 
Guidance 2011/C 172/01 or as per national regulatory requirements in participating  countries. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 750 
Protocol No. COMB157G2302   
 
[IP_ADDRESS]  Reporting of MS Relapse as SAE 
MS relapses are one of the efficacy endpoints in this study; hence they are exempt from SAE 
reporting although they may meet the SAE definition on the basis that they are considered 
medically significant and are frequently associated with hospi[INVESTIGATOR_059]. These events will 
therefore be reported on the MS relapse CRF instead of the SAE form. However, if, in the 
judgment of the Investigator, a MS relapse is unusually severe or medically unexpected and 
warrants specific notification, then an SAE form must be completed and submitted according to SAE reporting procedures outlined above.  
 
[IP_ADDRESS]  Reporting of Disability Worseni ng as SAE  
Disability  worsening is one of the efficacy  endpoints in this study; hence it is exempt  from  SAE 
reporting although it may meet the SAE definition “results in persistent or significant disability/incapacity” ( Sectio n 7.2 ). However, if, in the judgment of the Investigator the 
disability worsening is unusually severe or medically unexpected and warrants specific notification, then an SAE form must be completed and submitted according to SAE reporting 
procedures outlined above.  
 
7.3 Liver safety monitoring 
To ensure patient safety and enhance reliability in determining the hepatotoxic potential of an investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.  
The following two categories of abnormalities / adverse events have to be considered during the course of the study (irrespective of whether classified/reported as (S)AE):  
• Liver laboratory triggers, which will require repeated assessments of the abnormal 
laboratory parameter  
• Liver events, which will require close observation, follow -up monitoring and 
completion of the standard base liver CRF  pages  
Please refer to Table 13- 1 in Appendix 1 for complete definitions of liver laboratory triggers 
and l iver events.  
Every liver laboratory trigger or liver event as defined in Table 13- 1 in Appendix 1 should be 
followed up by [CONTACT_18657]. Detailed information is  outlined in Table 13 -2 in Appendix 1. 
For the liver laboratory trigger:  
• Repeating the liver function test (LFT) within the next week to confirm  elevation.  
These LFT repeats must be performed using the central laboratory if p ossible. If this is not 
possible, then the repeats can be performed at a local laboratory to monitor the safety of the patient. Repeats laboratory must then be performed at central laboratory as soon as possible. If 
a liver event is subsequently reported, any local LFTs previously conducted that are associated 
with this event must be reported on the Liver CRF pages.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736370] be entered on the appropriate unscheduled local laboratory CRF 
page.  
• If the elevation  is confir med,  close  observation of the patient  will be initiated,  including 
consideration of treatment interruption if deemed appropriate. 
For the liver events:  
• Repeating the LFT to confirm elevation as appropriate  
• Discontinuation of the investigational drug if  appropriate 
• Hospi[INVESTIGATOR_560100] 
• A causality assessment of the liver event via exclusion of alternative causes (e.g., 
disease,  co-medications)  
• An investigation of the liver event which needs to be followed until  resolution. 
These investigations can include serology tests, imaging and pathology assessments, hepatologist’s consultancy, based on Investigator’s discretion. All follow -up information, and 
the procedures performed  must  be recorded  on appropriate CRF  pages,  including the liver event 
overview CRF  pages.  
 
7.4 Renal safety monitoring 
The following two categories of abnormal renal laboratory values should be considered during the course of the study:  
• Serum  event:  
• confirmed (after ≥ 24h) increase in serum creatinine (sCR) of ≥ 25% compared to baseline during normal hydration status  
• Urine  event  
• new onset (≥ 1+) proteinuria; confirmed by [CONTACT_560193]/creatinine ratio (ACR) or urinary protein -creatin ine ratio (PCR) (if 
applicable)  
• new onset (≥ 1+), hematuria or  glycosuria 
Every renal laboratory trigger or renal event as defined in Table 14- 1 in Appendix 2 should be 
followed up by [CONTACT_560194] 2. Renal -related events should be recorded on the Renal event CRF pages.  
 
7.5 Reporting of study treatment errors including misuse/abuse 
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (European Medicines Agency (EMA) definition).  
Misuse  refers  to situations  where the medicinal  product is intentionally  and inappropriately used 
not in accordance with the  protocol. 
Abuse corresponds to the persistent  or sporadic, intentional excessive use of a medicinal  product, 
which is accompanied by [CONTACT_560195].  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 770 
Protocol No. COMB157G2302   
 
Study treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) CRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety only if associated with an SAE. Misuse  or abuse will be 
collected  and reported  in the safety  database irrespective of it being associated  with an AE/SAE.  
 
 
 
Treatment error 
type Document in Dose Administration (DAR) CRF (Yes/No)  Document in AE CRF Complete SAE form  
Unintentional study treatment error  Yes Only if ass ociated with 
an AE Only if associated with an SAE 
Misuse/Abuse Yes Yes, Yes, even if not associated with a SAE 
 
 
7.[ADDRESS_736371] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up t o determine outcome, including spontaneous or voluntary termination, details of 
the birth,  and the presence or absence of any birth  defects,  congenital abnormalities,  or maternal 
and/or newborn  complications.  
Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by [CONTACT_560196][INVESTIGATOR_066]. Pregnancy 
follow- up should be recorded on the same form and should include an assessment of the 
possible relationship to the study treatment . 
Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported 
on a SAE form.  
Pregnancy outcomes should be collected for the female partners of any males who took study treatment in this study. Consent to report information regarding these pregnancy outcomes 
should be obtained from the female partner.  
 
7.7 Prospective suicidality assessment  
The Columbia Suicide Severity Rating Scale (CSSRS) is a questionnaire that prospectively assesses Suicidal Ideation and Suicidal Behavior. The CS SRS must be administered at each 
visit, including unscheduled visits.  
A validated version of the CSSRS will be used to capture self -reported C -SSRS data via an 
interactive voice response telephone system (eCSSRS). The eCSSRS uses a detailed branched logic algorithm to perform the C -SSRS patient interview, evaluating each patient's suicidality 
ideation and behavior in a consistent manner. At the conclusion of each assessment, the Investigator will receive a detailed eCSSRS Findings Report via e -mail or fax. If the system 
assesses the patient as having positive suicidal signs, the Investigator will be immediately notified by [CONTACT_348195], email and/or via telephone.  
If, at any time after Screening and/or Baseline, the score is “yes” on item 4 or item 5 of the Suicidal Ideation section of the CSSRS or “yes” on any item of the Suicidal Behavior section, 
the patient must be referred to a mental health care professional for further assessment and/or  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736372] be reported as SAEs. For example, if a patient 
answers  “yes” to one of the questions in the Suicidal Behavior section,  an SAE  must  be reported 
if the event was life- threatening. All events of “Non- Suicidal Self -Injurious Behavior” 
(question also included in the Suicidal Behavior section) should be reported as AEs and 
assigned the appropriate severity grade.  
All SAEs relating to suicidal behavior must be reviewed by [CONTACT_1363].  
 
7.8 Accelerated elimination procedure related to active comparator 
teriflunomide 
Teriflunomide is eliminated slowly from the plasma. Without an accelerated elimination 
procedure, it takes on average 8 months to reach plasma concentrations less than 0.02 mg/L, although, because of individual variations in drug clearance,  it may take as long as [ADDRESS_736373] the blind and integrity of the present study (double -blind/double-dummy 
study of ofatumumab vs teriflunomide), a decision to initiate the teriflunomide -specific 
accelerated elimination procedure must be taken without knowledge of the pa tient's treatment 
assignment. 
It is recommended that patients who permanently discontinue study drug undergo the 
accelerated elimination procedure (during study Treatment epoch or during Safety Follow -up) 
if this is in the patient's best interest as determined by [CONTACT_560197]. This procedure (described below) must be carried 
out under the supervision of the Investigator.  
For patients who develop an SAE (e.g. serious infection, liver event) leading to study drug discontinuation per protocol criteria or per the Investigators clinical judgment, an accelerated 
elimination may similarly be considered.  
As described in the EU and US labels for teriflunomide (Aubagio
®), elimination of 
teriflunom ide can be accelerated by [CONTACT_560198]:  
• Administration of cholestyramine 8 g every 8 hours for 11 days. If cholestyramine 8 g 3 times a day is not well tolerated, cholestyramine 4 g 3 times a day can be  used. 
• Administration of 50 g oral activated charcoal powder every 12 hours for 11  days. 
• If either elimination procedure is poorly tolerated, treatment days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration  rapi[INVESTIGATOR_375]. 
The procedure should be documented  on the Accelerated  Elimination  Procedure CRF.  Any AEs 
reported during the procedure must be recorded on the AE  CRF.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 790 
Protocol No. COMB157G2302   
 
8 Data review and database management  
8.1 Site monitoring 
Before study initiation, at a site initiation visit or at an Investigator’s meeting, a Sponsor 
representative will review the protocol and CRFs with the Investigators and their staff. During 
the study, [COMPANY_001] employs several methods of ensuring protocol and Good Clinical Practice 
(GCP) compliance and the quality/integrity of the sites’ data. The field monitor will visit the 
site to check the completeness of patient records, the accuracy of entries on the (e)CRFs, the 
adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to 
ensure that study treatment is being stored, dispensed, and accounted for according to 
specifications. Key study personnel must be available to assist the field monitor during these 
visits. Continuous r emote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] CRA organization. Additionally, a central analytics organization may analyze data  & identify risks & trends for site operational parameters, and provide reports to [COMPANY_001] 
Clinical Teams to assist with trial  oversight. 
The Investigator must maintain source documents for each patient in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
patient's file. The Investigator must  also keep the original informed consent form  signed by [CONTACT_4677] (a signed copy is given to the  patient).  
The Investigator must  give the monitor access  to all relevant  source documents to confirm their 
consistency  with the CRF  entries.  [COMPANY_001] monitoring  standards require full verification  for the 
presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of 
SAEs, and of data that will be used for all primary variables. Additional checks of the 
consistency of the source data with the CRFs are performed according to the study- specific 
monitoring plan. No information  in source documents about the identity  of the patients/subjects 
will be  disclosed.  
 
8.2 Data collection 
Designated Investigator staff will enter the data required by [CONTACT_560199]/Remote  Data Capture (OC/RDC)  system.  Designated  Investigator site staff will not be 
given access to the system until they have been  trained.  
Automatic validation procedures within the system check for data discrepancies during and after data entry and, by [CONTACT_105273], allow the data to be confirmed 
or corrected online by [CONTACT_560200]. The Inve stigator must certify that 
the data entered into the electronic Case Report Forms are complete and accurate. After database lock, the Investigator will receive copi[INVESTIGATOR_105196].  
 
8.3 Database management and q uality control 
Sponsor staff (or Contract  Research  Organization  (CRO)  working on behalf  of Sponsor) review 
the data entered  into the CRFs  by [CONTACT_560201] v02 Clean  Confidential  Page [ADDRESS_736374] the data. If the electronic query system is not 
used, a paper Data Query Form will be faxed to the site. Site personnel will complete and sign 
the faxed copy and fax it back to Sponsor staff that will  make the correction to the database. 
The signed copy of the Data Query Form is kept at the Investigator  site. 
Concomitant medications entered into the database will be coded using the World Health 
Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic 
Chemical classification system. Concomitant procedures, non- drug therapi[INVESTIGATOR_560101] (MedDRA) terminology. 
Laboratory samples will be processed centrally a nd the results will be sent electronically to 
Sponsor (or a designated CRO).  
MRI scans will be analyzed centrally and derived results will be sent electronically to Sponsor 
(or a designated CRO).  
Randomization codes and data about all study drug(s) dispensed to the patient and all dosage 
changes will be tracked using an Interactive Response Technology (IRT). The system will be 
supplied by a vendor, who will also manage the database. The database will be sent 
electronically to Sponsor (or a designated CRO).  
Each occurrence of a code break via IRT will be reported to the clinical team and  monitor. The 
code break  functionality  will remain  available until study shut down or upon request  of Sponsor. 
The occurrence of relevant protocol deviations will be determine d. After these actions have 
been completed and the database has been declared to be complete and accurate, it will be 
locked and the treatment codes will be unblinded and made available for data analysis. Any 
changes to the database after that time can onl y be made after written agreement by [CONTACT_560202].  
 
8.4 Data Monitoring Committee 
A Data Monitoring Committee  (DMC)  will be in place to oversee the study. Details  are provided 
in the DMC  charter.  
The DMC  will be responsible for on-going review  of enrollment, safety  and, if requested  by [CONTACT_109393],  efficacy  data and will provide regular  assessments on the safety  and overall  risk to benefit 
ratio of the study conduct, advise the Sponsor of a need for protocol  modification/amendment 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736375] additional information or make 
recommendation including stoppi[INVESTIGATOR_560102]/or treatment , if needed.  
A Sponsor designee will be responsible for the timely coordination and delivery of the dat a to 
the DMC on a regular basis. The chair of the DMC will be responsible for providing 
summaries/executive reports of each DMC meeting to Sponsor, arranging on-going 
communication between members of the DMC, arranging meetings and maintaining files with 
all correspondence pertaining to the study.  
 
[ADDRESS_736376]  data at the time of EOS  (i.e. including partial  data 
from the Safety Follow -up epoch). Any data analysis carried out independently by [CONTACT_560203]. 
 
9.1 Analysis sets  
Full analysis set (FAS) : The FAS comprises  all randomized subjects  with assigned  treatments. 
Subjects will be analyzed according to the randomized treatment assignment following the intention -to-treat (ITT) principle, even if they actually received a different  treatment.  
The FAS will be used for the summary of demography and baseline c haracteristics as well as 
for all efficacy analyses.  
Per-protocol set (PPS) : The PPS is a subset of FAS, consists of all randomized subjects who 
take at least one dose of study medication and have no major protocol deviations that could 
confound the interpretation of analyses conducted on the FAS. Major protocol deviations will 
be determined according to the pre -defined protocol deviation criteria before treatment 
unblinding (e.g. non- compliance for a large proportion of the time in study). For analyses 
performed on the PPS, only on- treatment assessments will be used.  
The PPS will primarily  be used for the supportive analyses  of the primary  efficacy  variable and 
selected key secondary  variables.  
Safety set (SAF): The SAF set includes all subjects who received at least one dose of study medication. Subjects will be analyzed according to the actual treatment received. The Safety 
Set will be used for all safety analyses.  
 
9.2 Patient demographics and other baseline characteristics 
Demographics, MS disease history, MRI baseline characteristics, MS medication history and 
employment status, will be summarized by [CONTACT_64207].  
 
9.3 Treatments 
Exposure to investigational study medication is defined as the number of days spent on study drug divided by 365.25 days. In this double -dummy design all patient will receive capsules 
(active or placebo) and injections (active or placebo) to maintain the b lind. For the calculation 
of exposure to study medication  only the active drug will be considered. Intermediate  treatment 
interruptions will be subtracted from drug exposure. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736377] dose 
of study medication, plus the safety data cut -off of 100 days. Intermediate treatment 
interruptions will be included in time -at-risk calculations. Time -at-risk corre sponds to the time 
window used for adverse event reporting and can serve as a denominator to safety (e.g. in 
exposure- adjusted incidence rates). Time- at-risk will be summarized in a similar way to 
exposure to investigational study medication.  
 
9.4 Analysis of the primary variable  
The primary endpoint is the annualized relapse rate (ARR), which is defined as the number confirmed MS relapses in a year. In the primary analysis, the ARR is estimated based on the FAS which follows the intent -to-treat principle in a negative binomial model by [CONTACT_560204].  
Two variables are required for the calculation of the ARR (excluding covariates):  
• The cumulative  number of confirmed  MS relapses  by [CONTACT_560205]. The confirmation based on EDSS will be derived as defined i n section  6.4.1 . 
• The time -in-study by [CONTACT_560206] -risk of a confirmed MS relapse in the  study. 
 
9.4.1  Statistical model, hypothesis, and method of  analysis  
The null hypothesis is that there is no difference in the ARR between ofatumumab 20 mg sc once monthly and teriflunomide 14 mg po once daily in reducing the frequency of confirmed 
MS relapses as measured by [CONTACT_560207]. The alternative hypothesis is that there is a difference 
between the 2 treatment groups.  
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if the observed ARR on ofatumumab 20 mg sc is lower than on teriflunomide 14 mg po 
and if the null hypothesis can be rejected at the two- sided significanc e level of  0.05. 
The null hypothesis will be tested  based  on the FAS,  using a negative binomial regression  model 
with log -link, treatment and region as factors, number of relapses in previous year, baseline 
EDSS,  baseline  number of Gd-enhancing lesions and the patient's age at baseline as covariates. 
In the analysis, the response variable is the number of confi rmed relapses observed from each 
patient and the patient's time in study (natural log of time in years) is used as an offset variable 
to adjust for the varying lengths of patient's time in the study. The adjusted ARR (i.e., model - 
based estimate adjusted f or covariates) for each treatment and the corresponding 95% 
confidence interval, and ARR ratio (also expressed as percentage reduction relative to control 
group) along with the 95% confidence interval  for the ARR ratio and the corresponding p-value 
will be  obtained. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 830 
Protocol No. COMB157G2302   
 
The definition of Region is intended to correspond to that used for the stratification of the 
randomization. However,  the definition  of Region may be modified and defined  in the statistical 
analysis plan if that is indicated based on statistical criteria (e.g. non -convergence of models). 
In addition, the statistical analysis plan may define a process how the primary model can be 
simplified (e.g. by [CONTACT_560208]) in case of  non- convergence.  
 
[IP_ADDRESS]  Multiplicity  adjustment  
The planned submission consists of 2 studies of identical design (COMB157G2302 and COMB157G2301), each with multiple  endpoints. In order to control the type-I error rate (“false 
positive rate”)  at the level of the individual studies,  and at the level  of the submission  as a whole, 
the testing strategy illustrated in Figure 9 -1 below will be  implemented.  
 
Figure 9 -1 Testing procedure and type -I-error  control  
Testing procedure and type -I-error control in the planned ofatumumab submission which 
consists of studies COMB157G2302 and COMB157G2301 (both with identical design). 
Hypotheses can only be tested in sequential order as indicated by [CONTACT_37296]. The number  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 840 
Protocol No. COMB157G2302   
 
associated with each hypothesis (α, or α -α2) indicates the significance level at which that 
hypothesis can be tested.  If the null-hypothesis for the primary  objective (ARR)  can be rejected 
within  a study, MRI - and NfL -related hypotheses will be tested in sequential order within that 
study as long as all proceeding hypotheses can successfully be rejected. Disability- related 
hypotheses will only be tested in the combined data of the [ADDRESS_736378]. At the study- level, the type -I error rate (one - 
sided) is controlled at ≤ 0.025. In the submission, the type-I error  rate is controlled at ≤ 0.000625 
(=0.0252) for the primary hypothesis and at ≤ 0.025 when considering all  endpoints. 
The primary hypothesis (ARR) and all MRI - and NfL -related key -secondary hypotheses will 
be tested in hierarchical order within study ( Figure 9 -1). Th e testing procedure starts with the 
statistical test of the primary  null-hypothesis (ARR)  and continues to lower  ranking hypotheses 
as long as the proceeding null hypotheses can all be rejected in favor of ofatumumab in a two- 
sided statistical test with a  p-value ≤ 0.05. This testing procedure controls the type -I error rate 
to ≤ 0.[ADDRESS_736379]  the primary  null-hypothesis (ARR)  in favor of ofatumumab 
in a two -sided statistical test with p -value ≤ 0.05, disability- endpoints will be addressed in the 
combined data of COMB157G2302 and COMB157G2301, at the submission level. Disability endpoints will be tested in hierarchical order as indicated by [CONTACT_560209] 9-1. The testing 
procedure continues to the next lower  ranking disability -hypothesis as long as the previous null- 
hypothesis can be rejected in favor of ofatumumab in a two- sided statistical test with a  p-value 
≤ 0.[ZIP_CODE] (=2*[0.025-0.025
2]). 
Provided the primary  hypothesis can be rejected  in both studies,  disability -related  endpoints can 
be tested regardless of the outcome of MRI - and NfL -related endpoints, and vice- versa.  
Under the global null -hypothesis (i.e. no difference between ofatumumab and teriflunomide), 
the testing  procedure controls the type-I error rate (one-sided) at the study- level  to ≤ 0.025, and 
at the submission  level  to ≤ 0.000625 (=0.0252). Considering all possible configurations of true 
and false positive null hypotheses, the type -I error control at the level of the submission is ≤ 
0.000625 for the primary objective, and ≤ 0.025 for all  hypotheses. 
The type-I error  is controlled by [CONTACT_560210].  All confidence intervals  and p-values  in 
the study report will be presented without  adjustments.  
 
9.4.2  Handling of missing  values/censoring/discontinuations  
The primary NB (negative binomial) model with an offset for the time in study adjusts for missing  inform ation  (drop-out) under the assumption of non- informative  drop-out, information 
is missing at random, and constant relapse rate over time. According to the protocol, subjects who discontinue study treatment  should remain  in the study and follow  the assessme nt schedule. 
The primary analysis will use all available data collected in the double -blind treatment epoch, 
irrespective if collected after the permanent discontinuation of study treatment. In addition, a 
sensitivity  analysis  will be conducted to allow  for the possibility  that relapse rates  may be non- 
constant over time (i.e. higher during the onset-of action  of both drugs for a period of 8 weeks).  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 850 
Protocol No. COMB157G2302   
 
9.4.3  Sensitivity  analyses  
The primary analysis will be repeated based on all reported MS relapses (rather than on only 
the confirmed ones).  
The primary analysis will be repeated using the per -protocol set to provide an analysis of on- 
treatment data from subjects who have no major protocol violations. Relapses which occurred 
after permanent discontinuation of study medication will be excluded and natural log (time on 
study drug in years) rather than natural log (time on study in years) will be used as the offset 
variable in the nega tive binomial model.  
To estimate  relapse rates and the treatment  effect  between  ofatumumab 20 mg sc once monthly 
and teriflunomide  14 mg po once daily  during the initial “onset  of action”  period of 8 weeks  (≤ 
56 days=8*7 days), and relapse rates and the treatment effect thereafter (> 56 days; long- term 
efficacy) a sensitivity analysis will be conducted. This analysis will be implemented as a 
pi[INVESTIGATOR_560103] d ARR -ratios before and 
after week 8, but constant dispersion. Per patient, 2 cumulative count -records (confirmed 
relapses  ≤ 56 days, and > 56), and 2 corresponding time records  (time -in-study ≤ 56 days, and > 
56) will be calculated. The negative binomial model will be defined with the number of 
confirmed relapses as the response variable, with log -link and time -in-study as the offset 
variable. The model will use the same factors and covariates as the primary  model. 
For each time period (≤ 56 days, and > 56 days), the adjusted ARR (i.e., model -based estimate 
adjusted for covariates) and the corresponding 95% confidence intervals will be provided by 
[CONTACT_3148], together an ARR ratio between ofatumumab 20 mg sc once monthly and 
teriflunomide 14 mg po once daily (also expressed as percentage reduction relative to control 
group) with corresponding 95% confidence intervals and p- values.  
Additionally, the time-to-first relapse will be analyzed  in a Cox proportional hazards  model. In 
comparison with the primary analysis in a negative binomial model, the Cox proportional hazards model does not assume constant relapse rates (but rather it assumes proportional 
hazards).  The Cox proportional hazards  model will be specified  with treatmen t, region, number 
of relapses in previous year, baseline EDSS, baseline number of T1 Gd- enhancing lesions and 
the patient's age at baseline as  covariates.  
Additional sensitivity analyses may be defined in the analysis plan prior to database lock.  
 
9.5 Analysis of secondary variables  
9.5.1  Efficacy  variables  
All efficacy analysis will be done based on the FAS, unless explicitly stated otherwise  
 
[IP_ADDRESS]  Key-secondary efficacy  endpoints  
 
[IP_ADDRESS].1  Disability worsening (3 -month or 6 -month confirmed)  
A 3-month confirmed disability worsening (3mCDW) is defined as an increase from baseline 
in EDSS sustained for at least 3 months ( Table 9 -1). Analogously, a 6- month confirme d 
disability worsening (6mCDW) is defined as an increase from baseline in EDSS sustained for 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736380] 6 months. This means that after a scheduled or unscheduled visit at which the patient 
fulfills the disability worsening criterion, all EDSS assessments (scheduled or unscheduled) 
need to also fulfill the worsening criteria until the worsening (“the event”) can be confirmed at the first scheduled visit that occurs 3- months (or 6 months) after the onset of the worsening, or 
later.  
Censoring occurs in all patients who did not experience a 3mCDW (or 6mCDW) event in the 
study (censoring also occurs in patients who had a “tentative” disability worsening that could not be confirmed due to an early discontinuation or any another reason). The censoring time is 
defined as the time from the first dose to the last available EDSS assessment.  
 
Table  9-1 Criterion for disability worsening based on change in EDSS  score  
 
Total EDSS at baseline*  “Disability worsening” criterion  
0 ≥ +1.5  
1 to 5  ≥ +1 
≥5.5 ≥ +0.5  
EDSS=Expanded Disability Status Scale  
A 3-month confirmed disability worsening (3mCDW) can have an onset at any scheduled or unscheduled visit if 
the disability worsening criterion is met. A disability worsening can only be confirmed at a scheduled visit if, 
over a period of 3 months (≥ 90 day s=3*30) time interval, all assessments meet the worsening criterion.  
A 6-month confirmed disability worsening (6- mCDW) can have an onset at any scheduled or unscheduled visit 
if the disability worsening criterion is met. A disability worsening event can only be confirmed at a scheduled 
visit if, over a period of 6 months (≥ 166 days=6*30 -14) time interval, all assessments meet the worsening 
criterion.  
If a patients dies due to MS (EDSS=10 at any time), it will be considered a confirmed disability worsening regardless of the baseline EDSS or the change in EDSS.  
* Baseline EDSS is defined as the last EDSS assessment prior to the first dose of study medication (protocol 
inclusion criterion is EDSS 0 -5.5) 
 
Hypothesis and Analysis of disability worsening (3mCDW, 6mCDW)  
The hypothesis and the analysis methods will be identical for 3mCDW and 6mCDW. For 
brevity the hypothesis and analysis methods are only specified in full for 3mCDW.  
The null hypothesis is that there is no difference in the time to 3mCDW between ofatumumab 
20 mg sc and teriflunomide 14 mg po  
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if 
there is a reduction in risk (estimated hazard ratio from Cox -model< 1) in patients 
treated  with ofatumumab  compared  with teriflunomide  and the observed p-value for the 
between -treatment  comparison is less than the two-sided  significance level  of 
≤ 0.[ZIP_CODE] (=2*[0.025-0.0252]). The multiplicity adjustment explained in Section  
[IP_ADDRESS]  applies.  
Confirmatory analysis for disability- related endpoints: The confirmatory analysis of time - 
to-3mCDW will be done in a meta -analysis based on the combined FAS populations from 
COMB157G2302 and COMB157G2301.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736381]  ratio 
between  ofatumumab and teriflunomide  will be estimated  with 95% confidence interval  and p- 
value from the combined data from both studies in this meta -analysis. In addition, between- 
study heterogeneity will be tested as the type -[ADDRESS_736382] of the treatment-by- study interaction; the 
corresponding p- value wil l be provided. For information only, the hazard ratio for each study 
will be estimated by [CONTACT_560211] 95% confidence intervals and p-values.  
Supportive analysis: Kaplan -Meier curves (and/or cumulative incidence plots) will be 
provided by [CONTACT_560212]- study to present the 
time-dependent cumulative probability of subjects reaching 3mCDW.  
By-treatment  Kaplan -Meier  (KM)  estimates  (and/or 1- KM estimates)  will be calculated  for the 
combined study data at Month 6, and in 6 monthly intervals from there until less than 100 
patients per arm are at -risk, with 95% confidence intervals. Similar estimates will be provided 
by [CONTACT_3449]. 
To estimate  the hazard  ratio between  ofatumumab 20 mg sc once monthly and teriflunomide  14 
mg po once daily during the initial “onset of action” period of 8 weeks (≤ 56 days=8*7 days), 
and thereafter  (> 56 days; long- term efficacy)  a sensitivity  analysis  will be conducted. The Cox- 
proportional hazards model will be specified as above, but in addition a time -dependent 
indicator variable ([ADDRESS_736383] 8 weeks, 1 otherwise) and an indicator - 
by-treatment interaction will be included in the model. From this model separate hazard ratios 
with 95% confidence intervals  and p-values  will be estimated  for the first [ADDRESS_736384] ratio will consider all 
patients who discontinue from the study due to “lack of efficacy” as patients with a confirmed 
event. The event time for these patients will be calculated based on the date of the 
discontinuation from study relative to the first dose date. Additional analyses or imputation 
schemes may be described in the statistical analysis plan prior to database lock.  
 
[IP_ADDRESS].2  Disability improvement (6 -month confirmed)  
A 6-month confirmed disability improvement (6mCDI) is defined as a decrease from baseline 
EDSS sustained for at least 6 months ( Table 9 -2). Censoring occurs in patients who did not 
experience a 6mCDI  event  in the study.  The censoring time is defined  as the time from  the first 
dose to the last EDSS assessment.  
 
Table  9-2 Criterion for disability improvement based on change in EDSS  score  
 
Total EDSS at baseline*  “Disability improvement” criterion  
0 to 1.5  No improvement possible  
≥2 to 6  ≤ -1 
≥6.5 to 9.5  ≤ -0.5 
EDSS=Expanded Disability Status Scale; 6mCDI=6- month Confirmed Disability Improvement.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 880 
Protocol No. COMB157G2302   
 
 
 
Hypothesis and Analysis of disability improvement  
The null hypothesis is that there  is no difference in the time to 6mCDI  between  ofatumumab  20 
mg sc and teriflunomide 14 mg po 
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if 
there is an improved chance of a 6mCDI (estimated hazard ratio from Cox -model > 1) 
in patients treated with ofatumumab compared with teriflunomide and the observed p- value for the between -treatment  comparison is less than the two-sided  significance level 
of ≤ 0.[ZIP_CODE] (=2*[0.025-0.025
2]). The multiplicity  adjustment explained  in Section  
[IP_ADDRESS]  applies.  
Confirmatory analysis for disability- related endpoints: The confirmatory analysis of time - 
to-6mCDI will be done in a meta -analysis based on the combined FAS populations from 
COMB157G2302 and COMB157G2301.  
The null hypothesis will be tested  using a stratif ied Cox proportional hazards  model with study 
as stratum, treatment, and region as factors and baseline EDSS as a continuous covariate. The 
model will contain  a treatment -by-study interaction.  For confirmatory  purposes the hazard  ratio 
between  ofatumumab and teriflunomide  will be estimated  with 95% confidence interval  and p- 
value from the combined data from both studies in this meta -analysis. In addition, between- 
study heterogeneity will be tested as the type -[ADDRESS_736385] of the treatment-by- study i nteraction; the 
corresponding p- value will be provided. For information only, the hazard ratio for each study 
will be estimated by [CONTACT_560211] 95% confidence intervals and p-values.  
Kaplan -Meier  curves  (and/or cumulative  incidence plots) and by-treatment  Kaplan -Meier  (KM) 
estimates (and/or 1 -KM estimates) will be calculated for the combined study data at Month 6, 
and in 6 monthly intervals from there until less than 100 patients per arm are at -risk, with 95% 
confidence inter vals. Similar estimates will be provided by  [CONTACT_3449]. 
A similar analysis (Cox proportional hazards model, Kaplan- Meier curves) will be performed 
for 6mCDI sustained until the End of Study.  
 
[IP_ADDRESS].3  Number of Gd- enhancing lesions per  scan 
The null hypothesis is that there is no difference in the number of Gd- enhancing lesions per 
scan between ofatumumab 20 mg sc and teriflunomide 14 mg po  
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if 
there are fewer Gd -enhancing lesions per scan (estimated rate ratio from a negative 
binomial model< 1) in patients treated with ofatumumab compared with teriflunomide 
and the observed p-value for the between -treatment  comparison is less than the two- 6mCDI: A disability improvement can have an onset at any scheduled or unscheduled visit if the disability 
improvement criterion is met. A disability improvement can only be “confirmed” at a scheduled visit if, over a 
period of 6 months (≥166 days=6*30- 14) time interval, all assessments meet the improvement criterion. A 
6mCDI sustained until the End of Study is defined as a 6mCDI after which all EDSS assessments meet the disability improvement criterion through End of Study.  
*protocol inclusion criterion is EDSS 0 -5.5 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 890 
Protocol No. COMB157G2302   
 
sided  significance level  of 0.05. The multiplicity  adjustment explained  in Section  [IP_ADDRESS]  
applies.  
Confirmatory analysis of the number of Gd -enhancing lesions per scan: The confirmatory 
analysis of the number of Gd- enhancing lesions per MRI -scan will be done based on the FAS 
using a negative binomial regression model with log- link. The total number of G d-enhancing 
lesions (cumulative  count of Gd-enhancing lesions across  all the MRI -scans  per patient)  will be 
used as the response variable, and the natural log of the number of MRI -scans will serve as the 
offset variable to adjust for the different number of MRI -scans between patients related to the 
flexible  follow-up time in this study. The model will include treatment  and region (factors),  and 
age, and number of Gd- enhancing lesions at baseline as continuous  covariates.  
The number of Gd- enhancing lesions per scan will be estimated by [CONTACT_27180] 95% 
confidence interval. The between treatment effect will be calculated as rate ratio with 95% 
confidence interval and p- value. In addition the relative reduction in the number of Gd- 
enhancing lesion per scan will be computed as the rate ratio minus one (1) and expressed as a 
percentage.  
 
[IP_ADDRESS].4  Annualized rate of new or  enlarging T2  lesions  
The null hypothesis is that there is no difference in the number of new or enlarging T2 lesions 
between ofatumumab 20 mg sc and teriflunomide 14 mg po  
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if  
there are fewer new or enlarging T2 lesions (estimated rate ratio from a negative 
binomial model< 1) in patients treated with ofatumumab compared with teriflunomide 
and the observed p- value for the between -treatment comparison is less than the two - 
sided  significance level  of 0.05. The multiplicity  adjustment explained  in Section  [IP_ADDRESS]  
applies.  
Confirmatory analysis of the Annualized rate of new or enlarging T2 lesions: The confirmatory analysis of the annualized rate of new or enlarging T2 lesions will be done based on the FAS using a negative binomial regression model with log- link. The number of new or 
enlarging T2 lesions on the last available MRI scan relative to baseline will be used as the response variable, and the natural log of the time (in years) of the MRI -assessment from the 
baseline/Screening scan will serve as the offset variable to  adjust for the various lengths of 
follow- up times between patients in this study. The model will include treatment and region 
(factors), and age, and baseline volume of T2 lesions as continuous covariates.  
The number of new or enlarging T2 lesions per yea r will be estimated by [CONTACT_27180] 95% 
confidence interval. The between treatment effect will be calculated as rate ratio with 95% confidence interval and p- value. In addition the relative reduction in the number new or 
enlarging T2 lesions per year will be computed as the rate ratio minus one (1) and expressed  as 
a percentage.  
The number of new or enlarging T2 lesions are a cumulative  measure of disease  activity.  Since 
the number of new or enlarging T2 lesion is assessed relative to the MRI scan collected at 
Screening  (i.e. well before the start of study medication  intake),  it is expected  that this analysis 
underestimates  the true treatment  effect.  Therefore,  a supportive analysis  will be performed  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 900 
Protocol No. COMB157G2302   
 
based  on the new or enlarging T2 lesions between  the Month 12 scan and the End of Study scan 
(this analysis is described in Section  [IP_ADDRESS] ). 
 
[IP_ADDRESS].5  Neurofilament light  chain  
The null hypothesis is that there is no difference in NfL between ofatumumab and 20 mg sc 
teriflunomide 14 mg po by [CONTACT_24473] 3.  
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if NfL levels are already lower at month 3 in patients treated with ofatumumab compared with teriflunomide and the observed p- value for the between -treatment comparison is 
less than the two-sided  significance level  of 0.05. The multiplicity  adjustment explained 
in Section 9.4.1. 1
 applies.  
 
Confirmatory analysis of NfL: The NfL concentration (geometric mean concentration) will 
be estimated by [CONTACT_560213] 95% confidence intervals using a repeated 
measures model on the basis of all evaluable log- transformed NfL values. The treatment 
effect will be estimate d in terms of a geometric mean ratio with 95% confidence interval per 
time point. The statistical hypothesis test will be based on the treatment contrast and p -value 
obtained at month 3. An unstructured covariance matrix will be used. The model will include treatment, region and the time point as factors, and age, number of Gd- enhancing lesions at 
baseline, baseline T2 lesion volume and the log- transformed NfL baseline concentration as 
continuous adjustments. The treatment effect of ofatumumab versus teriflunomide will be 
visualized in a line plot with confidence intervals.  
 
 
[IP_ADDRESS].6  Brain volume loss  
The null hypothesis is that there is no difference in brain volume change between ofatumumab 
20 mg sc and teriflunomide 14 mg po  
• Superiority of ofatumumab 20 mg sc over teriflunomide 14 mg po will be concluded if there is less brain  volume loss (positive difference in slope from  the random coefficient 
model) in patients treated with ofatumumab compared with teriflunomide and the 
observed p- value for the between -treatmen t comparison is less than the two -sided 
significance level of 0.05. The multiplicity adjustment explained in Section [IP_ADDRESS] applies.  
Confirmatory analysis of brain volume loss: The percentage change from baseline in brain 
volume will be estimated on the basis of all scans up to the last available MRI scan that 
evaluated percentage brain volume change relative to baseline. A random coefficients model 
will be used as main  analysis  for this endpoint in order to adjust for the various length of follow- 
up time in this study (brain volume change was approximately linear over time and approximately normally distributed in 3 independent studies of the fingolimod Phase 3 
program). The random coefficients model will include treatment , region as fixed effects 
(factors), and time, number of Gd- enhancing lesions at baseline, baseline T2 volume, and 
normalized  brain  volume at baseline as continuous covariates.  Time  is defined  as the time from  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736386] dose date to the date of MRI  scan in year and will be calculated  by ((MRI scan date – date 
of last scan prior to the first dose of study medication) +1)/365.25. Time as a continuous 
covariate allows for estimation of different slopes and intercepts among treatment groups. The 
model will also contain random terms to account for deviations about the population slope and 
intercept. The statistical test will address the question whether there is a difference in the slope 
of brain  volume change by [CONTACT_2948]. The annual  rate of percent  change from  baseline in 
brain volume is approximated as the population slope within the treatment group. Since the random coefficients model allows for the estimation of different slopes and intercepts among 
the treatment  groups, differences  between  treatments  at any time can be summarized  using this 
model. Mod el estimates  of percentage brain  volume change at Month 12 and 24 will be provided 
by [CONTACT_560214] 95% confidence interval. Treatment differences will be 
estimated at the same time points with confidence interval and a p -value for the test of a 
difference in  slope. 
Additionally, percentage brain volume change (PBVC) and the annualized rate of brain atrophy (ARBA)  will be summarized  by [CONTACT_765].  ARBA  describes  the “averaged  annual percentage change” 
in brain volume. It is designed to adjust for differences in the time spent between [ADDRESS_736387] rates applies. ARBA = [(PBVC/100+1)
(365.25/days)-1]*100, where “PBVC” represents the 
percentage brain volume change obtained between 2 scans and “days” stands for the number of days between the 2 scans that are being compared. Cross -sectional comparisons at each visit 
will be made using ANCOVA models with  ARBA as the response variable, treatment and 
region as factors, number of Gd- enhancing lesions at baseline, baseline T2 volume, and 
normalized brain volume at baseline as continuous covariate. Line plots of percentage brain volume change over time by [CONTACT_560215]. 
In addition, the percentage change from  baseline in brain volume will be estimated  on the basis 
of all available MRI scans that evaluated percentage brain volume change relative to baseline in a repeated measures model. A repeated measure model with the percent change in brain 
volume from baseline up to end of study as the dependent variables with unstructured 
covariance matrix will be used. The model will include treatment and scanning time point as 
factors, region, number of Gd- enhancing lesions at baseline, baseline T2 volume and 
normalized  brain  volume at baseline as covariates.  For the purpose  of this model, visit windows 
will be used to map all available MRI assessments to Month 12 or 24. The comparison of 
treatment differences in mean at Month 12, 24 will be made using this  model. 
Percentage brain  volume change is cumulative  measure  of disease  activity.  Since  the percentage 
brain  volume change is assessed  relative  to the MRI  scan collected  at Screening  (i.e. well before 
the start of study medication  intake),  it is expected  that these  analyses  tend to underestimate  the 
true treatment difference between study  drugs. 
 
[IP_ADDRESS]  Other secondary efficacy  variables  
• The analysis of “Time of first relapse” and “Annualized relapse rates > 8 weeks after the onset of treatment” is described in ( Section 9.4.3 ) as sensitivity analysis to the primary 
an 
alysis.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 920 
Protocol No. COMB157G2302   
 
• The analysis of the “Risk of a 3mCDW > 8 weeks after the onset of treatment” and “Risk 
of a 6mCDW > 8 weeks after the onset of treatment” is described in ( Section [IP_ADDRESS].1 ) as 
a supportive analysis to the key- secondary 3mCDW and the 6mCDW,  respectively.  
• Time  to 6mCCD  will be analyzed  in the combined FAS from  studies COMB157G2301 and 
COMB157G2302, in a Cox proportional hazards model with study as s tratum, treatment 
and region as factors, and baseline SDMT as continuous  covariates.  
• Time  to 6mCDW  or a 6mCCD,  whichever  is reached  first, will be analyzed  in the combined 
FAS from studies COMB157G2301 and COMB157G2302, in a Cox proportional hazards model with study as stratum, treatment and region as factors, and baseline EDSS and 
baseline SDMT as continuous  covariates.  
• SDMT  scores  and change from  baseline will be summarized  by [CONTACT_443228].  The 
change from baseline will be analyzed and compared between treatments in a repeated measures mixed effects model.  
• Time to [ADDRESS_736388] 20% in the timed 25- foot walk test 
(T25FW) will be analyzed in the combined FAS from studies COMB157G2302 and COMB157G2301, in a Cox proportional hazards model with study as stratum, treatment, 
and region as factors  and the baseline T25FW- result  as a continuous covariate.  The baseline 
25TWT- result is defined as the last assessment prior to the first dose of study medication; 
the 20% worsening is defined relative to this reference  value.  
• Time  to 6-month confirmed  worsening of at least 20% in the 9-hole peg test (9HPT)  will be 
analyzed in the combined FAS from studies COMB157G2302 and COMB157G2301, in a 
Cox proportional hazards  model with study as stratum,  treatment,  and region as factors  and 
baseline 9HPT -result as a continuous covariate. The baseline 9HPT -result is defined as th e 
last assessment prior to the first dose of study medication; the 20% worsening is defined 
relative to this reference  value.  
• Change in T2 lesion  volume on MRI  will be summarized  by [CONTACT_765].  Cross- sectional  analyzes 
will be done by [CONTACT_2329] a rank ANCOVA with treatment and region (factors), and baseline T2 volume as a continuous  covariate.  
• Number of new or enlarging T2 lesions on MRI between Month 12 and EOS will be 
analyzed in a negative binomial regression model, and presented similarly to that used for the annualized rate of new or enlarging T2 lesions. The number of new T2 lesions on the 
EOS scan relative to the Month 12 scan will be used as the response variable, the natural 
log of the time (in years)  of the EOS  MRI -assessment  from  the Month [ADDRESS_736389] for the various lengths of follow -up times between patients in 
this study.  
• Proportion of patients free of clinical and MRI disease activity (No evidence of disease activ ity; NEDA -4) will be analyzed cross -sectionally at year 1 and year 2 in a logistic 
regression  model with treatment  and region as factor,  and age, baseline EDSS,  and number 
of Gd -lesions at baseline as covariates. NEDA -4 is defined as no 3mCDW, no confirmed  
MS relapse, no new or enlarging T2 lesions on any MRI scan compared to baseline, and 
brain  volume change > -0.4%/year on all MRI scans  (brain  volume as measured  by [CONTACT_560216], 
see Section  [IP_ADDRESS].5 ). The main  analysis  will consider only those patients  who were 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 930 
Protocol No. COMB157G2302   
 
followed-up to the assessment  time point in the analysis  (e.g. only patients  with ≥ 12 months 
of follow -up in the 12- month assessment of disease freedom, etc.). Intermediate missing 
values  (e.g. due to missing  MRI  assessments)  will be considered  not free of disease  activity. 
A sensitivity  analysis  will be conducted considering all patients  who discontinued from  the 
study prior to the assessment timepoint, or have missing MRI assessments prior to the 
assessment timepoint, as not free of disease  activity.  
• MSIS -[ADDRESS_736390]  score  (items  1-20), psychological impact  score  (items  21-29) and 
the corresponding changes from baseline will be summarized by [CONTACT_765]. The change from baseline at specific post -baseline visits will be compared between treatment groups using a 
repeated measures mixed effects  analysis.  
If ofatumumab significantly reduc es NfL as compared with teriflunomide, the following 
additional analyses  will be performed: In the subgroup of newly  diagnosed (within  3 years  prior 
to the screening visit), treatment- naïve (no prior MS DMT) patients, the hypotheses will be 
tested that patients with a high (>median) NfL concentration at baseline will experience more 
new or enlarging T2 lesions, a higher ARR and tend to have a worse disease course on EDSS 
during the study compared with patients with low (≤median) NfL concentration at  baseline:  
• The T2 lesion rate will be estimated using a negative binomial model similar to the one 
specified in section [IP_ADDRESS].4. In addition, the model will include a treatment-by- NfL 
baseline category interaction. The T2 lesion rate will be estimated by [CONTACT_560217].  The treatment  effect  will be expressed  as a lesion  rate ratio with 95% 
confidence interval, for low and high baseline NfL category, respectively. The statistical hypothesis test with regards  to the prognostic value of NfL for new lesion  formation  will be 
based on the high vs low baseline NfL category contrast in the terif lunomide group. 
• The ARR will be estimated using a negative binomial model similar to the primary model specified in section 9.4. In addition, the model will include a treatment -by-NfL baseline 
category  interaction.  The ARR will be estimated  by [CONTACT_560218]. 
The treatment effect will be expressed as an ARR -ratio with 95% confidence interval, for 
low and high baseline NfL category, respectively. The statistical hypothesis test with regards to the prognostic value of NfL for on-study relapses will be based on the high vs 
low baseline NfL category contrast in the teriflunomide  group. 
• The disease  course based  on EDSS  will be analyzed  as time to 3mCDW,  6mCDW  or 6mCDI 
using Kaplan- Meier curves and a Cox proportional hazard model based on the combined 
data from  COMB157G2301 and COMB157G2302. The model will include study as stratum, 
treatment, region and baseline NfL category as factors and baseline EDSS as a contin uous 
covariate. The treatment effect will be expressed as hazard ratio with 95% confidence interval,  for low and high baseline NfL category,  respectively.  The statistical hypothesis test 
of the prognostic value of NfL for disability changes will be based on the main effect of NfL category (due to the expected low number of events in this subgroup). It is 
acknowledged that the study will not be powered to show an effect on disability outcomes 
in subgroups. 
• The b
enefit/risk  profile  of ofatumumab in the subgroup of newly  diagnosed, treatment -naïve 
patients with high NfL will be compared to the overall trial results based on the above 
described efficacy analyses. The safety profile in the subgroup of newly diagnosed, 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 940 
Protocol No. COMB157G2302   
 
treatment -naïve pati ents with high NfL will be compared to the overall trial population by 
[CONTACT_560219]-by-side for the subgroup and the overall  trial. 
 
9.5.2  Safety  variables  
Safety analyses will be conducted using the safety (SAF) dataset. Patients will be grouped by 
[CONTACT_84810]. Unless explicitly otherwise stated, only data up to and including the safety  cutoff of 100 days after permanent  study drug discontinuation will be included in the 
analysis and data beyond this time point for a given patient will be excluded from the safety analysis.  The safety  cutoff of 100 days (5 x 20 days) takes  the long half-life of the comparator - 
drug into account.  
The a ssessment  of safety  will be primarily  based  on the frequency  of adverse  events  (including 
death and non- fatal serious adverse events). Additional safety assessments include laboratory 
tests, physical examination (including examination of skin), vital sign measures, ECG evaluations and assessment of suicidality. Clinically significant findings in these additional 
safety  assessments will be reported  as adverse  events  and analyzed  as such. In addition all safety 
assessments will be summarized or listed as appropriate. The analyses of additional safety assessments will be defined on the level of the statistical analysis  plan. 
 
[IP_ADDRESS]  Adverse events  
Treatment emergent adverse events (TEAE) will be reported up to and  including safety cut off 
of 100 days after permanent study drug discontinuation. All serious TEAEs and death will be 
included, regardless of safety cut -off. 
TEAEs will be summarized (number of cases as a percentage of number at risk) by [CONTACT_1570]. N umber and percentage of patients with TEAE will be summarized by [CONTACT_472502]. Serious TEAEs, drug related TEAEs and TEAEs leading to premature discontinuation from study drug will be presented in a similar format as advers e 
events. In addition, TEAEs will be reported by [CONTACT_3229].  
Given the flexible follow -up of the study, TEAEs will also be summarized by [CONTACT_560220]- adjusted incidence rates (assuming a Poisson -process for adverse events). This will 
be done for all  TEAEs, and for only serious TEAEs, per primary system organ class and 
preferred term. The analysis will be performed in a time -at-risk as defined in Section 9.3 . 
Similar tables can be produced for selected risks (e.g. SMQs) on an as -needed basis.  
 
[IP_ADDRESS]  Laboratory  data 
The summary of laboratory evaluations will be presented for 3 groups of laboratory tests: Hematology, Chemistry and Urinalysis.  
Laboratory data will be summarized by [CONTACT_560221], and by [CONTACT_560222] (baseline to 
most extreme post -baseline value). Laboratory data, and specifically liver enzymes, will also 
be summarized by [CONTACT_560223].  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 950 
Protocol No. COMB157G2302   
 
For liver enzymes, the number of subjects with newly occurring liver enzymes abnormalities 
will be summarized by [CONTACT_1570]. Newly occurring liver enzymes abnormalities are 
defined  relative  to the upper limit  of normal  (ULN).  Examp le of a newly  occurring liver enzyme 
event are ALT or AST > 3xULN & TBL > 2xULN & ALP ≤ 2xULN or a reported Hy’s Law case (refer also to Appendix 1).  
SMQ  and preferred  terms  searches  for drug- related  hepatic disorders will be conducted. Results 
of these searches will be analyzed and presented in a similar format as other adverse events. In 
case of liver events detailed listings will be  provided. 
In case of renal events, the overall frequency of events and percentage of patients with renal events during the treatment period will be summarized and detailed listings provided. 
Additional analyses of renal events can be defined in the statistical analysis plan.  
 
[IP_ADDRESS]  Vital signs  
Vital sign measurements and their change f rom baseline will be summarized with descriptive 
(mean, median, standard deviation, min, max) by [CONTACT_765]. The number and percentage of subjects with clinically notable vital signs will be presented.  
 
[IP_ADDRESS]  Suicidality  evaluations  
The Columbia Suicide Severity Rati ng Scale (C -SSRS) data will be mapped to Columbia 
Classification  Algorithm for Suicide  assessment  (C-CASA)  as per FDA guidance on suicidality.  
The proportion of subjects who have completed suicide, suicide attempt, preparatory actions 
toward imminent suicidal behavior, suicidal ideation, and self -injurious behavior without 
suicidal  intent as per the C- CASA  scale during the study will be summarized  by [CONTACT_2948]. 
 
[IP_ADDRESS]  Other safety  evaluations  
All clinically significant safety findings based on additional safety evaluations (e.g. ECG or 
physical examination including assessments of skin, lymph nodes, lung, etc.) must be reported as adverse events on the AE CRF. The statistical analysis of these findings will be done in the 
analysis of adverse events.  
Other safety data will be summarized or listed as appropriate.  
 
[IP_ADDRESS]  Safety evaluation during the Safety Follow -up epoch  
Safety data collected during the Safety Follow -up epoch includes adverse events, la boratory 
assessments to measure  B-cell repletion. All safety  assessments after study drug discontinuation 
will be analyzed, summarized or  listed.  
Safety data collected during the Safety Follow -up epoch will be reported separately. These 
analyses will inclu de laboratory assessments including B -cell repletion, adverse events, vital 
signs, MS relapses and change in EDSS. For patients who discontinued from study drug but 
followed the assessment schedule of the Treatment epoch, change variables will be defined 
relative to the end of treatment visit (EOT), for all other patients change is defined relative to 
the End of Study visit (EOS). Since post -treatment safety follow -up in the Safety Follow -up 
epoch may continue for up to 9 months (or longer if criteria for loner follow up are met) after  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 960 
Protocol No. COMB157G2302   
 
completion of the Treatment epoch study, the study report for the core study (Screening and 
Treatment  epoch) will be completed  based  on the completed  core study i.e. based  on all patients 
who have completed  the Treatment  epoch, and the partial  data from  the Safety  Follow-up epoch 
available at that time. A complete analysis of the post- treatment safety follow -up will be 
provided in an addendum to the study report when all patients who entered the Safety Follow - 
up epoch have completed this  epoch. 
 
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 970 
Protocol No. COMB157G2302   
 
 
9.5.5  PK/PD modelling  
PK concentration  data summarized  by [CONTACT_560224]-patient  listings  will be provided in 
the study report. 
 
 
 
 
 
9.5.6  Immunogenicity  assessment  
Samples will be analyzed for of the presence of human anti -drug antibodies (ADA). The data 
will be summarized  by [CONTACT_560225]  (i.e. proportion of patients  with ADA)  as an assessment 
of the immunogenicity potential of ofatumumab. A listing by [CONTACT_560226]. 
 
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736391].  
 
9.7.2  Blinded data  reviews  
The purpose of the blinded data reviews is to ensure an adequate sample size and follow -up 
time to address the scientific objectives of the study without un -necessarily exposing patients 
by [CONTACT_560227] -up duration as indicated by [CONTACT_560228].  
Blinded data reviews will be conducted in this study for:  
(1) Blinded sample size re -assessment: relapse - (and disability) - related assumptions will 
be re- assessed based on a review of blinded data to adjust sample size  if indicated by 
[CONTACT_560229]. This review will occur prior to the completion of  enrolment. 
(2) Declaration of End of Study: the ‘Information’ ( Section [IP_ADDRESS]) collected by [CONTACT_560230]. End of Study will 
be declared only once when sufficient information has been collected to address the 
study’s primary and key- secondary  objectives.  
 
[IP_ADDRESS]  Blinded sample size re-estimation  
A blinded data review  will be done prior to the completion  of recruitment  based  on the initially 
assumed sample  size. 
The purpose of the blinded sample size re -estimation is to re -adjust the sample size depending 
on the activity of the population. If indicated by [CONTACT_26739], the sample size of the study can be increased from initially 900 randomized patients to a maximum of 1250 randomized patients.  
• The ARR (λ) and the between -patients variability (κ, dispersion parameter) in the 
overall patient population (i.e., without revealing the treatment code) will be estimated from the blinded data by [CONTACT_6486] a negative binomial regression model with log- link to 
the data, with intercept and age at baseline as the only continuous covariate. Given the 1:1 randomization ratio and the assumed relapse rates by [CONTACT_3148] ( Section 9.8 ), the  
blinded ARR is expected at λ
blinded =0.224 and the dispersion parameter at 0.82. Sample  
size can be increased if the study acquires ‘Information’ for ARR at a lower rate than initially  anticipated.  
• A secondary objective of the blinded review is to review the rate of accumulation of disability. The time to the first 3mCDW and the time to the first 6mCDW will be 
reviewed based on Kaplan -Meier curves for the overall patient population without 
revealing the treatment code. These curves will be compared to those expected under the assumption of an exponential distribution of event times and the ha zard ratios 
provided in Section 9.8 . Sample size can be increased if rates are substantially lower 
than anticipated ( Table 9-3).  
 
Table  9-3 Anticipated cumulative event probabilities on  teriflun omide  
 
Time -at-risk 3mCDW  6mCDW  
6 months  4.0%  3.1%  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 100
0 Protocol No. 
  
 
1 year  7.8%  6.2%  
2 years  15% 12% 
3mCDW=3 -month Confirmed Disability Worsening; 6mCDW=[ADDRESS_736392] rates, due to the 1:1 randomization ratio, are assumed as the mean of those assumed for 
ofatumumab and teriflunomide ( Section 9.8 ). 
 
[IP_ADDRESS]  Review of blinded data to declare End of  Study  
The accumulating blinded data will be analyzed and End of Study (EOS) will be declared for 
both studies simultaneously when all of the following conditions are met.  
• Each study (COMB157G2302 and COMB157G2301) have individually collected ≥ 40.3 units of Information  for the primary  ARR endpoint ("Information" is defined  and explained 
in Section  [IP_ADDRESS] ). At this time-point both studies will provide 90% power for the detection 
of a 40% relative  treatment  effect  on ARR in the primary  statistical test at a one- sided  alpha 
level of  0.025. 
• In the combined data of the 2 studies (COMB157G2302 and COMB157G2301) ≥ [ADDRESS_736393] collected 
sufficient  information  to provide 90% power for the detection  of 38.6% (hazard  ratio=0.614) 
relative reduction in risk of a 3mCDW in a log -rank test at a one- sided alpha -level of 
0.025-0.025
2. 
• In the combined data of COMB157G2302 and COMB157G2301 studies ≥ [ADDRESS_736394] collected  sufficient 
information to provide 80% power for the detection of 38.6% (hazard ratio=0.614) relative  
reduction in risk of a 6mCDW  in a log- rank test at a one- sided  alpha- level  of 0.025-0.0252. 
[IP_ADDRESS]  Statistical ‘Information’ for annualized relapse rates  
The primary endpoint of the study is the annualized relapse rate (ARR). We assume that the 
number of MS relapses follows a negative binomial distribution, which is a common assumption in MS. The primary hypothesis will be tested in a negative binomial regr ession 
model based  on the estimation  of the ARR- ratio between  treatments  (the ‘estimate’).  The power 
of the statistical test of the primary  hypothesis (ARR)  does not depend on the sample  size or the 
treatment duration per se; instead, it depends on the Inf ormation collected.  
- Information is defined as the reciprocal of the estimate’s variance, as in a group 
sequential design.  
In the blinded review we will estimate the amount of information (I) generated by [CONTACT_560231] a blinded analysis -based review of the relapse activity (λ) of the recruited patient 
population and the observed dispersion parameter (κ) in the accumulate d study data. A 
mathematical  derivation of the ‘information’  for a negative binomial distribution  is provided in 
Appendix 5. 
Equation 1: Information I = [1/n {1/(λ
1T) + 1/ (λ 2T) + 2 κ}]-1 
where n = number of patients per arm,  T the common follow -up time (i.e., the study duration), 
λ1 = ARR for ofatumumab and λ 2 = ARR for teriflunomide, and κ = the dispersion parameter 
(κ > 0) which describes the between -patient variability.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 101
0 Protocol No. 
  
i
 tota
  
For this study,  ≥ 90% power is required  for the primary  endpoint. The sample  size assumptions 
for this study are initially T=1.5 years, λ 1=0.168, λ 2=0.28, and κ=0.82 which would provide 
I=40.3 units of statistical information  which  corresponds to 90% power for the statistical test of 
the ARR- ratio between ofatumumab and teriflunomide at the one -sided 2.5% alpha  level.  
Trial designs with another sample size, or follow -up time, but the same amount of statistical 
Information, also provide an equivalent power for the detection  of 40% reduction in ARR at the 
one sided 2.5% alpha level. Therefore the first EOS -c ri t e ri o n  i s  m e t  w h e n  I  ≥  [ADDRESS_736395] been collected.  
 
Estimating ‘Information’ for ARR in a blinded review  
As in a blinded sample size review ( Friede and Schmidli 2010 ), fitting a negative binomial 
model to the aggregate data (i.e., the relapse data of all patients  combined) provides an estimate 
of the overall ARR λ and the dispersion parameter κ. For an assumed rate ratio (clinically 
meaningful difference) of θ = λ 1/λ2, estimates can be obtained of the ARRs in the two groups, 
λ1 = 2* λ* θ/(1+ θ) for ofatumumab, and λ 2=2* λ/(1+ θ) for  teriflunomide.  
Since the treatment  allocation  of the patients  (i = 1,…n i) is unknown in this blinded review  but 
randomization was done in a 1:1 ratio, we make the assumption that the follow -up times in the 
two groups (j = 1,2 with 1 = ofatumumab and 2 = teriflunomide)  are the same,  i.e., that T.1 = T.2 
= T total/2 , where  Ttotal is the total of the follow-up times  at the review  time.  It is further assumed 
that the sum of the squared  follow-up times  is the same  in both groups, i.e., that Σi Ti12 = Σi Ti22 
=  Σ j  Σi  T  2/2 = T2 /2. The evaluation  of the information  in Appendix 5 based  on blinded  
i
nformation is then:  
Equation 2: Information I = [2/ (λ 1 Ttotal ) + 2/( λ 2 Ttotal ) + 4 κ T2 total/Ttotal2]-[ADDRESS_736396] EoS -criterion is met when  
≥40.[ADDRESS_736397] been collected. The study is then powered at ≥90% for the detection of a 40% reduction in ARR at the one -sided alpha level of 0. 025. 
 
9.8 Summary of sample size calculation 
Sample size requirements for this study are primarily driven by [CONTACT_560232] -related key 
endpoints. A total  of approximately 900 patients  will be randomized  to study  drug  in a 1:1 
ratio (450 per treatment arm) . A second study of identical design with the same sample size 
will be conducted in parallel. Both studies are independently powered to address the primary 
endpoint (ARR) and all key- secondary MRI  endpoints. 
Key-secondary outcomes related to disability will be analyzed in the combined populations of 
both trials, provided the primary null -hypothesis can be rejected in both studies. Other 
secondary efficacy endpoints, as well as safety will be analyzed by [CONTACT_3449].  
The total samp le size of this study can be increased from [ADDRESS_736398] 6, version 6.3, Cytel Inc.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 102
0 Protocol No. 
  
 
Primary endpoint:  
• ARR: The total sample size of 900 randomized patients for this trial is sufficient to 
achieve 90% power for the demonstration of superiority of ofatumumab over 
teriflunomide based on the primary endpoint  (ARR).  
 
Key-secondary endpoints:  
The power mentioned for the key-secondary  endpoints is conditional on the successful  rejection 
of the null hypothesis for the primary endpoint (ARR), and the successful rejection of all key- secondary  endpoints that are to be tested  at a higher hierarchical  level.  Multiplicity  adjustments 
and the testing procedure are defined in Section  [IP_ADDRESS] . 
• 3mCDW: A total sample size of 1800 patients across 2 studies of identical design is 
required  and sufficient  to provide ≥ 90% power and for the demonstration of superiority 
based on the 3mCDW.  
• 6mCDW  and 6mCDI:  A total sample  size of 1800 patients  across  2 studies of identical 
design is sufficient to provide ≥ 80% power for an analysis of 6mCDW and 6mCDI.  
• MRI endpoints: A total sample size of 900 randomized patients for this trial is sufficient to provide ≥ 80% power for all MRI endpoints which are part of the testing 
procedure (Number of Gd- T1 lesions per scan, annualized rate of new or newly 
enlarging T2 lesions, annualized rate of  BVL).  
• NfL:  A total sample  size of 900 randomized  patients  for this trial is sufficient  to provide 
a ≥ 90% power for an analysis of the NfL concentration in serum.  
 
9.8.1  Sample size for the primary endpoint  (ARR)  
A negative binomial distribution of relapses is assumed for the primary analysis; this is a 
common assumption in MS. The demonstration of a  relative reduction of the ARR in patients 
treated with ofatumumab (λ ofa=0.168) compared with those treated with teriflunomide 
(λter=0.28) by 40% (λ ofa / λter =0.6) with a power of 90% at a one -sided alpha -level of 0.025 in 
a study with 1.5 years follow -up and under the assumption of a dispersion parameter κ=0.82 
requires a sample size of 322 completers per treatment arm (644 completers for the study). 
Allowing for 20% uninformative dropouts equally distributed across treatment arms, a total 
sample  size of 805 randomized  patients  is required for the study to demonstrate superiority  of 
ofatumumab based on ARR. A sample size of 900 patients per trial (driven by [CONTACT_941] 3mCDW endpoint), under otherwise the same  assumptions as before,  would provide approximately 95% 
power for the demonstration of superiority of ofatumumab over teriflunomide at a one -sided 
alpha level  of 0.000625 (=0.025
2) using the pooled data from  2 studies of identical  design. The 
formula proposed by [CONTACT_540362]. 2007 was used for the sample  size calculation  for the primary 
endpoint. 
 
[IP_ADDRESS]  Justification of assumptions for primary  endpoint  
In the pi[INVESTIGATOR_36491], patients treated with teriflunomide 14 mg (the control treatment for this st
udy) had an ARR=0.32 ( Confavreux et al. 2014 ) and ARR=0.37 ( O’Conner et al. 2011). In 
an additional Phase 3 study of teriflunomide versus Interferon beta -1a, patients treated with  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 103
0 Protocol No. 
  
 
teriflunomide  14 mg had an ARR=0.26  which  was not significantly  different  from  that observed 
in patients treated with Interferon beta -1a (ARR=0.22). For the purpose of this study an ARR=  
0.28 is assumed for patients treated with teriflunomide 14 mg.  
Ocrelizumab is an anti -CD20 monoclonal antibody with a similar mode of action as 
ofatumumab but is administered  as infusion. In the ocrelizumab  Phase  3 trials  an ARR of 0.156 
(OPERA I) and 0.155 (OPERA II) ( Hauser et al. 2015 ) were observed for patients treated with 
Ocrelizumab 600 mg, the corresponding interferon beta -1a controls had an ARR of 0.292 
(OPERA I) and 0.290 (OPERA II); the corresponding relative reductions in ARR were 46% 
(OPERA I) and 47% (OPERA II). In the ocrel izumab Phase 2 trial, patients treated with 
ocrelizumab 600 mg had an ARR=0.13, those treated with 1000 mg an ARR=0.17 ( Kappos et  
al. 2011). Compared with the Interferon beta -1a control in the s ame trial (ARR=0.36), 
ocrelizumab 600 mg and 2000 mg reduced the ARR by 64% or 53%, respectively. Compared to placebo  controls from  the same  trial (ARR=0.64),  ocrelizumab  600 mg and 2000 mg reduced 
the ARR by 80% or 73%,  respectively.  
Ofatumumab 60 mg every 12 weeks administered subcutaneously showed in the Phase 2 trial (unpublished data) approximately 34% relative reduction in relapse rate versus placebo over 
the first 24 weeks, but 60% in the second 12 weeks (Week 12 to 24). The relative reduction of 
Gd-enhancing lesions of approximately 90% observed in patients treated with ofatumumab 
relative  to those treated  with placebo  was similar  to that observed with ocrelizumab  and placebo, 
suggesting similarly strong anti -inflammatory potency of ofatumumab and oc relizumab. Based 
on the combined findings, a relative reduction in the ARR of 40% is assumed between patients treated with ofatumumab compared to those treated with teriflunomide, which corresponds to 
an absolute ARR=0.168 for patients treated with ofatumumab, similar to that observed with 
ocrelizumab in Phase 2 and  3. 
The dispersion parameter of k=0.82 is assumed based on the values observed for relapse data   in the fingolimod  Phase  3 program. In the pi[INVESTIGATOR_560104]  3 program 290/1086=27% 
of the patients discontinued over 104 weeks ( O’Connor et al. 2011 ) in one trial, and 
348/1196=30% over 130 weeks in another one ( Confavreux et al. 2014 ). In OPERA I and 
OPERA II discontinuation rates were lower. For the purpose of the primary analysis we 
conserva tively assume that 20% of the randomized patients will not contribute to the primary 
analysis at all. This is a conservative assumption because patients who discontinue prematurely from  the study can contribute with partial  data (relapse  counts, exposure) to the primary  analysis. 
In this information -based design patients will be followed until the end of the trial (see EoS 
criteria), rather than to be observed for a fixed time period. Based on the 3mCDW endpoint it   
is anticipated that the majority of patients will be exposed for 1 to 2 years. For ease of 
calculation a fixed follow -up time of 1.5 years is assumed for the primary endpoint. Of note,   
the power for the primary endpoint will depend on the actual  follow-up. 
 
9.8.2  Sample size for 3- month confirmed di sability worsening  (3mCDW)  
For planning purposes only an exponential distribution of event times and proportional hazard 
is assumed. The cumulative event probability over 2 years is assumed as 15% vs 9.5% in patients  treated  with teriflunomide  vs ofatumumab, respectively.  The assumed  cumulative  event 
rates  translate  to a relative  risk reduction of 38.6% (hazard  ratio=0.614) in patients  treated  with 
ofatumumab compared  with teriflunomide.  The detection  of a hazard  ratio of 0.[ADDRESS_736399] with 90% power at a one- sided alpha -level of 0.025-0.0252 requires 178 qualifying 
events. Allowing for 20% dropouts over [ADDRESS_736400] between  2.5 to 3 years.  
For comparison to these assumptions, in the pi[INVESTIGATOR_560105], the cumulative probability of a 3- month confirmed disability worsening over 2 years in patients treated with 
teriflunomide 14 mg was 15.8% ( Confavreux et al. 2014) and 20% ( O’Connor et al. 2011), 
respectively. Furthermore, in combined ocrelizumab Phase 3 studies ( Hauser et al. 2015 ) the 
Kaplan -Meier  estimates  were 15.2 and 9.8 at year 2 for interferon  beta-1a and ocrelizumab  600 
mg, respectively; this corresponds to a hazard ratio 0.6 (40% relative risk reduction between 
ocrelizumab and interferon  beta- 1a). 
 
9.8.3  Sample size for 6- month confirmed disability worsening (6mCDW)  
The cumulative  event  probability over 2 years  is assumed  as 12% vs 7.548% in patients  treated 
with teriflunomide vs ofatumumab, respectively. The assumed cumulative event rates translate to a r elative risk reduction of 38.6% (hazard ratio=0.614) in patients treated with ofatumumab 
compared with teriflunomide. The detection of a hazard ratio of 0.[ADDRESS_736401] with 
80% power at a one- sided  alpha- level  of 0.025-0.025
2 requires  133 qualifying events.  Allowing 
for 20% dropouts over 2 years in both arms, a total sample size of 1662 randomized patients is required (831 per arm).  
For comparison: In combined  ocrelizumab  Phase  3 studies (OPERA  1 and OPERA  2, Hauser  et 
al. 2015) the Kaplan -Meier estimates were 12.0 and 7.4 at year 2 for interferon beta- 1a and 
ocrelizumab 600 mg, respectively; this corresponds to a hazard ratio 0.6 (40% relative risk reduction between ocrelizumab and interferon  beta-1a). 
 
9.8.4  Sample size for 6- month confirmed disability improvement  (6mCDI)  
The cumulative event probability over 2 years is assumed as 12% vs 18.8% in patients treated 
with teriflunomide vs ofatumumab, respective ly. The assumed cumulative event rates translate 
to a relative increase in chance by 63% (hazard ratio=1/0.614=0.163) in patients treated with ofatumumab compared with teriflunomide. The detection of a hazard ratio of 1/0.[ADDRESS_736402] with 80% power at a one -sided alpha -level of 0.025- 0.025
2 requires 133 qualifying 
events. Allowing for 20% dropouts over 2 years 1052 patients who contribute to the analysis are required; due to the definition of 6mCDI, patients with a baseline EDSS < 2 cannot 
contribute to this analysis. Based on the combined fingolimod Phase 3 trials (FREEDOMS, 
FREEDOMS II and TRANSFORMS, data on file) it is assumed that approximately 35% of all randomized patients will have baseline EDSS < 2. Hence, 1620 (1052/0.65) randomized 
patients are required to provide 80% power.  
 
9.8.5  Sample size for number of Gd -enhancing lesions per  scan  
We assume a negative binomial distribution of the number of Gd- enhancing lesions per scan. 
Assuming 0.26 Gd- enhancing lesions per scan for teriflunomide and a 90% relative reduction 
with ofatumumab (i.e. 0.026 Gd-enhancing lesions per scan for ofatumumab), and a dispersion 
parameter κ Gd=5.3 (as observed in the combined FREEDOMS and FREEDOMS II studies  for 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 105
0 Protocol No. 
  
 
the same parameter, data on file), a total sample size of 210 patients with available MRI scans 
would be sufficient to provide 90% power for the statistical test at a  one- sided alpha 0.025. 
Allowing for 20% dropouts, a total sample size of 264 randomized patients (132 per arm) is 
required for this endpoint.  
 
9.8.6  Sample size for annualized rate of new/newly enlarging T2  lesions  
We assume  a negative binomial distribution  of the number of T2 lesions.  Assuming  2.1 new or 
newly enlarging T2 lesions over 1.5 years for teriflunomide (1.4 new or enlarging T2 lesions per year with a mean follow -up of 1.5 years) and an 80% relative reduction with ofatumumab 
(i.e. 0.42 T2 lesions over  1.5 years; 0.28 lesions per year for ofatumumab) and a dispersion 
parameter κ
Gd=3.1 (as observed in the combined fingolimod Phase 3 placebo- controlled trials, 
data on file) for the same  parameter),  a total sample  size of 74 patients  with available MRI  scans 
would be sufficient to provide 90% power for the statistical test at a one -sided alpha 0.025. 
Allowing for 20% dropouts, a total sample size of 94 randomized patients (47 per arm) is 
required for this endpoint.  
 
9.8.7  Sample size for  NfL 
We assume  a log-normal distribution  for NfL concentrations. At month 3, geometric mean  NfL 
concentrations of μ1=25 pg/ml in teriflunomide and μ2=17pg/ml in ofatumumab  treated  patients 
are assumed, leading to an assumed treatment difference on the log -scale of 0.386 pg/ml. We 
further assume a common standard deviation of 0.700 pg/ml. A total sample size of 139 randomized  patients  with available NfL assessments would be sufficient  to provide 90% power 
for the statistical test at a one- sided  alpha 0.025. Allowing  for 20% dropouts, a total sample  size 
of 174 patients (87 per arm) is required for this endpoint.  
 
9.8.8  Sample size for annualized rate of brain volume loss (BVL)  
We assume a normal dis tribution for the percentage brain volume change. Assuming a mean 
annualized rate of BVL of 0.45% on teriflunomide and 0.338% on ofatumumab (25% relative 
reduction) and a common standard deviation of 0.5%, a sample size of 621 patients with 
available MRI assessments would provide 80% power at a one- sided alpha level of 0.025. 
Allowing  from  20% dropouts, a total sample  size of 778 randomized  patients  are required  for 
this endpoint (ca. 390 per  arm).  
 
10 Ethical  considerations  
10.1 Regulatory and ethical compliance 
This clinical  study was designed and shall  be implemented,  executed  and reported  in accordance 
with the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) Harmonized Tripartite Guidelines for 
Good Clinical Practice, with applicable local regulations (including European Directive 
2001/20/EC, US CFR 21, and Japanese Ministry of Health, Labor, and Welfare), and with the 
ethical principles laid down in the  Declaration of  Helsinki.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 106
0 Protocol No. 
  
 
10.2 Informed consent procedures 
Eligible patients/subjects may only be included in the study after providing written (witnessed, 
where required by [CONTACT_6617]), IRB/IEC -approved informed consent, or, if incapable of 
doing so, after such consent has been provided by a legally acceptable representative(s) of the patient. In cases where the patient's representative gives consent, the patient must be informed 
about the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she must indicate assent by [CONTACT_560233] a separate assent form. Informed consent must be obtained before 
conducting any study- specific procedur es (e.g. all of the procedures described in the protocol). 
The process  of obtaining informed consent must  be documented in the patient  source documents. 
[COMPANY_001] will provide to Investigators in a separate document a proposed informed  consent form 
that complies with the ICH GCP guideline and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_560234]/IEC,  and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/IEC  approval. 
Women  of child  bearing  potential must  be informed that taking the study treatment  may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate  in the study they must  adhere  to the contraception  requirement  for the duration of 
the study and period after discontinuation of study drug. If there is any question that the patient 
will not reliably comply, they must not be entered in the  study. 
 
10.3 Responsibilities of the Investigator and IRB/IEC 
Before  initiating  a trial, the Investigator/institution  must  obtain approval/favorable opi[INVESTIGATOR_131312]/Independent Ethics  Committee  (IRB/IEC)  for the trial protocol, 
written informed consent form, consent form updates, subje ct recruitment procedures (e.g., 
advertisements) and any other written information to be provided to patients/subjects. Prior to study start, the Investigator is required to sign a protocol signature [CONTACT_5389]/her 
agreement to conduct the study in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
[COMPANY_001] monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of 
Novarti s, IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site 
is requested by a regulatory authority, the Investigator must inform [COMPANY_001] immediately that this request has been made.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 107
0 Protocol No. 
  
 
10.4 Publication of study protocol and results 
The key design elements of this protocol will be posted in a publicly accessible database such 
as clinicaltrials.gov. In addition, upon study completion and finalization of the study report  the 
results  of this trial will be either  submitted  for publication and/or posted in a publicly accessible 
database of clinical trial results.  
 
10.[ADDRESS_736403] Quality Management (QM) system that includes all activities involved in quality assurance and quality control, including the assignment of roles and responsibilities, the reporting of results, and the documentation of actions and escalation of 
issues identified during the review of quality metrics, incidents, audits and inspections.  
Audits of Investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_105295]  (CQA),  a group independent from  those involved 
in conducting, monitoring or performing quality control of the clinical tr ial. The clinical audit 
process uses a knowledge/risk based approach. 
Audits are conducted to assess GCP  compliance with global and local  regulatory  requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001]  processes.  
 
11 Protocol adherence  
This protocol defines the study objectives, the study procedures and the data to be collected on 
study participants.  Additional assessments required  to ensure safety  of patients/subjects  should 
be administered as deemed necessary on a case by [CONTACT_413]. Under no circumstances is an Investigator allowed to collect additional data or conduct any additional procedures for any 
research related purpose involving any investigational drugs under  the protocol. 
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an Investigator feels a protocol deviation would improve the conduct of the study this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC and health  authorities, where required,  it cannot be implemented.  
 
11.[ADDRESS_736404] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  Only  amendments  that are intended to eliminate  an apparent  immediate  hazard 
to patients/subjects may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified. 
Notwithstanding the need for approval of formal protocol amendments, the Investigator is expected to take any immediate action required for the safety of any patient included in this 
study, even if this action represents a deviation from the protocol. In such cases, the reporting 
requirements identified in Section [ADDRESS_736405].  
Archelos  JJ, Storch  MK, Hartung HP. (2000) The role of B- cells and autoantibodies in multiple 
sclerosis. Ann Neurol;  47:694-706 
Arzerra® US prescribing information (1/2016). 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125326s062lbl.pdf  
Barro C, Benkert P, Disanto G, et al (2018) Serum neurofilament as a predictor of disease  
worsening and brain and spi[INVESTIGATOR_560106]. BRAIN, 141;2382-2391 
Bouaziz JD, Yanaba K, Venturi GM et al. (2007) Therapeutic B- cell depletion impairs  adaptive 
and autoreactive CD4+  T-cell activation  in mice.  Pro. Natl.  Acad.  Sci. [LOCATION_003];  104: [ZIP_CODE]-[ADDRESS_736406] RHB. DeLuca J, Phillips G et al (2017) Validity of the symbol digit modalities test as 
a cognition performance outcome measure for multiple sclerosis. Mult Scler 23(5)721-733 
Confavreux C, O'Connor P, Comi G et al. (2014) Ora l teriflunomide for patients with relapsing 
multiple  sclerosis:  a randomized, double-blind, placebo -controlled, Phase  3 trial. Lancet  Neurol; 
Mar;13(3):247-56 
Disanto G, Barro C, Benkert P, et al.(2017) Serum Neurofilament Light: A Biomarker of 
Neuronal Da mage in Multiple Sclerosis/ ANN NEUROL 81: 857 -870 
 
Freedman MS. (2013) Teriflunomide in relapsing multiple  sclerosis:  therapeutic  utility.  
Ther Adv Chronic Dis;  4(5):192-205 
Friede T, Schmidli H. (2010) Blinded sample size reestimation with negative binomial counts in superiority and non- inferiority trials. Methods Inf Med; 49(6):618-24 
Frohman EM, Racke MK, Raine  CS. (2006) Multiple  sclerosis – the plaque and its pathogenesis. 
New Engl J Med;  354:942-955 
Hauser  SL, Waubant  E, Arnold DL et al. (2008) B- cell Depletion  with Rituximab  in Relapsing - 
Remitting Multiple Sclerosis. New Engl J Med; 358:676-688 
Hauser  SL, Comi  GC, Hartung HP et al. (2015) Efficacy  and safety  of ocrelizumab  in relapsing 
multiple  sclerosis - results  of the interferon -beta-1a-controlled, double-blind, Phase  III OPERA 
I and II studies. ECTRIMS Online Library. Hauser S. Oct 9, 2015;  116634 
Hobart J, Lampi[INVESTIGATOR_007] D, Fitzpatrick R, et al. (2001) The Multiple Sclerosis Impact Scale (MSIS - 
29) A new patient -based outcome measure. Brain; 124:962-973 
Hobart J, Cano S (2009) Improving the evaluation of therapeutic interventions in multiple 
sclerosis: the role of new psychometric methods. Health Technology Assessment; 13: No. 12  
Kappos L, Li D, Calabresi PA et al. (2011) Ocrelizumab in relapsing- remittin g multiple 
sclerosis: a Phase 2, randomized, placebo -controlled, mutlicentre trial. Lancet; 378:1779-[ADDRESS_736407]  PW, Anderson J. (2007) Analysis of exacerbation  rates  in asthma 
and chronic obstructive pulmonary disease:  example from  the TRISTAN study. Pharmaceutical 
Statistics; 6:89 -97 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 109
0 Protocol No. 
  
 
Klaus Lehmann -Horn, MD, Helena C.Kronsbein, MD, Martin S. Weber, MD (2013) 
Targeting  B-cells in the Treatment  of Multiple  Sclerosis.  Ther  Adv Neurol Disorders;6(3):161- 
173 
Kuhle J, Barro C, Disanto G, et al.(2016) Serum Neurofilament light chain in early relapsing 
remitting MS is increased and correlated with CSF level and with MRI measures of disease 
severity Vol 22(12)1550-1559 
Lublin FD, Reingold SC, Cohen JA et al. (2014) Defining the clinical course of multiple 
sclerosis. Neurology; 83:278-286 
Lund FE (2008) Cytokine -producing B lymphocytes – key regulators of immunity. Curr Opin 
Immunol. 20(3):332–38 
McDonald WI, Compston A, Edan G, et al. (2001)  Recommended diagnostic criteria for 
multiple  sclerosis:  guidelines from  the International Panel  on the diagnosis of multiple  sclerosis. 
Ann Neurol;  50:121-27 
McFarland HF (2008) The B -cell--old player, new position on the team. N Engl J Med; 
358:664-5 
O’Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized  Trial  of Oral Teriflunomide 
for Relapsing Multiple Sclerosis. N Engl J Med;  365:1293-303 
Panitch H, Goodin DS, Francis G, et al (2002) Randomized, comparative study of interferon 
beta- 1a treatment regimens in MS: The EVIDENCE Trial. Neurology; 59(10):1496-1506. 
Pi[INVESTIGATOR_60066] F, Kockum I, Khademi M, et al.(2017): Plasma neurofilament light chain levels in patients with MS switching from injectable therapi[INVESTIGATOR_560107]. MSJ 1 -9 
Polman CH, Reingold S, Banwe ll B, et al. (2011) Diagnostic criteria for multiple sclerosis: 
2010 revisions to the McDonald criteria. Ann Neurol; 68:292-302 
Radue E -W, Sprenger T, Gaetano L, et el (2015) Teriflunomide slows brain volume loss in 
relapsing  MS: a SIENA  analysis  of the TEMSO  MRI  dataset.  ECTRIMS  Online Library.  Radue 
E. Oct 10, 2015;  116702 
 
Siller N, Kuhle J, Muthuraman M, et al.(2018) Serum Neurofilament light chain is a 
biomarker of acute and chronic neuronal damage in early multiple sclerosis MSJ 1-9 
Soerensen PS, Lisby S, Grove R et al. (2014) Safety and efficacy of ofatumumab in relapsing- 
remitting multiple sclerosis. Neurology; 82:573-581 
Sormani MP, Bonzano L, Roccatagliata L,  et al. (2009) Magnetic resonance imaging as a 
potential surrogate for relapses in multiple sclerosis: a metaanalytic approach. Ann Neurol. 
65(3):268-75 
Sormani MP, Bruzzi P (2013) MRI lesions as a surrogate for relapses in multiple sclerosis: a 
meta -analy sis of randomised trials. Lancet Neurol 2013; 12: 669-676 
 
Wingerchuk DM, Lennon VA, Pi[INVESTIGATOR_298092], et al. (2006) Revised diagnostic criteria for 
neuromyelitis optica. Neurology; 66:1485-89 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 110
0 Protocol No. 
  
 
13 Appendix 1: Liver event and Laboratory trigger Definitions 
and Follow -up Requirements  
Table  13-1 Liver Event and Laboratory Trigger  Definitions  
 
 Definition/ threshold  
LIVER LABORATORY TRIGGERS  • [ADDRESS_736408] < ALT / AST ≤ [ADDRESS_736409] 
• 1.[ADDRESS_736410] < TBL ≤ [ADDRESS_736411] 
LIVER EVENTS  • ALT or AST > 5 × ULN  
• AP > 2 × ULN (in the absence of known bone pathology)  
• TBL > 2 × ULN (in the absence of known Gilbert  syndrome)  
• ALT or AST > 3 × ULN and INR >  1.5 
• Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and 
TBL > 2 × ULN [mainly conjugated fraction] without notable increase in AP to > 2 × ULN)  
• Any clinical event of jaundice (or equivalent  term)  
• ALT or AST > 3 × ULN accompanied by (general)  malaise,  
fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
• Any adverse event potentially indicative of a liver  toxicity*  
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage- related 
conditions; t he non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms  
 
 
Table  13-2 Follow Up Requirements for Liver Events and Laboratory  Triggers  
 
Criteria  Actions required  Follow -up monitoring  
Potential Hy’s Law  • Discontinue the study  treatment  ALT, AST, TBL, Alb, PT/INR, AP and  
casea immediately  GGT until resolutionc (frequency at  
 • Hospi[INVESTIGATOR_18552], if clinically appropriate  Investigator discretion)  
 • Establish causality   
 • Complete liver CRF   
ALT or AST    
> 8 × ULN  • Discontinue the study treatment 
immediately  ALT, AST, TBL, Alb, PT/INR, AP and  
GGT until resolutionc (frequency at  
 • Hospi[INVESTIGATOR_560108])  
 • Establish causality   
 • Complete liver CRF   
> 3 × ULN and  • Discontinue the study  treatment  ALT, AST, TBL, Alb, PT/INR, AP and  
INR > 1.5  immediately  GGT until resolutionc (frequency at  
• Hospi[INVESTIGATOR_18552], if clinically appropriate  
• Establish causality  
• Complete liver CRF  
> 5 to ≤ 8  × ULN  • Repeat LFT within 48  hours  
• If elevation persists, continue follow- up 
monitoring  
• If elevation persists for more than 2 
weeks, discontinue the study drug  
• Establish causality  
• Complete liver CRF  Investigator discretion)  
 
 
 
ALT, AST, TBL, Alb, PT/INR, AP and  
GGT until resolutionc (frequency at 
Investigator discretion)  
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 111
0 Protocol No. 
  
 
 
Criteria  Actions required  Follow -up monitoring  
> 3 × ULN  
accompanied by 
[CONTACT_18688] 
 
 
 
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic) 
ALP (isolated)  
> 2 × ULN (in the 
absence of known 
bone pathology)  
 
TBL (isolated)  
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)  
 
  
 
> 1.5 to ≤ 2 ×  ULN 
(patient is 
asymptomatic) • Discontinue the study treatment 
immediately  
• Hospi[INVESTIGATOR_497004]  
• Establish causality  
• Complete liver CRF  
• Repeat LFT within the next  week  
• If elevation is confirmed, initiate close observation of the  patient  
 
• Repeat LFT within 48 hours  
• If elevation persists, establish causality  
• Complete liver CRF  
 
• Repeat LFT within 48 hours  
• If elevation persists, discontinue the study drug immediately 
• Hospi[INVESTIGATOR_497004]  
• Establish causality  
• Complete liver CRF  
• Repeat LFT within the next  week  
• If elevation is confirmed, initiate close observation of the patient  ALT, AST, TBL,  Alb, PT/INR, AP and  
GGT until resolution
c (frequency at 
Investigator discretion)  
 
 
 
Investigator discretion  
Monitor LFT within [ADDRESS_736412], TBL, Alb, PT/INR, AP and  
GGT until resolutionc (frequency at 
Investigator discretion)  
Test for hemolysis (e.g., reticulocytes, 
haptoglobin, unconjugated [indirect] 
bilirubin)  
 
Investigator discretion  
Monitor LFT within 1 to 4 weeks or at 
next visit  
Jaundice  • Discontinue the study treatment immediately  
• Hospi[INVESTIGATOR_18554]  
• Establish causality  
• Complete liver  CRF ALT, AST, TBL, Alb, PT/INR, AP and  
GGT until resolution
c (frequency at 
Investigator discretion)  
Any AE potentially indicative of a liver 
toxicity*  • Consider study treatment interruption or 
discontinuation  
• Hospi[INVESTIGATOR_560109]  
• Establish causality  
• Complete liver CRF  Investigator discretion  
 
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in AP to > 2 × ULN  
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResol ution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at 
three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6 months, (4) liver transplantation, and (5) death.  
 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 112
0 Protocol No. 
  
 
14 Appendix 2: Specific Renal Alert Criteria and  Actions  
Table 14 -1 Specific Renal Alert Criteria and Actions  
 
Serum Event  
Serum creatinine increase  
25 – 49% compared to baseline  Confirm 25% increase after 24- 48h 
Follow up within 2 -5 days  
Acute Kidney Injury: Serum creatinine increase ≥ 
50% compared to baseline  Follow up within 24 -48h if possible 
Consider study treatment interruption  
Consider patient hospi[INVESTIGATOR_059] /specialized treatment  
Urine Event  
New dipstick proteinuria ≥ 1+  
Albumin - or Protein -creatinine ratio increase ≥ 2 -fold 
Albumin -creatinine ratio (ACR) ≥ 30 mg/g or ≥ 3 
mg/mmol;  
Protein -creatinine ratio (PCR )≥ 150 mg/g or > 15 
mg/mmol  Confirm value after 24 -48h 
Perform urine microscopy  
Consider study treatment interrupt ion / or 
discontinuation  
New dipstick glycosuria ≥ 1+ not due to diabetes  Blood glucose (fasting) 
Perform serum creatinine,  ACR 
New dipstick hematuria ≥ 1+ not due to trauma or 
menstruation  Urine sediment microscopy 
Perform serum creatinine, ACR  
For all renal events:  
Document contributing factors in the CRF : co-medication, other co- morbid conditions, and additional diagnostic 
procedures performed  
Monitor patient regularly (frequency at Investigator’s discretion) until either:  
Event resolution: sCr within 10% of baseline or protein- creatinine ratio within 50%  of baseline, or  
Event stabilization: sCr level with ±10% variability over last 6 months or protein -creatinine ratio stabilization at a 
new level with ±50% variability over last 6 months.  
 
15 Appendix 3: Safety monitoring  Guidance  
15.1 Guidance on monitoring of patients with symptoms of 
neurological deterioration suggestive of PML 
Should a patient develop any unexpected neurological or psychiatric symptom/signs in the 
opi[INVESTIGATOR_118362] (e.g. cognitive deficit, behavioral changes, cortical visual disturbances or any other  neurological cortical  symptoms/signs any symptom/sign  suggestive of an increase 
of intracranial pressure) or accelerated neurological deterioration, the Investigator should schedule a complete physical and neurological examination and an MRI as soon as possible 
before beginning any steroid  treatment.  Conventional MRI  as defined  in the protocol as well as 
additional scanning such as Fluid- Attenuated Inversion Recovery (FLAIR) and Diffusion- 
weighted  imaging  (DWI) sequences  are recommended  to aid in differential  diagnosis. The MRI 
must be evaluated by [CONTACT_527683].  The Investigator will contact [CONTACT_560235]. A copy 
of the unscheduled MRI  should be sent to the MRI  Evaluation Center  designated  by [CONTACT_560236]. AE/SAEs need to be filed as  appropriate. 
If the MRI shows new MS lesions consistent with an MS relapse, assessment and treatment of the relapse will be performed as described in the protocol ( Section 6.4.1 and Section 5.5.6 , 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 113
0 Protocol No. 
  
 
respectively). In case of new findings in the MRI images in comparison with the previous 
available MRI which are not compatible with MS lesions, the study drug will be discontinued 
and other diagnostic evaluations need to be performed at the discretion of the Investigator. If  
new lesions are detected on the MRI which may be infectious in origin it is recommended to collect  a cerebrospi[INVESTIGATOR_560110].  Analysis of the CSF sample  including cellular, 
biochemical,  PCR,  and microbiological analysis  (e.g. herpes  virus, JC virus) to confirm/exclude 
an infection  should be performed.  In the event  of suspected  CNS  infection  (PML),  a CSF aliquot 
should be sent to a central laboratory (designated by [CONTACT_1034]) for confirmatory testing.  
Only  after the evaluations have excluded  diagnoses other than MS and after discussion  with the 
Medical Advisor at [COMPANY_001], the study drug may be  restarted.  
 
15.[ADDRESS_736413] (with site contact [CONTACT_560237] a clinical study with investigatio nal and control agents with potential 
immunosuppressive effects)  and to show this to any local  healthcare provider they may consult 
and ask that the Investigator be  contact[INVESTIGATOR_530].  
In the case of suspected or confirmed serious (CTCAE, Grade 3 -4) or atypi[INVESTIGATOR_188609], study 
drug interruption should be considered. The Investigator should inform the Sponsor Medical 
Advisor of any such cases.  
When evaluating a patient with a suspected infection, the most sensitive tests available should be used (i.e. that directly detect the pathogen, as with PCR).  
The Investigator should consider early treatment with specific antimicrobial therapy on the basis of clinical diagnosis or suspi[INVESTIGATOR_560111], 
as appropriate. The Investigator should inform  the Sponsor Medical  Advisor of any such cases.  
Investigators should consider the added immunosuppressive effects of corticosteroid therapy 
for treatment of MS attack/relapse and increase vigilance regarding infections during such 
therapy and in the weeks following administration.  
In oncology patients treated with ofatumumab, cases of fatal hepatitis B virus (HBV) reacti vation and fatal infection due to hepatitis B in patients who have not been previously 
infected have occurred (refer to local ARZERRA
® prescribing information). The MS patients 
enrolled in the study who are at potential risk of HBV reactivation (e.g. patie nts with evidence 
of prior HBV infection (anti -HBc positive and HBsAg negative) and whose HBV DNA test is 
negative at Screening, should be closely monitored for signs of active HBV infection or 
reactivation  during the study. In patients  with suspi[INVESTIGATOR_560112]  (active/reactivation), 
laboratory testing for HBV should be done. For patients who show evidence of hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti -HBc 
positive), the Investigator is advised to consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral  therapy. 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 114
0 Protocol No. 
  
 
In patients who develop reactivation of HBV while receiving study drug, immediately 
discontinue study drug and institute appropriate treatment and follow up.  
15.3 Guidance on immunization 
The safety of and ability to generate a primary or anamnestic response to immunization with 
live, live -attenuated or inactivated vaccines during ofatumumab treatment h as not been 
investigated. The response to vaccination could be impaired when B -cells are depleted.  
It is recommended  that the Investigator review  the patient's immunization  history as part of the 
initial Screening procedure for a patient being considered f or treatment with ofatumumab. 
Vaccination of the patient, in compliance with local area vaccination guidelines for the patient population being treated,  is recommended  prior  to administration  of ofatumumab. In particular, 
prior to administration of ofatumumab, hepatitis B vaccination, in patients with risk factors for hepatitis  B infection  or in areas  with a high prevalence of hepatitis  B, as per local  area treatment 
guidelines should be  considered. 
Administrati on of live or live -attenuated vaccines must be avoided during and after 
treatment with ofatumumab and until B -cell counts are normalized.  
 
15.4 Guidance on monitoring of patients with low immunoglobulin 
levels  
After baseline, the immunoglobulin levels (IgM and IgG) will be measured at each visit from 
Month 1 to EOS  by [CONTACT_560238]. 
They will only be communicated to the site after baseline in case of notably low levels. A notably low IgG level is defined as a level that is 20% below the LLN and a notably low IgM 
level is defined as a level 10% below the LLN. Following notification, the immunoglobulin 
level should be repeated within [ADDRESS_736414] be 
discontinued and the immunoglobulin levels needs to be monitored at the Investigator’s 
discretion until levels return back to normal limits. The patient should be evaluated and 
monitored for infections on a regular basis. Immunoglobulin substitution therapy as pert local 
medical practice is all owed. Re -initiation of the study drug can only be considered once the 
immunoglobulin levels are back within normal  limits.  
 
16 Appendix 4: List of drugs/drug classes with teriflunomide 
interaction potential  
Based on the double -blinded design, the Investigator will need to consider the drug interaction 
potential of teriflunomide when the blinded study drug is co- administered with c ertain classes 
of drugs. The below information has been obtained from the US teriflunomide (Aubagio®) 
prescribing information (Revised 10/2014):  
 
Effect of teriflunomide on CYP2C8 substrates  
Teriflunomide is an inhibitor of CYP2C8 in vivo . In patients taking teriflunomide, exposure of 
drugs metabolized by [CONTACT_097]2C8 (e.g., paclitaxel, pi[INVESTIGATOR_051], repaglinide, rosiglitazone) may 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page [ADDRESS_736415] the dose of the concomitant drug(s) metabolized 
by [CONTACT_097]2C8 as  requi red. 
 
Effect of teriflunomide on warfarin  
Coadministration of teriflunomide with warfarin requires close monitoring of the international 
normalized ratio (INR) because teriflunomide may decrease peak INR by [CONTACT_3450] 25%.  
 
Effect of teriflunomide on or al contraceptives 
Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with teriflunomide.  
 
Effect of teriflunomide on CYP1A2 subst rates 
Teriflunomide may be a weak inducer of CYP1A2 in vivo . In patients taking teriflunomide, 
exposure of drugs metabolized  by [CONTACT_097]1A2  (e.g.,  alosetron, duloxetine, theophylline, tizanidine) 
may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) 
metabolized by [CONTACT_097]1A2 as  required.  
 
Effect of teriflunomide on organic anion transporter 3 (OAT3)  substrates  
Teriflunomide inhibits the activity of OAT3 in vi vo. In patients taking teriflunomide, exposure 
of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients 
and adjust the dose of the concomitant drug(s) which are OAT3 substrates as  required. 
 
Effect of teriflunomide on BCRP and organic anion transporting polypeptide B1 
and B3 (OATP1B1/1B3) substrates  
Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo . For a patient t aking 
teriflunomide,  the dose of rosuvastatin should not exceed  10 mg once daily.  For other substrates 
of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), 
especially  HMG -Co reductase inhibitors (e.g.,  atorvastatin,  nateglinide, pravastatin,  repaglinide, 
and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased  exposures to the drugs while  patients  are taking teriflunomide. 
Additional drugs belonging to the classes above include but are not limited to:  
• rifampi[INVESTIGATOR_2513] (a medicine used to treat tuberculosis and other  infections) 
• carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin (for  epi[INVESTIGATOR_002]) 
• St. John’s wort (a herbal medicine for  depression) 
• indometacin, ketoprofen (for pain or inflammation)  
• rosuvastatin for hypercholesterolemia (for treatment of high cholesterol)  
• sulfasalazine (for inflammatory bowel disease or rheumatoid  arthritis)  
• cholestyramine (for high cholesterol or relief from itching in liver disease); may accelerate elimination of teriflunomide (refer also to Section  7.8) 

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 116
0 Protocol No. 
  
 
17 Appendix 5: Statistical appendix (information from a 
controlled clinical trial with count  data)  
Background  
The ARR is the primary clinical endpoint in this Study. The trial compares ofatumumab with 
teriflunomide.  
 
Objective  
To mathematically  derive the information  obtained from  a clinical  trial in MS on the ARR ratio 
of test versus control, on the log- scale based  on a negative binomial distribution.  The treatment 
effect is based on the estimation of the ARR -ratio (the ‘estimate’) between ofatumumab and 
teriflunomide. The information is defined as the reciproc al of the estimate’s variance, as in 
group sequential  designs. 
 
Model  
We assume that the number of relapses follows a negative binomial distribution, which is a common assumption in MS trials.  More  specifically,  the available  data for patient  i in treatment 
arm j is: 
Y
ij = number of relapses in follow -up time T ij, 
for i = 1,…n j and j = 1,2 (1 = test, 2 = control). 
The negative binomial model is then written as: 
Yij   ~ NegBin( λ j Tij , κ) , 
with annual relapse rate λ j (> 0) and over -dispersion parameter κ (> 0). 
With this parametrization,  
E(Y ij) = μ ij and Var(Y ij) = μ ij (1 + κ μ ij), where μ ij = λ j Tij. 
An estimate of λ j is given by r j = Y .j / T.j , where Y .j = Σ i Yij and T .j = Σ i Tij. 
Using  the delta -method (see details  in a next section),  a normal  approximation for the logarithm 
of the estimated relapse rate ratio is  obtained: 
log(r 1/r2) ~ N(log(λ 1/λ2) , 1/(λ 1 T.1) + 1/(λ 2 T.2) 
+ κ{Σ i Ti12 / T.12 + Σ i Ti22 / T.22}) 
The information is the reciprocal of the variance, ie, information:  
I = [ 1/(λ 1  T.1  ) + 1/(λ 2  T.2  ) + κ{Σ i Ti12/T.12   + Σi Ti22/T.22}]-1 (1) 
For the case where T ij =T, n j = n, 
Information I = [1/n {1/(λ 1T) + 1/ (λ 2T) + 2κ}]-1 (2) 
Of note: Study designs with different parameterizations, but an equivalent amount of 
information also have an equivalent power for the detection of the specified treatment effect at a fixed alpha -level.  

[COMPANY_001]  
Amended Protocol version v02 Clean  Confidential  Page 117
0 Protocol No. 
  
 
Blinded evaluation of the information  
As in a blinded sample size review ( Friede and Schmidli 2010 ), fitting a negative binomial 
model to the aggregate data (i.e. the relapse data of all patients  combined) provides an estimate 
of the overall  annual relapse rate λ and of the dispersion κ. For an assumed  rate ratio of θ = λ1/λ2, 
we obtain estimates of the annual relapse rates in the 2 groups, λ 1 and λ2. 
We also make the assumption that the follow-up times  in the 2 groups are the same,  i.e., that 
T.1 = T.2 = T total/2 , where T total is the total of the follow -up times  at the review  time.  We further 
assume that the sum of the scuared follow -up times is the same in both groups, i.e., that Σ i Ti12 = Σ i T 2 = Σ j Σi Tij2 / 2 = T2 total/2. 
i2 
The evaluation of the Information (1) based on blinded information is then  
Information I = [2/(λ 1  Ttotal ) + 2/(λ 2  Ttotal ) + 4  κ T2total/Ttotal2]-1 (3) 
where λ 1, λ2, and κ are the re -estimated values at the blinded  review.  
Note: if T ij =T, n j = n, then Ttotal = 2 n T, and T2 total = 2 n T2, and one obtains again (2).  
Additional details (delta -method)  
For a random variable X with expectation μ and variance σ2 , the transformed random variable 
g(X) has approximately expectation g(µ) and variance σ2 g’(µ)2 (delta -method). 
For the estimate of λ j given by r j = Y j/Tj, we have:  
E(r j) = λ j and Var(r j) = λ j/Tj + κ λ j2 Σi Tij2/T.j2 
Using the delta -method, the log- transformed annual relapse rate estimate has expectation and 
variance:  
E(log(r j)) = log(λ j) 
Var(log(r j)) = 1/(λ j T.j ) + κ Σ i Tij2/T.j2 
Hence, approximately:  
log(r j) ~ N(log(λ j)), 1/(λ j T.j) + κ Σ i Tij2/T.j2) 
Note that for the special case of T ij = T, we obtain:  
log(r j) ~ N(log(λ j), 1/(λ j n T) + κ/n)  
This approximation is used for sample size calculation and re -calculation with negative 
binomial count data ( Keene et al. 2007, Friede and Schmidli 2010 ). 
